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ABSTRACT  
An Exploration of the Relationships between Chronic Pain, Inflammation, and 
Herbal Medicine 
 
    Termeh Feinberg  
   
Introduction: Inflammation is often a component of chronic pain, yet its potential role in fibromyalgia 
syndrome (FMS) remains inconclusive. FMS is a complex chronic pain condition affecting ~2% of the 
population; management is challenging and treatment options remain limited. Many herbs contain 
antiinflammatory properties, and herbs indicated for analgesia and rheumatic conditions have traditionally 
been used in Appalachia. Despite the popularity of herbs in the US, determinants and patterns of herbal 
use with regard to pain management have not been well studied, particularly in Appalachia, where 
prevalence of chronic pain and related comorbid conditions is high and access to medical care is often 
reduced. In this series of three studies, we investigate the: 1) relation of FMS to serum C-reactive protein 
(CRP) in a large Appalachian population; 2) demographic, lifestyle, and health-related correlates of herbs 
and other complementary health approaches (CHAs) used for pain in a sample of Appalachian chronic 
pain patients, using a newly developed survey instrument; and, 3) the relation of herbal supplement use to 
FMS in two nationally representative samples of U.S. adults (NHIS 2007 and 2012), as well as trends in 
patterns of herbal use over time.   
Methods: All participants completed comprehensive health surveys in these three cross-sectional studies. 
To investigate the relation between diagnosed FMS and serum levels of the proinflammatory marker CRP 
(Study 1), we used data on 52,535 adult Ohio Valley residents (FMS =1,125), collected in 2005-2006 as 
part of the C8 Health Project. Medical history, including physician diagnosis of FMS, was ascertained via 
self-report. To determine the correlates and patterns of herbal and other CHAs used specifically for pain 
in an Appalachian chronic pain population (Study 2), we collected data on 301 patients from four WV 
pain and rheumatology clinics using our newly developed survey instrument, the Complementary Health 
Approaches for Pain Survey (CHAPS) (2014-2016); correlates relating specifically to pain were measured 
using the Short-Form Global Pain Scale (SF-GPS). To assess the relation of diagnosed FMS to herbal 
supplement use (at 30 days, past 12 months, and ever) and to examine potential changes in the patterns of 
use over time (Study 3), we used data from the 2007 and 2012 National Health Interview Surveys (NHIS) 
(N = 20127 and N = 30672 adults, respectively).  Logistic and linear regression (complete-case analysis) 
were used to examine associations and to evaluate the potential modifying influence of gender and 
number of health conditions; multivariate models were adjusted for an array of demographic, lifestyle, and 
health factors. To account for missing data (Study 2), we also conducted additional sensitivity analyses 
using multiple imputation.  
Results: Study 1. In this large Appalachian population, mean serum CRP was significantly higher among 
participants reporting a diagnosis of FMS than those without FMS (5.54± 9.8 vs.3.75±7.2 mg/L, 
p<0.0001)). CRP serum level showed a strong, positive association with FMS (unadjusted OR for highest 
vs. lowest quartile=2.5 (CI 2.1,3.0; P for trend(p<0.0001); adjustment for demographics and lifestyle 
factors attenuated but did not eliminate this association (adjusted odds ratio (AOR) for highest vs. lowest 
quartile = 1.4, (CI 1.1, 1.6).  The addition of body mass index (BMI) and comorbidities to the model 
further weakened the relationship between CRP and FMS (AORs, respectively, for highest vs lowest CRP 
quartile=1.2 (CI 1.0,1.4) and 1.1 (CI 0.9, 1.3), suggesting that these factors may partially explain the 
observed associations. Study 2: In our sample of 301 WV chronic pain patients, 8% reported using herbs 
and 58.8% reported using other CHAs, including mind-body practices (28.9%),; acupuncture, 
manipulative treatments, massage, and/or movement therapies (28.1%), and non-herbal dietary 
supplements (53.6%).  Herbal use in this sample was marginally, inversely associated with age (OR 
 adjusted for education=0.97 (CI 0.94,1.01) and positively associated with education (OR adjusted for 
age=4.94 (CI 1.6,15.3); Herbal use also showed strong positive associations with use of other CHAs ( 
(AOR=11.5 (CI 1.5,87.9); specific CHA AORs ranging from 2.4 to 10.3). Use of other CHAs was 
marginally, inversely associated with age (OR adjusted for education/exercise=0.98 (CI 0.96,1.0), and 
significantly and positively associated with education and physical activity (AOR’s for Bachelor’s+ vs. 
<HS/GED= 2.7 (CI 1.1,6.4; Exercise per 30 min p/w increment = 1.14 (CI 1.01,1.3); concomitant use of 
other CHAs was significantly and positively associated with all CHA categories after adjustment for 
multiple confounders. Neither herbal use nor CHA use overall was associated with pain severity or use of 
prescription medications. Sensitivity analyses using multiple imputation did not appreciably change any 
observed associations.  Study 3. Prevalence of diagnosed FMS was significantly higher in 2012 compared 
to 2007 (1.7% vs. 1.3%), whereas reported use of herbs declined from 57 to 41% for ever use (p <0.0001). 
In both nationally representative samples of US adults (NHIS 2007, 2012), adults with FMS were 
significantly more likely to use herbs at 30 days, 12 months, or ever relative to adults without FMS; these 
positive associations remained highly significant even after controlling for a broad array of demographic, 
lifestyle, and health-related factors (Ranges: 2007 AOR’s = 2.3 – 2.7; 2012 AOR’s = 1.5 – 1.6; 
p’s<.0001).    
Conclusion:  Results of these studies suggest that 1) FMS is positively associated with serum CRP, an 
association that may be largely explained by obesity and comorbidity, suggesting the role of inflammation 
in this chronic pain syndrome may be complex 2) CHA use specifically for pain in chronic pain patients in 
northern WV is high, and although overall reported use of herbs for pain is low, many herbs were reported 
by those disclosing herbal use; and 3) the use of herbs is strongly and positively associated with FMS 
diagnosis. Further prospective research is needed to confirm these findings, to further explore the role of 
inflammation in FMS to further investigate the patterns and determinants of herbal and related CHA use 
in FMS and other chronic pain populations, including those in Appalachia and other poor, underserved 
areas.  
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CHAPTER 1: Project overview   
Introduction   
   
Fibromyalgia, a Chronic Pain Syndrome  
Impact of Chronic Pain Syndromes  
  
Chronic pain, defined as ongoing or recurrent pain, lasts beyond the usual course of acute illness 
or injury for more than three to six months, and is both debilitating and costly.  Over 20% of adults may 
eventually experience chronic pain (1-3), and as many as 100 million individuals are affected in the 
United States alone (4).  The effects of pain exact tremendous health care costs, rehabilitation and lost 
worker productivity, as well as the emotional and financial burden placed on patients and their families. 
The costs of unrelieved pain result in longer hospital stays, increased rates of re-hospitalization, increased 
outpatient visits, and decreased ability to function fully leading to lost income and insurance coverage; 
unrelieved chronic pain problems often lead to work disability and maintenance of health insurance (5).  
Chronic pain costs the U.S. more than $635 billion annually in medical costs and lost productivity, which 
equates to approximately $2,000 per person in the U.S. The Institute of Medicine stresses the importance 
of increased research into the translation of effective treatments into practice and into the distribution, 
prevalence, and burden of pain (6).    
   
Fibromyalgia Syndrome Prevalence & Risk Factors  
  
Fibromyalgia syndrome (FMS) is a non-fatal rheumatologic chronic pain syndrome affecting 
approximately 0.5-5% of populations in developed countries (7), including 1.75% of those in the U.S. (8).  
FMS is a “central” pain syndrome characterized by a constellation of somatic symptoms that are typically 
present in addition to widespread pain (e.g., fatigue, sleep disturbance, memory, and mood problems) 
(912).  FMS is also characterized by morning stiffness, headaches, and increased sensitivity to loud 
noises, bright lights, and temperature extremes; women with FMS often report painful menstrual periods 
(13). Although FMS affects both sexes and people of all ages, the majority (80-90%) have been Caucasian 
(13, 14) middle-aged women (13). Family members of FMS patients are at a higher risk for FMS (15); the 
cause is unknown.   
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Between 80 and 90% of people diagnosed with FMS are middle-aged women, although FMS can 
affect both sexes and people of all ages (13). FMS is similar to many regional pain syndromes in that 
peripheral or mechanical factors do not contribute, or contribute only minimally to the widespread chronic 
pain typifying FMS; standard laboratory tests fail to reveal a physiologic reason for the pain experienced 
(16). The cause of FMS is still poorly understood, and there are currently no diagnostic laboratory tests for 
FMS, with diagnosis typically based on distribution of pain (with at least 11 of 18 painful ‘tenderpoints’ 
for at least 3 months, according to 1990 American College of Rheumatology Diagnostic Criteria (17), and, 
updated 2010 diagnostic criteria incorporating quality-of-life impact of FMS(17)) and exclusion of other, 
competing causes of pain. Because there are no established objective tests, and very limited management 
options for FMS, some doctors may conclude a patient’s pain is not real, or they may tell the patient there 
is little they can do (18).  
  
Etiology of Fibromyalgia Syndrome  
  
While the etiology of FMS is unknown, there may be a number of factors involved. Many people 
associate the development of FMS with a physically or emotionally stressful or traumatic event, such as 
an automobile accident or repetitive injuries, while some link it to another illness (11). FMS occurs 
spontaneously in others, and limited research has investigated if it may be caused by a virus that changes 
the way the brain perceives pain (11).  People with FMS may have abnormal spinal fluid levels of 
Substance P, a chemical which helps to transmit and amplify pain signals to and from the brain (11).  
Despite the potential variation in underlying cause(s), however, it is clear that people with FMS have an 
increased sensitivity to pain. Because genes regulate the way the body processes painful stimuli, people 
with FMS may have a gene or genes that cause them to react strongly to stimuli that most people would 
not perceive as painful (19).  Several genes have been identified to occur more commonly in FMS 
patients; studies indicate that women who have a family member with FMS are more likely to have FMS 
themselves; several cerebrospinal MircoRNAs were recently identified in FMS cases in a small 
casecontrol study (20).  However, it is unknown if heredity is solely responsible, or if shared 
environmental factors play a role as well.   Further research on the perception of pain and related variables 
among people with FMS is needed.    
Like arthritis, FMS is considered a rheumatic condition, a medical condition that impairs the 
joints and/or soft tissues and causes chronic pain; individuals with higher BMI (21), autoimmune 
conditions (22), osteoarthritis (23), kidney (24), respiratory (25), cardiovascular (24), liver (26), and 
endocrine (24) disease, diabetes (27), severe allergies (24) and sinus disease (28), stomach conditions (24, 
26), and headache (29) may be more likely to have FMS. Those with FMS are also more likely to have 
3  
  
two or more coexisting pain conditions in addition to FMS, suggesting the plausibility of a common 
underlying cause; however, shared mechanisms between comorbid conditions and FMS have remained 
largely unexplored (13).  
  
Role of Inflammation in Chronic Pain Syndromes and Fibromyalgia Syndrome  
  
Chronic pain remains an unresolved problem in human medicine which greatly impairs quality of 
life and prolongs treatment. Developing and identifying effective therapies is difficult due to the array of 
mechanisms and signaling pathways through which chronic pain may be generated (30, 31).  A common 
underlying mechanism of chronic pain is the presence of inflammation at the site of the damaged or 
affected tissue (31), and inflammatory responses in the peripheral and central nervous systems play key 
roles (32).  The release of pro-inflammatory and immunoactive substances such as cytokines (which are 
chemical messengers and can also be anti-inflammatory), neurotrophic factors, and chemokines initiate 
local actions and can result in a more generalized immune response by directly activating nociceptive 
sensory neurons, leading to or promoting the generation of prolonged pathologic pain (33), and, 
ultimately, to a persistent chronic pain condition (31).    
Certain inflammatory cytokines are also involved in nerve-injury/inflammation-induced central 
sensitization, and are related to the development of contralateral hyperalgesia (an extreme, exaggerated 
reaction to a stimulus) and allodynia (central pain sensitization following painful, often repetitive 
stimulation) (33).  FMS is a condition that typically causes hyperalgesia and allodynia (34).    
Although inflammation, as a characteristic reaction of tissues to injury or disease marked by 
physical swelling, redness, heat, and pain, is not a classical symptom of FMS (18), further investigation is 
necessary to rule out the existence of chronic, low-level inflammation among people with FMS.  
Currently, cytokines are being investigated by the National Institutes of Health (NIH) in lab/pre-clinical 
studies to determine the extent to which chronic pain in FMS patients is associated with the activation of 
cells in the nervous system (18).  The possible link between systemic inflammation and FMS must be 
investigated since existing studies suffer from limited generalizability and potential misclassification bias. 
Some of these investigations (35-49), but not others (43, 50) reported increased likelihood of FMS among 
those with elevated levels of various pro-inflammatory indicators.  However, only five of these studies 
measured C-reactive protein (CRP) (44, 47-49, 51), which is a marker of inflammation that is a commonly 
ordered lab workup among patients whose symptoms may indicate the presence of FMS (16); Four 
suggested a positive association between CRP and FMS (44, 47-49). In addition, interpretation of findings 
in these studies is hindered by small sample sizes. To date, only one large, cross-sectional, population-
based study has examined the association of CRP to FMS (48). The study excluded women, and combined 
FMS with other pain syndromes, rendering assessment of the specific relationship between CRP and FMS 
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difficult. Thus, the role of inflammatory mediators in FMS also needs to be elucidated by larger, 
population-based studies.  
  
Current treatments for Fibromyalgia Syndrome  
  
Family physicians, general internists, rheumatologists, and some pain clinics treat those who have 
FMS (13).  However, not all physicians are familiar with FMS and its treatment.  Therefore, some FMS 
patients experience difficulty in receiving diagnosis and consistent care for their symptoms.  Treatment for 
FMS and other chronic pain conditions is often poorly handled.  
Although there is ‘gold’ level evidence (Cochrane) that supervised aerobic exercise training has 
beneficial effects on physical capacity and FMS symptoms (52), and some evidence that cognitive 
behavioral therapy may provide a small incremental benefit in reducing pain, negative mood and disability 
at the end of FMS symptom treatment and at long-term follow-up (53) (Appendix A), people with FMS 
are typically treated with pain medicines, antidepressants (54), muscle relaxants, and sleep medicines (11). 
Often, neuromodulators (substances which alter the way nerves communicate with each other, affecting 
the overall activity level of the brain, potentially reducing the amount of pain (55)) and anti-epileptics are 
used for treating FMS. These and other drugs used to treat FMS carry significant side effects and include 
Gabapentin (56), Fluoxetine (57), Pramipexole (57), Amitriptyline (54), Duloxetine (58, 59), and 
Tramadol plus Paracetamol (57).  Although three drugs (Lyrica, Cymbalta, and Savella) have been 
approved by the FDA for treatment, they also carry significant side effects (57, 60, 61), and the 
mechanism by which these drugs produce their effects is unknown. For some FMS patients, these drugs 
are not effective (11). Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) inhibit prostaglandins, which 
play a role in pain and inflammation; these are given as treatment for FMS symptoms (18), but carry 
significant side effects for as many as 25% of long-term users (62).    
For a subset of people with FMS, narcotic medications are prescribed for severe muscle pain. 
However, concrete evidence is lacking regarding the efficacy of narcotics for the management of chronic 
pain for the majority of those with FMS.  Many doctors hesitate to prescribe narcotics for long-term use 
because of the potential that the person taking them will become physically or psychologically dependent 
on them (18).  However, more than four-fifths of FMS patients receive opioid therapy (63); Because 
specific recommended treatments for this chronic disease are highly variable, a consensus on effective 
treatment for the disease is not known (64-66).  Pharmaceuticals used for other diseases may be prescribed 
as treatment for FMS, but there is limited quality research to support this practice, particularly regarding 
Phenytoin (67), Clonazepam (68), Carbamazepine (61, 69), Topiramate (70), Pirlindole (71), Valproate 
(61, 72), Lamotrigine (61, 73), Lacosamide (61, 74), and lastly, the narcotic Oxycodone (75).    
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Complementary Health Approaches (CHA) are often used by those with chronic pain. Further, the 
American College of Rheumatology suggests that people with FMS consider non-drug treatments in 
addition to their pharmaceutical approaches, and that certain CHAs may be helpful in managing FMS 
symptoms. However, many of these treatments, including herbal dietary supplements, have not been well 
tested in FMS patients (76-78).    
While Mind-Body therapies (a group of CHAs such as meditation, hypnotherapy, relaxation, and 
guided imagery) may improve self-efficacy, quality of life, and pain for people with FMS, systematic 
reviews and meta-analyses on other treatments for FMS indicate a need for further research in the areas of 
acupuncture (79), multidisciplinary rehabilitation for musculoskeletal disorders (a commonly used 
intervention) (80), resistance training (81), and traditional Chinese medicine (82).  We attempted to 
conduct a meta-analysis in December 2014 to assess if herbal use (including Eastern or Western) was 
simply a placebo effect for FMS treatment.  The inclusion criteria were randomized clinical trials only 
including FMS patients, compared herbs with placebo or pharmacological therapies, and included clinical 
outcomes assessing FMS symptom severity and/or pain and/or quality of life. However, no trials met this 
criteria, indicating a lack of research assessing the potential impact of herbs on FMS.  
   
Opioids: an Imperfect Treatment for Chronic Pain   
  
Over the past decade, the worrisome trend of increased prescription and utilization of opioids for 
the treatment of chronic nonmalignant pain, including FMS, has emerged (83).  Opioid pain relievers— 
also called prescription painkillers—such as Oxycodone, Hydrocodone, Fentanyl, and Hydromorphone, 
were responsible for three-fourths of all prescription drug overdose deaths in the United States in 2010 
(84). Despite recommendations against the use of opioids for the treatment of FMS, evidence suggests 
widespread and increasing clinical utilization (85).  Recent evidence shows that over four-fifths of FMS 
patients receive opioid therapy and that treatment using approved medications not only does not reduce 
this trend but also tends to increase opioid utilization rates (63).  Nationally, deaths involving opioids 
(using age-adjusted data) have more than quadrupled since 1999 (84).  West Virginia ranks among the 
worst states for its health disparities, especially for opioid pain medication misuse and abuse. West  
Virginia’s overdose death rate for 2010 (28.9 per 100,000 population) was more than double the national  
rate (12.4 per 100,000 population), which has also been climbing over time (86).                                                                    
Opioid treatment for chronic pain management presents a great challenge in the unique demographic of  
Appalachia. Many chronic pain patients experience poor treatment outcomes (2). Chronic and malignant  
pain is difficult to manage, partially due to limited efficacy and negative side effects from conventional 
medical therapies, but also because some physicians are reluctant to prescribe opioids (6), while others 
overprescribe them (85).  West Virginia has the third highest national ranking for prescription opioid use 
6  
  
in FMS patients (~19.4%) (87); many patients become dependent on opioids, and opioid use and misuse 
remain an important topic in West Virginia (86).    
Understanding the usage and efficacy of other, safer forms of chronic pain treatment are 
necessary, and may include CHAs.  CHA use exists in chronic pain patient populations (88-94), and 
encompasses a variety of therapeutic modalities not customarily prescribed by medical doctors to treat 
chronic pain, such as natural products (e.g., herbs, dietary supplements, etc.) and mind and body practices  
(e.g., yoga, meditation, etc.), as well as the practices of traditional healers, Ayurvedic medicine,  
Traditional Chinese Medicine, homeopathy, and naturopathy, among other non-mainstream approaches.  
Most people using CHA approaches use them along with conventional treatments (90, 95, 96), and 
patients often do not disclose the use of CHAs to their physicians (97, 98); the appropriate role for CHAs 
in the primary care of chronic pain remains controversial.  Physicians disagree with one another and with 
their patients about the cost, validity, and effectiveness of individual CHAs (99).  CHA use may reflect 
greater autonomy among a population of patients who wish to direct their own health care and are less 
dependent upon conventional medicine (88), with patients choosing CHAs because of concerns over the 
safety of conventional medicine (100).   
Given the continuing rise in fatalities due to opioid misuse, expanding treatment options for pain 
is a necessary step in reversing the explosion of deaths on a national- and a state-level for WV.  A deeper 
understanding of the relationship between analgesic CHAs (such as herbs), which may be safer and more 
well-tolerated than opioids and current pharmaceutical treatments, and the role of inflammation affected 
by those potential treatments, is warranted.  
  
  
Herbal Medicine – a Complementary Health Approach (CHA)  
The Evolving Definition of Complementary and Alternative Medicine (CAM)  
  
More than 30 percent of adults and about 12 percent of children use health care approaches 
developed outside of mainstream Western, or conventional, medicine (88). Surveys have yielded differing 
conclusions in explaining the increasing popularity of these approaches (88, 89, 101-103).  When 
describing these approaches, people often use the terms “alternative” (If a non-mainstream practice is used 
in place of conventional medicine) and “complementary” (if a non-mainstream practice is used together 
with conventional medicine), and these various approaches (called “therapies” or “modalities” in previous 
literature) have, until recently, been called “CAM” (Complementary and Alternative Medicine).  
However, true alternative medicine is uncommon, as most people who use nonmainstream approaches use 
them along with conventional treatments.  Therefore, the National Center for Complimentary and 
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Integrative Medicine (NCCIH), a division of the National Institutes of Health (NIH), recently suggested 
the use of the umbrella term “Complementary Health Approaches” in discussing practices and products of 
non-mainstream origin, and “Integrative Health” when talking about incorporating complementary 
approaches into mainstream health care (104).  ‘CAM’, therefore, will henceforth be considered 
“Complementary Health Approaches” (CHA) in this dissertation.  Examples of CHA approaches include 
(but are not limited to) acupuncture, aromatherapy, biofeedback, chiropractic care, energy healing, folk 
remedies, herbal medicine, homeopathy, hypnosis, imagery and relaxation techniques, lifestyle diet, 
massage, megavitamins, naturopathy, Reiki, copper bracelets, and yoga (105, 106).    
In Integrative Health and self-prompted use of CHAs, treatments are individualized for each 
patient, and when a practitioner is present, treatments may be individualized for each patient at each 
session (107).  Sufficient anecdotal evidence suggests that many folk cures do produce their anticipated 
result (108), warranting additional research regarding the efficacy of these treatments.  It is clear that CHA 
usage is popular; in 2007, about $14.8 billion was spent on the purchase of non-vitamin, nonmineral, 
natural CHA products in the United States (109).  According to the 2012 National Health Interview 
Survey (NHIS), which included a comprehensive questionnaire regarding the use of CHAs by Americans, 
17.7% of American adults reported consuming dietary supplements other than vitamins and minerals in 
the past year, making these products the most popular CHA used in the U.S. (104).    
Compared with nonusers, CHA users tend to be women, white, middle-aged, of higher income, 
and better-educated (90, 106, 110-116).  The use of CHA approaches is higher for chronic conditions than 
for acute conditions (112, 116), and users are more likely to be wellness-oriented (116, 117), with the 
primary use for health promotion (89, 90, 116, 118).    
  
Definition of Herbal Medicine  
  
Herbs (plant-derived products, also known as ‘Botanicals’, ‘Phytotherapies’, ’Phytomedicine’, 
and some ‘biologically based therapies’) are sometimes used to affect health status through biological 
activity within the body, and are most often sold as dietary supplements. Herbs are part of the broader  
CHA group of approaches called ‘Natural Products’, which also include vitamins and minerals (which are 
not plant-derived). The use of herbs for potential health benefit is sometimes called ‘Herbal medicine’ and 
is part of many ‘Folk Medicine’ traditions indigenous to specific populations around the world.   
Herbs are available for use as supplements, tinctures (alcoholic and non-alcoholic extracts), loose herbs 
for making teas/infusions/decoctions, and are sometimes prepared as salves or ointments for topical use 
(119, 120).  Some traditional uses indicate the smoking of herbs for health benefit.  However, this 
dissertation does not specifically include the smoking of herbs and will avoid specific investigation of the 
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herb Marijuana (Cannabis sativa, indica, and ruderalis) in this proposed project, due to pending legality 
issues in the U.S. involving its growth, distribution, and use for recreational and health purposes.  It is 
possible that this omission may result in the under-ascertainment of herbal use prevalence.  In this 
research project, herbs will be referred to as “herbs”, “herbal supplements”, or “herbal medicine” (in lieu 
of “herbal remedies”), depending on the specific aim of the project.   
Herbal medicine is also used as a complement to or as a component of other CHA approaches, including 
Ayurveda, folk medicine or traditional healing, naturopathy, Traditional Chinese Medicine, and to a lesser 
degree, specialized diets such as the macrobiotic diet.  However, because existing research does not 
commonly discuss herbal use as a component of other CHA modalities, our aims will utilize and focus on 
research which relates specifically to the definition set forth by the Center for Disease Control (CDC)  
National Center for Health Statistics for ‘Nonvitamin, nonmineral dietary supplements’; specifically, the 
latter are defined as herbs or other nonvitamin supplements (including those in pill, capsule, tablet, liquid 
or other form)  that have been labeled as dietary supplements.  Whenever discrimination is possible, we 
will limit our analyses to include only plant-based products (the NIH definition of ‘herbs’).       
Because of the historical value placed on the sharing of herbal knowledge through ‘Folklore’ and 
‘Folk Medicine’ in Appalachia (defined as a tradition of treating sickness by herbs, ethnic foods, prayers, 
healing objects, magic and dance ceremonies (121)), these terms will be considered as herbal medicine use 
in this project whenever it is clear that herbs were part of a healing regimen, to limit possible 
misclassification bias. Plant materials used for making folk medicines include the roots, bark, wood, sap, 
and leaves of plants (122).  
Many of the top-selling herbs in the US have been subjected to clinical trials in Europe and are 
currently recognized as beneficial for a range of health conditions by respected international health 
authorities,  including the World Health Organization, The European Scientific Cooperative on 
Phytomedicine and the German Commission E. (123).  However, the vast majority of herbs and their 
components have yet to be studied; even among relatively well-researched herbs, specific active 
components have yet to be identified, and potential interactions with other constituents of the herb, other 
herbs, and pharmaceuticals remain largely unexplored.  The US Food and Drug Administration (FDA) 
does not regulate herbal products, and frequently, herbal products contain adulterants and manufacturers 
make unsubstantiated (and sometimes illegal) claims regarding specific health benefits.  However, herbs 
remain a popular tool for the self-management of health among many people.  
  
History and Prevalence of Herbal Medicine in the United States & Appalachia  
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Although herbal medicines are considered a CHA in the West, herbal medicine remains a primary 
source of medicine in many parts of the world, including present day China, India, and many countries in 
South America and Africa (123).  Since aboriginal times, more than one thousand plants have been used 
for medicines in the United States and Canada.  Native American exchanges with European settlers were 
important contributions to folk medicine (122), and both groups believed that a plant existed for every 
malady known to humankind (124).  In the 1990s, specifically, Complementary and Alternative Medicine  
(‘CAM’, the term used before CHA) gained increasing popularity in the United States (90, 91, 106, 125, 
126).  The prevalence of adults using herbs increased from 2.5% in 1990 to 12.1% in 1997 (106, 125) in 
some of the earliest U.S. prevalence studies.  Several groups also reported relatively high rates of herb and 
supplement use, including women (125, 127-135), middle aged adults (125, 128, 134), Caucasians (125, 
128, 129, 132, 133), Asians (125, 130, 136), and Latinos [106].  One study showed higher herbal 
supplement use among minority populations (127).  
Because we observed varied prevalence rates for herbal use, we conducted a preliminary 
systematic literature review (Appendix C) assessing the herbal use in the United States general 
population; our review was restricted to large studies (N≥500) of adults aged at least 18 years and 
published between 2001-2012, and we excluded studies assessing specific conditions such as diabetes and 
cardiovascular disease, among others.  A total of 32 eligible studies were identified for inclusion. 
Collectively findings indicated that rates of medicinal herb use averaged 18.1%, ranging from ~5% in a 
group of physicians (137) to ~38.5% in a sample of Asian Americans (138). African Americans reported 
the lowest rates of herbal use (15.3%), followed by Hispanics (19.4%) and Non-Hispanic Whites (19.9%) 
(109, 116, 118, 137-165).  Overall mean rates of herbal use were similar to the national prevalence rates 
for nonvitamin, nonmineral dietary supplement consumption cited in 2002 (18.9%), 2007 (17.7%), and 
2012 (17.7%); together, use of herbs and other supplements remains the most popular complementary 
health approach in the U.S (166).  Other gaps identified included a botanical use classification as either 
too narrow or too broad to enable generalizability of results, in addition to confusing presentation of 
results. Commonly cited suggestions for future studies included drug/botanical interactions, further 
investigation of the concurrent utilization of other CHAs, and increased understanding of beliefs and 
experiences which may act as enabling factors for herbal use.   
Appalachia is a mountainous region in the eastern United States spanning southern New York to 
northern Mississippi, including all of West Virginia and parts of 12 other states (167).  It is one of the 
most botanically diverse regions in the world (124); Appalachia’s many micro-habitats are home to some 
2,500 plant species, of which some 1,100 have been reported to have medicinal properties (168).  As 
recent as the 1990s, there was written anecdotal evidence of medicinal plant and home remedy use in the 
Appalachian region, particularly among the elderly population (169).  These plants have a rich tradition in 
oral history and folklore; while some plants are well-known only from older accounts, others have been 
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and continue to be used in the preparation of pharmaceuticals.  Digging for the herbs Ginseng (also known 
as “sangin” or “digging sang”), wild cherry, goldenseal, sassafras (124), and other medicinal herbs was 
noted as a general occupation as early as 1886 (170-172), and prior to WWII was a vital part of the local 
economy of Southern Appalachia (124); several of these herbs continue to be harvested in WV (Image 1) 
(120, 122, 173-178).  
The Appalachian region remained the principal primary source of crude drugs (i.e., raw plant 
material) (124) until the 1980s (179) and the advent of synthetic drugs (124); Appalachian forests 
continue to provide the primary domestic source of wild native plants used in the American drug industry.  
Much of the value of the plants harvested and used in the Appalachian region remain largely unknown and 
often undocumented.  However, much of the oral history of the area is destined to be irretrievably lost to 
future generations unless it is collected in the very near future (121, 179).  Rates of herbal use in the 
Appalachian region have never, to our knowledge, been investigated, with the exception of one study in 
2523 older North Carolina adults which reported a prevalence rate of 19.3%  (141).   
Historically, people living in remote, isolated regions of southeastern KY found it necessary to 
formulate their own medicines, cures, and treatments for their self-diagnosed ills because of the scarcity 
and inaccessibility of trained physicians, nurses, and hospitals (179).  Most families kept a tonic on hand 
for whenever someone felt “puny” (sluggish, weak), also known as the folk illness “low blood” (124) 
(Figure 1).  When engaging in research to assess herbal use, it is important for investigators to be aware of 
self-diagnosed health conditions that may be part of folk illness tradition, rather than evidence-based 
diagnoses made by physicians.   Because herbs were traditionally self-administered, people may continue 
to self-diagnose based upon folk illnesses; there has been contemporary practice of several widespread 
and culturally significant systems of “traditional” or “folk” medicine in eastern regions of NC and VA 
(108), and anecdotal evidence hints at its existence as far south as Alabama and potentially as far north as 
West Virginia.  A single plant, such as Sarsaparilla or Sassafras, could serve as a health tonic for some of 
these folk illnesses, but often several plants were used (124).  Qualitative analyses of patient sessions with 
herbalists, lay midwives, and “root doctors” (who formed part of a traditional ethnomedical system 
utilizing plant roots among African Americans, which in turn, influenced health behaviors among white 
and Native Americans in the rural South) in various rural counties in the central Piedmont and eastern NC 
from 1978-1991 demonstrated that individuals generally agreed herbal remedies worked effectively to 
cure most minor, “natural” ailments, which are a type of folk disorder (Figure 1).  Qualitative research on 
folk medicine in Appalachia indicates a current revival of herbal medicine usage (Figure 2) (121, 180).  
However, aside from a few very limited studies on specific patient populations, distributions, patterns, and 
correlates have yet to be determined for herbal use in this particular region.  
Physical barriers, as well as social and economic distinctions, have played a role in historical 
Appalachian herbal usage. Herbal consumption by Appalachian populations has varied depending on the 
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history and place; types of herbs consumed has largely derived from  European and American herbal texts 
of the nineteenth century, which were likely learned through European and Native American tradition 
(179, 181). Herbal medicine appeared to be unevenly distributed in a North Carolina population study, 
with one or two practicing herbalists in any given rural community (1978-1991). Herbalists still actively 
practicing may treat hundreds or even thousands of people a year (182).  Traditional herbalists have many 
years of experience in collecting and preparing plants, know the properties of many different varieties and 
species, and observe over time the empirical effects of their remedies on different illnesses.  Traditional 
herbalism, however, is a skill that appears to be dying out as existing practitioners grow older.   
Traditional herbalists often understand the “proper” ways to prepare plants, and as their knowledge is lost 
with time, the likelihood of negative side effects and toxicity among users may increase (108).    
Although the landscape of healthcare has evolved through time, the rurality of the Appalachian 
region, particularly in WV, may continue to contribute to the usage of herbal medicine.  Isolation from 
hospitals, doctors, and pharmacies have, and to some extent, continued to characterize many populations 
resident in Appalachia today (122).  It is not surprising that people facing these conditions of rurality may 
rely on traditional remedies such as herbs, and/or folk practitioners, many of whom are both accessible 
and willing to offer advice or treatment on short notice, often in their own homes (182).    
Prevalence estimates of CHA use, including herbal use in WV, are largely unknown; a 
crosssectional study among primary care clinics from nearly three decades ago (N=170) found that 73% of 
patients used one or more folk medicine remedies, which are a CHA including herbs (mean= 4.5 
remedies) (183).  A more recent cross-sectional study on pregnant WV obstetrics patients (N=578) 
showed 45.2% of the participants used herbal medications, with acquisition from a plethora of retailers: 
grocery stores (40%), discount stores (21.8%), mail-order catalogs (11.3%), herbalists (7.0%), in-home 
sales by friends and fellow church members (4.0%), and pharmacies (3.8%).  Two percent of participants 
grew and harvested their own herbal medicines (184).  In lieu of largely absent prevalence rates for herbal 
use in Appalachia, there is anecdotal evidence of Appalachian (185), specifically WV, herbal usage in 
anthropological literature (175, 186-190).  Within the last 40 years, WV was documented as having an 
unusually strong tradition of folk medicine (191).    
  
Herbal Medicine Use for Fibromyalgia Syndrome (FMS) and other Pain Conditions  
Pain-related disorders are the most commonly reported conditions for which patients use CHA 
approaches (86, 88, 93, 105, 106).  A systematic review of the prevalence of CHA use in international 
rheumatology patients, specifically FMS patients, indicated about two-thirds of patients who had FMS 
were using at least one type of CHA by 1998 (192).  Among the mixed study designs, three UK studies 
indicated that 20% (N=78) (193, 194) and 35% (N=94) (194, 195) of Rheumatoid Arthritis patients used 
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herbal medicines, while 78% (N=90) (194, 196) of FMS patients used dietary supplements (including the 
use of herbal supplements).   
Results of a 2002 US national survey suggest that bodily pain, chronic conditions, and functional 
impairment are associated with the use of CHAs among midlife and younger adults (156).  The same 
survey showed 3.3% of those with Arthritis, Gout, Lupus, and FMS used natural products (160).  Another 
study utilizing the same survey showed that those who worked less than full time were more likely to use 
herbs compared with those who worked full time or more (116), which may indicate support for our 
hypothesis that people with disabling diseases which keep them from working full time, such as FMS, 
have an increased utilization of herbal supplements.      
A U.S. study of CHA approaches among primary care patients receiving opioids (N=908)  as a 
primary treatment method for chronic pain showed that 6.8% used herbs and supplements, and that 44% 
had used at least one CHA approach in the past year.  CHA utilization was significantly related to age, 
female gender, pain severity, income, pain diagnosis of neck and upper back pain, and illicit drug use 
(93).  Twenty-one percent of FMS cases used opioids, as well as herbs and dietary supplements (which 
were not plant-derived) 42.9% (mean = 2.8 per person) of the time, compared to 23% (mean = 2.2 per 
person) of the controls in a national case-control study (FMS = 434, Control = 198).  Authors found no 
evidence of FMS status being associated with any specific herb.  This was a moderately strong study, but 
limitations included lack of a random sample/significant differences on all demographic variables 
between cases and controls, self-reported data, and a low sample size for controls using herbs, severely 
limiting the statistical ability to compare herbal use between the two groups.  Herbs used most often by 
those with FMS were Ginkgo (3.7%), Garlic (3.0%), Ginseng (3.0%), Echinacea (2.5%), Evening 
Primrose oil (2.3%), and Valerian (2.3%) (197).  Although a number of studies have examined general 
herbal use among specific populations, no population studies have asked pain patients about herbs used 
specifically for pain. Additionally, whether opioids can be reduced by introducing herbal medications 
remains to be studied.  
  
Herbal Medicines used for Pain: a beneficial treatment for Fibromyalgia in Appalachia?  
  
Pain-related disorders are the most commonly reported conditions for which patients use CHAs 
(86, 104-106, 198).  The history of Willow (Salix spp.) and other salicin-rich plants, which were 
precursors to Aspirin, is an example of the role botanicals have played in the management of pain (123).  
A meta-analysis of Capsicum (a compound extracted from the fruit of Chili peppers C. frutecens and 
others) for the treatment of pain, reported that topical Capsaicin was superior to placebo for the treatment 
of chronic pain due to neuropathic and musculoskeletal disorders (with trials of moderate to high quality); 
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the FDA has approved Capsaicin as an over-the-counter topical cream (199).  There is a great deal of 
historical evidence which reveals extensive use of botanicals for the relief of pain, and plants with 
analgesic, anti-inflammatory and/or anti-spasmodic activities continue to be used (123).  However, there is 
a need for research regarding the use and efficacy of herbs that may benefit those with FMS and its 
comorbidities, especially in the Appalachian region, where opioid prescription drug misuse and abuse 
have skyrocketed, and safer, effective treatments aside from other existing pharmacological therapies for 
those with FMS are clearly needed.   
Existing Cochrane reviews and meta-analyses regarding herbal efficacy for chronic pain 
syndromes often co-occurring with or similar to FMS (Appendix A) include Passiflora (200), Valerian 
(201), and Kava (202) for anxiety disorders, compounds Qishe and Extractum Nucis Vomicae for chronic 
neck pain (203), Feverfew for preventing migraine (204-206), St. John's Wort for major depression (207), 
and mixed herbal medicine(s) for low back pain (208), irritable bowel syndrome (209), and rheumatoid 
arthritis (210) (unless otherwise noted, Latin botanical names are omitted in this paper when source 
identification is unclear; otherwise, they are denoted following their common name).  Of these, sufficient 
data are available only to evaluate Kava and St. John’s Wort, with Kava demonstrating a significant 
treatment effect for anxiety (202), and St. John’s Wort demonstrating effects on depressive symptoms 
superior to placebo and comparable to standard antidepressant treatments (207).  
A practicing Canadian herbalist specializing in the treatment of FMS recommends groups of herbs 
targeting various aspects of FMS, including muscle stiffness and pain, a lack of energy, pain and lack of 
sleep, joint pain and inflammation, depression and digestive disturbance, and “brain fog” impaired 
memory. Over 37 herbs are recommended (211), many of which have also been cited in qualitative 
Appalachian herbal literature for the treatment of symptoms that overlap with FMS symptoms (FMS is not 
cited in historical Appalachian herbal literature since it is a relatively new diagnosis, although the related, 
older term “rheumatism” is used extensively) (Appendix B).  
A qualitative study of rheumatism treatments used by a prominent Appalachian herbalist (first 
located in Southern Appalachia, followed by residency in West Virginia) identified twenty-three different 
plants used for rheumatism (212).  Similar findings have been reported for various other illnesses, both in 
contemporary field studies and in older regional collections of herbal texts (213-215).  A literature review 
of qualitative herbal literature (Appendix B) cites the anecdotal use of 101 herbs in the Appalachian 
region for pain relief (121, 179, 180, 216-219) , rheumatism (121, 169, 178-180, 182, 191, 216-218), and 
arthritis (121, 169, 178, 179, 191, 212, 217, 218), while 12 were used for inflammatory issues (121, 179, 
180, 217, 218), 3 for alleviation of sleep troubles (121, 169, 179), and 4 for headache (179, 180, 217).  It 
is not clear if these herbs continue to be used for these conditions in Appalachia.  
Herbs that have been used historically in the Appalachian region,  and for which there is some 
evidence of efficacy include: Willow (Salix sp.) for pain (220-223) and headache (224); Phytolodor herbal 
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extract blend, which includes Ash bark (although a different Fraxinus species than that used in 
Appalachia) for musculoskeletal issues (123); Black Cohosh (Cimicifuga racemosa) and chamomile  
(Chamomilla recutita) for sleep (225-227); Hops (Humulus lupulus) for sleep (223, 228) and analgesia 
(223, 229, 230); Evening Primrose (Oenothera biennis) for rheumatoid arthritis (231); Ginger 
(Zingiber officinale ) for rheumatic pain and musculoskeletal disorders (223, 232, 233); and 
Peppermint (Mentha piperita) for headache (223, 234, 235).  
Herbs for which some evidence of efficacy for FMS symptoms or related conditions exist, but for 
which no usage in the Appalachian region has been cited, include Chili pepper (C. frutecens and others),  
Cat’s Claw (Uncaria tomentosa), Devil’s Claw (Harpagophytum procubens), Feverfew (Tanacetum 
parthenium), St. John’s Wort (Hypericum perforatum), and Valerian (Valeriana officinalis) (123).   
Despite the apparent promise of several herbs for relief of pain and related symptoms, there are few 
population-based studies, high-quality trials, systematic reviews, and meta-analyses regarding the use and 
efficacy of herbs that may benefit those with FMS and associated comorbidities. Therefore, further 
research on herbs as a potential treatment for FMS is needed, specifically in the Appalachian region where 
opioid use is epidemic.    
  
Relationship of Herbal Medicines, Inflammation, and Chronic Pain  
  
A common underlying mechanism in the generation and promotion of chronic pain is the presence 
of inflammation at the site of the damaged or affected tissue (31); inflammatory responses in the 
peripheral and central nervous systems may also play key roles in the etiology of chronic pain (32).  When 
the synthesis of prostaglandins is inhibited, inflammation may result, ultimately leading to pain.   
Chronic inflammation is characterized by a proliferation of fibroblasts and formation of blood vessels 
(angiogenesis), as well as an influx of chronic inflammatory cells, namely granulocytes (neutrophils, 
eosinophils, and basophils), lymphocytes, plasma cells and macrophages (236). When macrophages 
become activated, they produce cytokines and chemokines, some of which, in turn promote inflammation.  
C-reactive protein (CRP), part of an acute response to underlying infection or tissue injury (237-239), is 
now also believed to be a marker of chronic systemic inflammation (240).  Because CRP levels have 
neither seasonal nor diurnal variations and are not influenced by food intake (237-239), CRP assay is 
commonly included as part of the diagnostic laboratory workup for many proinflammatory diseases, 
including FMS.       
Herbs with evidence of anti-inflammatory action (in vitro and in vivo) which have historically 
been used in the Appalachian region (although exact rates of use are unknown) include Chamomile 
(Chamomilla recutita) (225-227), Dandelion (Taraxacum officinale) (223, 241-243), Common Elder 
(Sambucus canadensis) (223, 241, 244, 245), Eucalyptus (E. globulus) (223, 246), Hops (Humulus 
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lupulus) (223, 243, 247), Mint (243), Watercress  (243), Licorice (Glycyrrhiza glabra) (223, 248), Witch 
Hazel (Hamamelis virginiana) (223, 249), Skullcap (Scutellaria baicalensis) (250-252), Willow (Salix 
spp.) (223, 253, 254), and selected components of Skullcap (Scutellaria baicalensis) (255), Willow (Salix 
spp.) (256), Ginger (Zingiber officinale) (233, 257-261), Ginseng (Panax quinquefolia) (262, 263), and 
Horse Chestnut (Aesculus hippocastanum) (223, 264, 265).  Leukocytes, which are associated with 
cytokine production in both immune response and inflammatory processes, are mobilized by the herb 
Echinacea (Echinacea spp.) as well (223, 266-268); moreover, in a 15-day experimental study in a female 
rat model of arthritis, CRP values decreased significantly in those administered Echinacea, compared to 
untreated animals (269).  Oroxylin A, a natural flavonoid from Skullcap (Scutellaria baicalensis), 
significantly attenuated expression of inflammatory mediators (i.e., iNOS and COX-2) and cytokines (i.e., 
TNF-alpha, IL-1beta, and IL-6), in an estrogen receptor-dependent manner, suggesting anti-inflammatory 
effects (270).    
Herbs for which some evidence of efficacy of anti-inflammatory action, but for which current 
prevalence rates in the Appalachian region have, to our knowledge, never been measured, include the 
ethanolic extract of Cat’s Claw (Uncaria tomentosa) (123), Thunder God Vine (Tripterygium wilfordii)  
(123, 271), Stevia (243), Cinnamon (243) , Turmeric (243), Mate (243), Boswellia (Boswellia serrata) 
(123), and Lavender (272), among others.    
The relationship between many herbs and inflammatory markers may also be mediated in part by 
the elucidation of related antioxidant activity.  Oxidative damage to membrane lipids, DNA, proteins, and 
lipoproteins, increases risk for several autoimmune and inflammatory diseases (273).  Herbs are a rich 
source of polyphenol compounds (274) and their antioxidant activities are several times higher than those 
of vegetables (275) and fruits (276). Antioxidants contained in herbs may also  suppress oxidative stress 
and related damage in the gastrointestinal tract before being absorbed (273), and thus, could modulate the 
level of oxidative stress by enhancing anti-inflammatory capacity (277, 278).  
Because certain inflammatory cytokines are related to the development of contralateral 
hyperalgesia (an extreme, exaggerated pain response) and allodynia (central pain sensitization following 
painful, often repetitive stimulation) (33), which FMS patients experience (34), and because the 
modulation of inflammation and oxidative stress by herbs can be beneficial (277), the possible links 
between systemic inflammation and FMS, as well as herbal use and FMS, clearly warrant further 
investigation.  
  
Challenges in Herbal Medicine Research  
Methodological issues specific to research on herbal medicines include misclassification, 
ethnocentric, and recall biases.  Areas in need of further exploration include the dialogue between 
physicians and patients regarding herbal use, safety, and efficacy; specifically, patient under-reporting of 
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herbal use to health providers should be examined. Studies utilizing biobehavioral approaches may help 
bridge this gap, and aid in understanding/clarifying motivating factors in an individual’s decision to use 
herbal medicine.  Rigorous efficacy research on herbs remains sparse.  Both rigorous population-based 
epidemiologic studies and high quality clinical trials are needed; moreover, also needed is the 
dissemination of evidence-based information that allows for clear interpretation regarding safety, efficacy, 
and limitations.  
The most universal and basic definition of an herb is ‘plant-derived material’.  Herbs go by many 
names, often creating confusion among researchers and the public, and can lead experienced researchers 
to overlook research on plants of interest.  Additionally, most available research is only available in the 
Chinese language (279), which may result in an ethnocentric bias in herbs considered safe and efficacious 
among differing populations.    
Misclassification bias often exists, even in high-quality meta-analyses, due to the differences in 
constituents between the same herbs grown in different locations, prepared or processed under differing 
conditions, plant parts used, dose, and even plant variety.  Therefore, the “pooling” of different products 
to reach conclusions about the efficacy of a single herb is often difficult, if not impossible (123).   
Additional misclassification bias exists due to the “lumping” of other biologically-based therapies with 
herbs, such as vitamin or minerals, homeopathic supplements, fish oil supplements, and 
prebiotics/probiotics.    
In many traditional medical systems, combination herbal formulae are more the rule than the 
exception.  Many herbal practitioners individualize formulations and hold that combinations of plants may 
work together in a synergistic fashion, although this area has not been the subject of much scientific 
research (123).  CHA users frequently use “bundles” of approaches rather than just one therapy in 
isolation (107), which can result in potential misclassification bias among CHA users who participate in 
poorly-designed observational studies, and clinical trials where exclusion criteria do not consider 
polypharmacy of herbal products and other CHAs.     
A regrettable aspect of most folk medicine sources is that they provide scant information on 
dosage amount and intake regimen; dosing is often based on the number three or nine (times per day), and 
dosage directions may be vague (e.g., stipulating only “a potent” or “a right smart amount” of herb) (124).  
Recall bias in reporting specific herbs used may exist because of the more informal interactions which 
occur when herbalist practitioners meet with patients, compared to those which occur in clinical settings 
(182), where documenting procedures are more standardized.  Additionally, preparation methods of herbs 
can vary greatly, and are typically not described in literature focused on herbal preparations that are not 
herbal supplements – and even for supplements, preparation and verification methods are not consistently 
described.   
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Not all physicians inquire about CHA use among their patients (137).  A UK systematic review 
indicated that, although patients believed CHAs to be effective, their doctors indicated skepticism about 
the usefulness of CHA in rheumatology (192, 194).  Commonly, there is miscommunication between 
physicians and patients about CHA approaches for which potential safety concerns can arise.  Patient care 
may be improved if this miscommunication is addressed.  This communication gap arises from differences 
in cultures and belief systems: thus it requires a blend of intellectual flexibility and nonjudgmental 
openness as it enables the physician to weave the patient’s “explanatory model”, which includes CHA use 
as well as the application of their own understanding of geographically relevant folk illnesses [Figure 1]), 
into the fabric of care (108).   
There is a clear need for the utilization of behavioral theories in measuring factors related to 
herbal use, as this can help to guide clinical practice.  The reasoning behind current national trends in 
herbal use are unclear; trends may be due to factors other than individuals’ willingness to follow 
traditional remedies passed down through families or communities, often with accompanying 
magicoreligious healing practices/folk healing. It is plausible that changes in environmental factors, 
communication within families and communities, and in the health care system overall may have 
contributed to an overall decline in the identification, preparation, and usage of traditional herbs in the 
U.S. and in the Appalachian region; there has been variation in herbal trends since the large, population 
studies of the 1990s (90, 106, 125, 280). Conversely, these or factors may have increased the usage of 
already-prepared herbs in supplement form, which are often readily available from multiple sources (e.g. 
Walmart) and promoted through various media (e.g. Dr. Oz television show, which attracts ~3.5 million 
daily television viewers)(281). Additionally, it is important to note “no individual ever completely 
replicates a single tradition” (108), which adds further complexity in understanding the reasoning for 
changes in herbal use trends.  In our preliminary systematic review on the prevalence of herbal use among 
the general population in the US (Appendix C) (N=32 studies) (109, 116, 118, 137-165), only 7 studies 
(~22%) documented using social, behavioral, or economic theories/models as a guide (116, 145, 150,  
152, 153, 156, 163). These theoretical approaches included the Anderson-Newman Behavioral Model of  
Health Services Utilization, the Socio-Behavioral Model of Healthcare Utilization, Grossman’s model of  
Health Capital Investment, and Leventhal’s Self-Regulatory Model. By using behavioral theories such as 
the Transtheoretical model and others, researchers and clinicians can begin to understand some of the 
drivers for changes in out-of-pocket healthcare costs associated with CHAs, and may alter the dialogue 
between patients and physicians to enable better treatment and ongoing, effective care for poorly managed 
chronic pain syndromes such as FMS.  
Lastly, the proof required by participants in folk-medical tradition is very different from that 
demanded by medical researchers.  For members of the former group, the efficacy of a home remedy, an 
herbal cure, or a magical procedure can be verified through anecdotal or experiential evidence alone (182).  
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Some treatments are presumed to depend on the unique characteristics of the healer and on features of the 
healer-patient relationship (107).  However, scientific research sometimes corroborates folk belief, as in 
the case of foxglove (Digitalis purpurea), which was prescribed as a heart tonic by community herbalists 
long before pharmacological studies confirmed its cardiotonic properties (182).  There are many 
differences in the information flow pathways of efficacy research to the ultimate use of an herbal product 
versus a prescription (Rx) drug (Figure 3).  The most obvious differences are: 1) Herbal use can occur 
even in the face of no or minimal scientific evidence.  This differs from patient and clinician expectations 
regarding efficacy, and the ordered flow in prescription drug use, due to all constituents/ingredients 
known in the beginning of the Rx life cycle; 2) Herbal use often originates from anecdotal/qualitative 
literature.  Therefore, the safety/efficacy is usually not known vs. a known safety/efficacy profile for Rx 
drugs; 3) Social media, social networks, and industry largely control the flow of information regarding 
evidence for herbal product use.  Therefore, all information may be considered equally weighted evidence 
of efficacy among many herbal consumers.  During a person’s lifetime interaction with an herb, their 
perceived safety and efficacy of the herb may change depending on which source is recommending the 
herbal product.  Although this may also occur with Rx drugs, it may be less likely due to more rigorous 
efficacy research requirements from the FDA and other regulatory bodies; 4) Doctors and pharmacists act 
as gatekeepers for Rx drug access, whereas there is no gatekeeper for herbal product access, since herbs 
are unregulated and potential users often have multiple avenues of access (i.e. pharmacies, health food 
stores, etc.).  The current focus of herbal research is largely to identify constituents of herbs and their roles 
in various physiological pathways (282); thus, there may be a long waiting period before rigorous clinical 
research can verify the safety and efficacy of a wider variety of herbs, emphasizing the importance of 
conducting primary- and secondary-data analysis.  When RCTs cannot be conducted, however, or when 
the results of RCTs may not be generalizable to the real world of CHA practice, it is necessary to use 
other study designs (107). Based on this, and the differences noted in the efficacy research information 
flow pathways of Rx drugs vs. herbs (Figure 3), epidemiological studies can play an important role for 
consumers of herbal products.  For these reasons, researchers in this field must pay special attention to 
providing clear interpretations of their results for the public. 
  
Summary    
Complementary Health Approaches (CHAs) are frequently utilized to treat chronic pain 
syndromes, however, rigorous observational and clinical studies of herbal medicine are largely lacking. 
Additionally, no epidemiological studies have examined herbal use in Appalachian pain populations, 
where opioid misuse and abuse is epidemic. There is limited evidence suggesting those with  
Fibromyalgia Syndrome (FMS), a chronic pain syndrome with unknown etiology for which opioids are 
often prescribed, frequently use herbal medicine to help with FMS symptoms.  Further, the Appalachian 
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region, particularly West Virginia, has a rich history of anecdotal herbal medicine use for many symptoms 
overlapping with those of FMS.  Understanding the correlates of herbal use in this population (including 
pain level as a potential motivator for herbal use) as well as patterns of herbal medicine among pain 
populations over time, will provide a window into patient health behaviors physicians may not be aware 
of. Importantly, these studies will also lay the foundation for efficacy studies examining interactions and 
synergistic effects of herbal medicine with opioids and other analgesic drugs. Further elucidation of the 
relationship between inflammation and FMS is also necessary due to the inconsistency of existing studies; 
understanding the potential role of inflammation in FMS is important since the presence of inflammation 
is intrinsically tied to chronic pain, and many herbs are used for their antiinflammatory and analgesic 
effects (Conceptual Model for this dissertation found in Figure 4).    
Self-management of chronic pain is in the current translational focus of the National Institutes of 
Health (NIH); additionally, the NIH Pain Consortium has stated that the understanding and treatment of 
pain remains incomplete, thus, research with a theoretical underpinning is needed to determine the extent 
for which specific CHAs, including herbs, are used in pain populations, specifically, FMS. Further 
elucidation of the relationship between pain and inflammation is also essential. This research is critical, 
since pain is poorly handled by current treatment methods.    
  
Rationale  
  
1) Chronic pain management for FMS by conventional treatments is often 
inadequate, perhaps contributing to the elevated use of CHAs such as herbal medicine 
among chronic pain patients;  
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2) While the use of herbs, like certain other CHAs, is likely high among those with chronic pain, 
little is known regarding herb use in specific chronic pain populations, including those who suffer from 
FMS;  3) Increased understanding of the patterns, correlates, and determinants of herbal and other CHA 
use is particularly important in chronic pain populations, given they are also likely to be on 
pharmacological treatments, including opioids, with the potential for interaction and/or abuse;   
4) Appalachian adults, who reside in areas with some of the highest rates of opioid overdose 
deaths in the US, may be more likely to consume herbs for health benefit, given their rich traditions of 
herbal harvesting and consumption; and,  
5) Increased understanding of herbal medicine and other CHA use in this population may aid in 
identifying new and potentially safer treatments for pain management, and help elucidate underlying 
mechanisms.  
  
Specific Aim 1   
Investigate if elevated blood serum levels of pro-inflammatory C-reactive protein (CRP) are 
associated with Fibromyalgia Syndrome (controlling for potential health factors, demographic 
variables, and lifestyle factors).  
Objective 1.1. Determine the association between CRP and FMS diagnosis.  
Hypothesis 1.1. Those with a FMS will have significantly elevated blood serum levels of CRP    
compared to those without FMS.    
  
Specific Aim 2   
To examine, in two nationally representative samples (2007 and 2012), potential associations 
between herbal supplement use and FMS diagnosis (controlling for potential health factors, 
demographic variables, and lifestyle factors) and potential changes in patterns of herbal use in this 
population over time.   
Objective 2.1. Determine if those with a diagnosis of FMS were more likely to use herbal  
supplements than those without FMS in 2007 and 2012.  
Hypotheses 2.1. Those with a FMS diagnosis will be more likely to use herbal supplements than  
those without fibromyalgia syndrome in both 2007 and 2012.    
Objective 2.2. Determine if the prevalence of herbal supplement use among those with FMS  
diagnosis changed between 2007 and 2012.  
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Hypothesis 2.2. Prevalence rates for herbal supplement use will increase over time among those   
with FMS.    
   
Specific Aim 3   
Using a newly developed pain survey instrument, explore the patterns and correlates of herbal  
medicine use in a sample of WV pain patients, including potential variation by pain  status.    
Objective 3.1. Assess potential correlates of herbal medicine and other CHAs used in northern West 
Virginia (WV) pain patients, through the use of our recently established and pilot-tested pain survey 
utilizing a theoretically-guided novel CHA/herbal medicine measurement tool   
Hypothesis 3.1. Herbal medicine used for pain in Northern WV will be significantly associated with 
a variety of demographic, lifestyle, and health factors, including the use of other complementary 
health approaches and many health conditions.   
Objective 3.2. Provide a list of patient-reported herbal identification, with accompanying 
frequencies  
Hypothesis 3.2. Northern WV pain patients will report a variety of herbs used for pain management  
  
The three specific aims/studies listed above correspond to chapters two, three, and four. Chapter 
5 presents a summary of key findings of these studies, strengths, limitations, potential public health 
implications as well as potential direction and recommendations for future research.   
To our knowledge, no research has investigated inflammation as a potential mediator between 
herbal use and chronic pain, nor characterized varying levels of pain as a motivator for herbal medicine 
use.  Additionally, no research (to our knowledge) has attempted to quantify the herbs potentially used in  
Appalachian folk medicine for pain   
The Institute of Medicine stresses the importance of increased research into the translation of 
effective treatments into practice and into the occurrence and cost of pain (6).  Each aim of this 
dissertation will use cross-sectional data to enhance our understanding of the prevalence, patterns, and 
correlates of the herbal medicine use among those with chronic pain.  This information will help inform 
practitioners working with chronic pain populations, will lay the groundwork for additional exploration 
regarding the role of inflammation in chronic pain, identify new and potentially safer treatments for pain 
management, and may form the foundation for larger survey studies, future prospective studies, and 
clinical trials.    
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CHAPTER 2: The association of Fibromyalgia to serum C-reactive protein in a large 
Appalachian population  
  
Introduction   
   
   Chronic pain, defined as ongoing or recurrent pain that extends beyond the usual course of acute illness 
or injury for at least three to six months, is debilitating and costly. Over 20% of adults experience chronic 
pain at some point in their lives (3). Fibromyalgia syndrome (FMS) is a rheumatologic chronic pain 
syndrome affecting approximately 0.5-5% of populations in developed countries (7), including 1.75% of 
those in the U.S. (8). FMS is characterized by a constellation of somatic symptoms that are typically 
present in addition to widespread pain (e.g., fatigue, sleep disturbance, memory, and mood problems), for 
which no clear cause can be found (9). FMS is typically accompanied by morning stiffness, and 
sensitivity to loud noises, bright lights, and temperature extremes; women with FMS often report painful 
menstrual periods (13). Although FMS affects both sexes and people of all ages, the majority (80-90%) 
have been Caucasian (13, 14) middle-aged women (13). Family members of FMS patients are at a higher 
risk for FMS (15); the cause is unknown.   
While the etiology of FMS remains poorly understood, the widespread pain of FMS is thought to 
reflect abnormal central nervous system sensory information processing, with altered function in pain 
pathways and neuroendocrine disturbance (9); Inflammatory processes may also play a significant role in 
the pathogenesis of FMS (283). Although several MicroRNAs have been associated with FMS and 
symptom severity (19), diagnosis of FMS remains challenging, and there are currently no definitive 
diagnostic laboratory tests for the disease (18).  
C-reactive protein (CRP), previously considered a biomarker of underlying infection or tissue 
injury (237), is now also believed to reflect chronic systemic inflammation (240). CRP is considered a 
reliable proinflammatory biomarker (237) and is often included as part of the diagnostic laboratory 
workup for many rheumatological conditions (237). While CRP is often included in the diagnostic 
workup for FMS, the relationship of CRP to FMS has not been clearly established.  
Inflammation, as a characteristic reaction of tissues to injury or disease marked by physical 
swelling, redness, heat, and pain upon clinical examination, is not a classical symptom of FMS (18). 
Inflammatory cytokines promote the development of contralateral hyperalgesia (an extreme, exaggerated 
reaction to pain) and allodynia (central pain sensitization following painful, often repetitive stimulation) 
(33). FMS is typically characterized by both (34), and most (35-49), but not all recent studies (43, 50) 
have suggested a possible link between systemic inflammation and FMS. Of these, five studies measured 
CRP (44, 48, 49, 51, 284); four suggested a positive association between CRP and FMS (44, 48, 49, 284).  
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However, to date, only one large, cross-sectional, population-based study has examined the association of 
CRP to FMS (48). The study excluded women, and combined FMS with other pain syndromes, rendering 
assessment of the specific relationship between CRP and FMS difficult.   
Moreover, to our knowledge, no studies to date examining the association of CRP to FMS have 
investigated the potential mediating effects of sleep or mood disturbance, factors linked to both elevated  
CRP levels and FMS (285-288). Few have assessed the influence of elevated BMI (287,  
289),comorbidities, and other correlates (290). This large, population-based study will fill the gaps in our 
understanding of the potential influence(s) of mood, sleep, BMI, and comorbid conditions on the 
relationship between CRP and FMS.   
In this study, we investigated the relation of serum CRP levels to FMS in a large population of 
Appalachian adults. We hypothesized that CRP serum levels would be significantly and positively 
associated with diagnosed FMS after adjustment for potential confounding factors.    
  
   
   
Methods   
   
Data Source   
This cross-sectional study used data from the C8 Health Project, which was conducted as part of 
the settlement of a class-action lawsuit stemming from drinking water contamination by  
Perfluorooctanoic Acid (PFOA) released from the DuPont Washington Works Plant near Parkersburg,  
WV, USA (291). Data collection was conducted in 2005-2006 on individuals living or working in 6 
PFOA-contaminated public water districts in West Virginia (WV) and Ohio (including those exposed to 
contaminated private-well drinking water) since 1951; a total of 69,030 individuals participated in the 
study, including 81% of eligible adults (291). Project data collection was administered by an independent 
company, Brookmar, Inc. (Parkersburg, WV), and was conducted under the authority and supervision of 
the Wood County, WV, Circuit Court. Participants completed a comprehensive health questionnaire and 
volunteered a blood sample after completing individual consent forms for both. Demographic data and 
health survey completion were verified by trained project staff (291). Project procedures, blood 
processing and assay methods, along with quality-assurance measures, have been described in detail 
elsewhere (291). Briefly, following collection of each blood sample, serum was separated from red blood 
cells into single-use aliquots by centrifusion, and was refrigerated at individual data collection sites until 
daily pickup from a large, independent, accredited clinical diagnostic laboratory (LabCorp, Inc., 
Burlington, NC, USA). Samples were transported to a regional processing center (LabCorp, Inc.,  
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Columbus, OH) where they underwent analysis by latex immunoturbidimetry on a COBAS Integra 800 
(Roche, Germany). The West Virginia University (WVU) IRB permitted access to the de-identified data 
by WVU investigators. Demographic, lifestyle, and health characteristics were determined via self-report; 
diagnoses of certain disorders, including diabetes and cardiovascular diseases, were further verified via 
chart review.   
  
Study Population  
Our analysis excluded participants who were missing data on age or <18 years of age (n= 12471, 
18.1%), pregnant (n = 640, 1.1%); those reporting a cancer diagnosis and receiving treatment for 
diagnosed cancer other than non-melanoma skin cancer (n = 437, 0.77%) to eliminate potential bias 
introduced by varied CRP levels as a result of chemotherapy treatment; those with service-related 
disabilities (n= 710, 1.3%); and those who did not complete both the survey and blood work (n= 468, 
0.83%). Participants with extreme body mass index (BMI) values (<10.5 and >60.0) were also excluded 
to eliminate potential information bias (n= 94, 0.17%). Further exclusion of persons with missing data on 
CRP and FMS (n = 40, 0.002%) and other covariates of interest (n = 1673, 3.1%), with the exception of 
covariates for which missing data on >10% of participants occurred (for which a ‘missing’ category was 
included in analysis), yielded a final study sample of 52,535, including 51,410 FMS-free controls and 
1,125 adults with FMS (Figure 1).  
   
Variables   
Outcome Variable. Our primary, dichotomous outcome variable was FMS diagnosis, which was 
ascertained via self-report response to the question “Have you ever been diagnosed with Fibromyalgia?” 
Exposure Variable. Our primary exposure variable was serum level of inflammatory marker CRP 
(mg/L).  C8 Health Project coordinators recoded CRP values below the level of detection to 50% of the 
lowest level (i.e., “<0.3”→0.15).  Likewise, values above the level of detection were recoded to 50% 
above the maximum level.   
Covariates. In addition to age, gender, race, education, employment, marital status, income, alcohol or 
tobacco use, and exercise program status, comorbid conditions were also selected a priori as covariates if 
known or suspected to be associated with FMS and/or CRP. These included BMI (21), autoimmune 
conditions (22), osteoarthritis (23), kidney (24), respiratory (25), cardiovascular (24), liver (26), and 
endocrine (24) disease, diabetes (27), severe allergies (24) and sinus disease (28), stomach conditions (24, 
26), and headache (29). PFOA serum level and reproductive factors (292) were also examined as 
covariates.   
    25  
Potential mediating and modifying factors. Potential mediating and modifying factors included fatigue, 
sleep impairment (26), mood disturbance (24, 26, 286), age (13), gender (13), obesity (289), tobacco use 
(293), statin use (294), and reproductive factors (292).  
   
Statistical Analysis    
We conducted complete-case analyses using SAS 9.4 (Cary, NC, USA). Logistic regression 
analyses were used to evaluate the independent association of CRP level to FMS status, and to assess the 
influence of potential confounding, mediating, and modifying factors. The primary explanatory variable 
of interest, CRP, was analyzed as a continuous and categorical variable (study population quartiles, with 
the lowest percentile group used as the referent). Linear trends for CRP quartiles were assessed using 
polynomial contrasts. Differences between participants missing any data were assessed using logistic 
regression. Cox-Snell R2 values measured the predictive power of models. All p-values shown are 
twosided.  
All demographic characteristics, in addition to lifestyle factors significantly differing by FMS, 
were controlled for in multivariate models. BMI was categorized using the National Institutes of Health 
clinical classifications (scores of <25=‘Underweight or Normal weight’; 25 – 29.9=‘Overweight’; 30 –  
34.9=‘Obese Class 1’; and, 35+=‘Obese Classes 2/3’) (295).   
We evaluated the influence of both specific comorbid conditions and total number of comorbid 
conditions on the relation of CRP to FMS. A comorbidity index was created based on number of chronic 
comorbid conditions reported; these included: autoimmune disorders (defined as having any diagnoses of 
immune disease, lupus, or rheumatoid arthritis), osteoarthritis, allergies or frequent sinusitis, kidney 
disease, respiratory conditions (asthma, emphysema, chronic obstructive pulmonary disorder, bronchitis), 
heart disease, liver disease, endocrine disorders (thyroid, Addison’s, or Cushing’s disease), diabetes, or 
frequent headaches. This index was evaluated as both a continuous and categorical variable (‘none’, ‘1 
comorbidity’, 2 comorbidities’, and ‘3+ comorbidities’).  
We assessed potential mediating influences of sleep impairment and mood disturbance. A 
composite sleep quality variable, with higher scores indicating poorer sleep quality, was derived from 
responses to individual questions regarding the frequency of short sleep, fitful sleep, insomnia, and/or  
daytime somnolence (scored as follows: 3=’frequently’, 2=’sometimes’, 1=’rarely’, and 0 =’never’, for 
each). Mood disturbance was also assessed as a composite variable from responses to four individual 
questions, with higher scores indicating frequent mood swings, irritability, fatigue, and/or inability to 
concentrate (where 3=’frequently’, 2=’sometimes’, 1=’rarely’, and 0 =’never’).  
Additionally, we assessed the potential modifying influence of age (<45 vs. >45 years), tobacco 
use (‘current’/‘not currently using tobacco’), gender, obesity (BMI<30 vs. ≥30) current menstruation 
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(yes/no), menopausal status (peri- or post-menopausal/premenopausal), statin use (yes/no), and sleep 
impairment and mood disturbance (scores of <6 vs.>6, respectively) on the association between CRP and 
FMS.    
We also conducted separate ancillary analyses adjusting for statin use (yes/no), PFOA serum 
level (ng/mL, evaluated as quartiles), and reproductive characteristics (women only) to determine the 
potential confounding influence of these factors on any observed association between CRP and FMS.  
Reproductive factors assessed included menopausal status (‘pre-menopausal,’ ‘peri-or post-menopausal,’ 
or ‘unsure’), parity (number of pregnancies), and age at menarche (‘16+ years of age’/‘other age or 
unsure’).   
The first regression model assessed the crude association of CRP levels to reported FMS 
diagnosis. The second model was adjusted for demographic and lifestyle covariates, while additional 
models adjusted for BMI and comorbid conditions, as well as sleep and mood disturbance (separately and 
combined, respectively). We conducted additional analyses to evaluate the potential confounding 
influence of statin use, PFOA serum level, and (in female participants) reproductive history (i.e., 
menopausal status, age at menarche, and parity).   
The potential mediating effects of BMI and comorbid conditions, as well as sleep impairment and 
mood disturbance were examined using separate logistic regression models. We also conducted ancillary 
analyses excluding autoimmune disorders. To evaluate the potential modifying effects of age, smoking, 
gender, obesity, current menstruation, menopausal status, statin use, sleep impairment, and mood 
disturbance, we conducted multivariable analyses; interactions were assessed by including the 
corresponding multiplicative-interaction term in the statistical models.   
  
Results   
  
Relative to participants with complete data, those with missing data on key covariates had a 
higher number of comorbidities and were more likely to be poorly educated or to be retired, disabled, or 
unemployed (p’s ≤.002), but did not differ in other factors. Demographic and lifestyle characteristics are 
displayed in Table 1. Study participants were predominantly white (97.2%), female (52.4%), and married 
or cohabitating (68.9%). Participant age ranged from 18.0 to 105.2 years, averaging 45.3 (SD = 16.1) 
years. Most participants were employed or students (64.1%) and overweight (69.0% BMI>25, mean BMI  
= 28.5, SD = 6.3), while nearly half did not currently consume alcohol (51.1%) and never smoked 
(43.5%). CRP serum levels varied from 0.15 to 250.6 (mean CRP level = 3.79, SD = 7.2) mg/L.  
FMS was present in 2.1% of the study population (n = 1125). After adjustment for demographic 
and lifestyle factors, the odds of FMS increased 2% for every year-unit increase in age (Adjusted odds 
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ratio (AOR) = 1.02, 95% confidence interval (CI): 1.02, 1.03 (Table 1)), with a significantly higher mean 
age among FMS cases (M = 51.1, SD = 11.6) compared to controls (M = 45.1, SD = 16.2). Those aged 
45-64 years were 8.3 times more likely (AOR = 8.28, CI 4.91, 13.95) than those in the age group 18-24 
years to have FMS. Those with FMS were nearly 11 times more likely to be female (AOR = 10.68, CI 
8.53, 13.37). Participants who were employed or students were less likely to have FMS than all others, as 
were those with <12th grade education, compared to those with higher educational attainment. Relative to 
participants who were married or cohabitating, those who were single were almost 40% less likely to 
report a diagnosis of FMS (AOR = 0.63, CI 0.47, 0.84). Participants who reported current consumption of 
alcohol were slightly less likely to report a diagnosis of FMS (35.8% vs. 49.2%, respectively; AOR = 
0.86, CI 0.75, 0.98), and women who had experienced menopause were about 80% more likely to have an 
FMS diagnosis compared to pre-menopausal women (AOR = 1.82, CI 1.49, 2.21).  
Health characteristics of the study population are detailed in Table 2. Mean BMI was 
significantly higher among FMS cases (M = 30.47, SD = 7.2) than controls (M = 28.49, SD = 6.3), and 
was significantly and positively associated with FMS after adjustment for demographic and lifestyle 
factors (AOR per unit BMI increase= 1.02, CI 1.01, 1.03). Relative to those with a BMI <25, participants 
who were obese were significantly more likely to have FMS (AOR = 1.24, CI 1.02, 1.49; and, AOR = 
1.43, CI 1.18, 1.74, for BMI 30-35 and BMI >35, respectively). There was a 60% increase in FMS 
diagnosis for each additional comorbidity (AOR = 1.60, CI 1.54, 1.67 (Table 2); participants reporting a 
diagnosis of 3 or more comorbidities were 10.5 times more likely to have FMS (AOR = 10.46, CI 7.90, 
13.84) compared to those with no comorbidities. FMS was likewise strongly and positively associated 
with most chronic conditions evaluated, including in order of decreasing magnitude osteoarthritis (AOR = 
3.86, CI 3.34, 4.45), autoimmune disease (AOR = 3.43, CI 2.89, 4.06), allergies/chronic sinusitis (AOR =  
2.91, CI 2.51, 3.38), frequent headaches (AOR = 2.03, CI 1.78, 2.31), and kidney (AOR = 1.72, CI 1.47, 
2.01), respiratory (AOR = 1.89, CI 1.64, 2.17), endocrine (AOR = 1.82, CI 1.57, 2.12), and liver (AOR =  
1.51, CI 1.06, 2.16) diseases.   
FMS cases reported higher sleep (M = 7.3, SD = 3.3 vs. M = 3.9, SD = 3.5) and mood disturbance 
scores (M = 7.3, SD = 3.4 vs. M = 4.5, SD = 3.7) than did controls (Table 2). After adjustment for 
demographic and lifestyle factors, FMS remained strongly and positively related to scores for both sleep 
(AOR = 1.23, CI 1.21, 1.25), and mood disturbance (AOR = 1.19, CI 1.17, 1.21).  
Relation of CRP to FMS. Mean CRP (mg/L) was significantly higher among FMS cases (M = 5.54, SD 
= 9.8) compared to controls (M = 3.75, SD = 7.2) (Table 3). CRP serum level showed a positive 
association with FMS (unadjusted OR for highest vs. lowest quartile = 2.50, CI 2.10, 2.97; P for trend 
<.0001); adjustment for demographic and lifestyle factors substantially attenuated but did not eliminate 
this association (AOR for highest vs. lowest quartile = 1.35, CI 1.13, 1.62; P for trend <.0001). Analysis 
of CRP as a continuous variable yielded similar findings, with odds of FMS increasing by 2% for each 
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one mg/L of CRP rise (unadjusted OR = 1.02, CI 1.01, 1.02); adjustment for demographic and lifestyle 
factors slightly attenuated this association (AOR = 1.01, CI 1.00, 1.01).   
The addition of BMI and comorbidities to the model further weakened the relationship between 
CRP and FMS (AORs for highest vs. lowest CRP quartile = 1.17 (CI 0.96, 1.42) and 1.10 (CI 0.92, 1.32), 
for BMI and comorbidities, respectively; and, combined OR = 1.07 (CI 0.88, 1.30)) suggesting that these 
factors may at least partially explain the observed associations (Table 3). The inclusion of mood 
disturbance and sleep impairment, separately and combined, only slightly attenuated the association of 
FMS to CRP after adjustment for demographic and lifestyle factors (AOR = 1.01, CI 1.00, 1.01) (Table 
4). These findings suggest that any mediating effect of these factors was modest.    
Additional adjustment for statin use, PFOA, and female reproductive characteristics (menopausal 
status, age at menarche, and parity) did not appreciably change the relationship between CRP and FMS.  
Similarly, exclusion of those with rheumatoid arthritis and other autoimmune conditions did not 
appreciably affect risk estimates. Likewise, we found no evidence for a modifying effect of age, tobacco 
use, gender, obesity, menopausal status, or other factors on the relationship between CRP and FMS.   
  
Discussion   
   
This is the first large, population-based investigation to examine the relationship between CRP 
and FMS, to assess the potential influence of BMI and comorbid conditions on this relationship, and to 
evaluate the potential mediating role of mood and sleep impairment. In this cross-sectional study of a 
large Appalachian population, CRP serum level showed a positive association with FMS, which remained 
significant after adjustment for multiple demographic and lifestyle factors, including age, gender, 
education level, employment, marital status, alcohol, and tobacco use. Adjustment for BMI and comorbid 
conditions substantially attenuated this relationship. These findings are broadly consistent with those 
from a recent cross-sectional investigation of 5110 Norwegian men; cases with FMS/Chronic Pain 
Syndrome showed a strong, positive relationship to high sensitivity-CRP level (OR for >10 mg/L vs. <1 
mg/L = 2.6, 95% CI: 1.4, 4.6, p = .002; P for trend = .006) after adjustment for age, education, smoking, 
and cholesterol medication (48). In contrast, as stated in the introduction, findings from smaller 
casecontrol studies examining the association between CRP and FMS have been inconsistent (44, 46, 49, 
51), perhaps due to varying sample sizes and differing selection criteria among controls; of the four 
casecontrol studies published to date, only one reported significantly higher CRP levels in FMS patients 
compared to healthy controls after adjustment for age, sex, and race (44).  
As indicated above, the inclusion of BMI in our model substantially attenuated the association of 
FMS to CRP, suggesting BMI may have largely explain the elevated CRP levels in FMS; this was second 
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to the inclusion of comorbidities. Only one study to date has considered the potential contribution of BMI 
to the profile of CRP in FMS, with a strong and positive correlation (44). Ours is the first study to assess 
the contribution of multiple comorbidities on the relation of CRP and FMS. Additionally, in agreement 
with our study, others have suggested a mediating effect of BMI on the relation between CRP and FMS; 
FMS symptom improvement has followed weight loss among several FMS cases (296), and a 
longitudinal study revealed regular exercise and maintenance of body weight lowered the risk of FMS 
(297). Additionally, one case-control study found that after adjustment for demographic factors, BMI was 
the only significant contributor in a model exploring the relation between CRP and FMS (r = .062, p <  
0.001) (44).   
  Comorbidities characterized by pain may contribute to the development of FMS; shared pain 
mechanisms between FMS and other conditions with a similar underlying pathophysiology (e.g., tension 
headache) or as a comorbidity characterized by inflammation or ongoing peripheral damage (e.g., 
autoimmune disorders and osteoarthritis) and FMS have recently been explored (9, 23, 298). Our study 
found that as the number of comorbidities increased, the odds of FMS increased as well.    
Additionally, the presence of sleep impairment and mood disturbance modestly attenuated, but 
did not eliminate, the association between CRP and FMS. No existing studies have examined the role of 
sleep impairment on this relationship. We found no evidence supporting mood disorder as an effect 
modifier, similar to a study finding where CRP level did not differ by psychiatric status among those with  
FMS (47). The influence of sleep impairment and mood disturbance on the relation between CRP and 
FMS in our study likely reflects a bidirectional relationship.   
The prevalence rate of FMS in our study (2.1%) mirrored recent estimates for the U.S. population 
(8, 299). Consistent with previous studies, we found the likelihood of FMS diagnosis was increased in 
middle-aged females (8, 13). However, in contrast to findings from two large studies (8, 300), those who 
were married or reported higher levels of education were more likely to report FMS.  Females who had 
experienced menopause were 1.8 times more likely to have FMS than those who had not; however, a lack 
of epidemiological research exists in the topical area of sex hormones, neurotransmitters, and FMS. We 
observed no significant association between age at menarche or parity and FMS, unlike a German 
casecontrol study of 653 middle-aged women (FMS cases = 36) which found, after controlling for age, 
those with FMS had significantly later menarche and were less likely to have ever been pregnant (301).   
In agreement with previous cross-sectional and longitudinal studies (8, 297, 302), BMI was 
strongly and positively related to reported FMS in this large Appalachian population. Additionally, higher 
BMI has been associated with an increased risk of FMS after adjustment for mood and/or other health 
factors (8, 297), including familial FMS diagnosis (302). Likewise, consistent with findings from a recent 
cross-sectional study of a nationally representative sample of U.S. adults (N = 8446, FMS cases = 201) 
(8) FMS showed significant positive associations to multiple comorbid conditions in our study after 
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adjustment for demographic and lifestyle factors; these included cardiovascular disease, rheumatoid 
arthritis and other autoimmune disorders, kidney, respiratory and liver diseases, and frequent headache. 
Osteoarthritis was also associated with a nearly 4-fold likelihood of FMS, dissimilar from a large, 
national analysis of U.S. electronic medical records (N = 587961, FMS cases = 4296) of only a 
(unadjusted) 2-fold likelihood (303). In contrast to other large studies of U.S. adults (8, 303), diabetes 
was not associated with FMS in this sample of Appalachian adults.    
The strengths of this study were its high response rate, population-based design, and large sample 
size; this was the largest comprehensive community study conducted to date in the Appalachian region.  
We were able to control for a large number of potential confounders, including comorbid conditions.  
Misclassification of CRP was unlikely due to standardized assay procedures used.   
This study targeted a population of predominantly white Appalachian adults, potentially limiting 
generalizability. Possible misclassification of FMS may have occurred depending on time the participant 
was diagnosed and the physician’s awareness and use of the American College of Rheumatology 
classification criteria for FMS first established in 1990. In particular, poor or incomplete recognition of 
FMS by healthcare providers may have led to under-ascertainment (304). However, such 
underascertainment would be expected to bias the observed associations toward the null. FMS, in addition 
to most other assessed health conditions, was based on self-report, possibly leading to response or 
misclassification bias. To our knowledge, no clinical validation study has assessed the agreement between 
self-report and medical record-verified data on FMS.   
Unmeasured confounding may have also contributed to our findings, although our ability to 
control for a large number of both known and potential risk factors for FMS diminishes this possibility. 
Our study also lacked specific information on certain conditions previously linked to FMS, including 
sleep apnea and irritable bowel syndrome. Although contact with former residents of counties used for 
study inclusion was attempted, some may not have participated in the study, possibly introducing 
sampling bias. Lastly, we cannot draw any conclusions regarding causality due to the lack of a temporal 
component in our cross-sectional study design.  
   
Conclusion   
   
In this large cross-sectional study of Appalachian adults we observed a significant, positive 
association between serum CRP and diagnosed FMS, which was largely explained by elevated BMI and 
chronic comorbid conditions. Adjustment for sleep and mood disturbance only modestly attenuated this 
association, suggesting that BMI and chronic comorbid conditions may largely account for elevated CRP 
levels among FMS patients over the presence of sleep and mood disturbance. Further prospective 
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research is needed to determine the relation of CRP and other inflammatory markers to the development 
and progression of FMS, and to clarify the potentially complex role of obesity and comorbidities, in the 
potentially causal pathway between inflammatory markers and FMS.     
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CHAPTER 3: Prevalence Trends and the Association between Herbal Supplement Use and 
Fibromyalgia Syndrome in two National Samples (2007-2012)    
  
Introduction   
   
Fibromyalgia syndrome (FMS) is a rheumatologic chronic pain syndrome affecting 
approximately 0.5-5% of populations in developed countries (7), including 1.75% of those in the U.S.(8). 
FMS is characterized by a constellation of somatic symptoms that are typically present in addition to 
widespread pain (e.g., fatigue, sleep disturbance, memory, and mood problems), for which no clear cause 
can be found (9). Additionally, those with FMS also experience high rates of comorbidity, such as 
autoimmune disease (22), osteoarthritis (23), kidney (24), respiratory (25), cardiovascular (24), liver (26), 
diabetes (27), stomach conditions (24, 26), and headache (29). Although FMS affects both sexes and 
people of all ages, the majority (80-90%) of cases occur in Caucasian (13, 14) middle-aged women (13).  
Chronic pain, such as that accompanying FMS, is difficult to manage; this is partially due to 
limited efficacy of conventional pharmaceutical therapies and the significant side effects associated with 
these medications. In addition, although specific clinical criteria for FMS, first developed by the 
American College of Rheumatology (ACR) in 1990, have been in effect for over 25 years, many 
physicians remain unfamiliar with FMS and FMS treatment (305).  Therefore, many FMS patients have 
experienced difficulty in receiving diagnosis and consistent care for their symptoms, particularly before 
less constrictive ACR criteria were introduced in 2010 (306), which additionally gauges impact of FMS 
upon quality of life through the use of an impact score (17).  
Although there is no evidence of efficacy for opioids as treatment for FMS (18, 75), more than 
80% of FMS patients receive opioid therapy (63). Some physicians are reluctant to prescribe opioids (6), 
while others overprescribe them (85), even though prescription drug overdose deaths involving opioids 
(using age-adjusted data) have more than quadrupled since 1999 (84). People with FMS are also typically 
treated with antidepressants (54), muscle relaxants (11), as well as other pain (54) and sleep medicines 
(11). Drugs commonly used off-label to treat FMS include Gabapentin (56), Fluoxetine (57), Pramipexole 
(57), Amitriptyline (54), and Tramadol plus Paracetamol (57), among others (307); all carry significant 
side effects. Although three drugs (Anticonvulsant Lyrica/Pregabalin, and Serotonin-norepinephrine 
reuptake inhibitors Cymbalta/Duloxetine (58, 59) and Savella/Milnacipran) have been approved by the 
FDA for FMS treatment, they also carry significant side effects (57, 60, 61), and the mechanisms by 
which these drugs alleviate FMS symptoms is unknown. For some FMS patients, these drugs are not 
effective (11). Chronic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are also given as treatment for 
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some pain symptoms (18), but likewise carry significant side effects for as many as 25% of long-term 
users (62).    
Complementary Health Approaches (CHAs) (formerly referred to as ‘Complementary and  
Alternative Medicine’, or ‘CAM’ by the National Institute for Complementary and Integrative Medicine) 
are medical and health care systems, practices, and are often used by those with chronic pain(308). The 
ACR suggests people with FMS consider non-drug treatments in addition to their pharmaceutical 
approaches, and that certain CHAs may be helpful in managing FMS symptoms. Many of these 
treatments, including herbal dietary supplements, have not been well tested in FMS patients for safety 
and efficacy (76-78).  Although CHA use is popular in the U.S., patients often do not disclose their use of 
CHAs to their physicians (97, 98), largely because the role of CHA in chronic pain management remains 
controversial.  Physicians disagree with one another and with their patients about the cost, validity, and 
effectiveness of individual CHAs (99).  The use of CHA use may reflect greater autonomy patient 
populations who are less dependent upon conventional medicine and wish to direct their own health care  
(88); some patients also use CHAs due to concerns over the safety of conventional medicine (100). 
Compared with nonusers, CHA users tend to be women, white, middle-aged, of higher income, and 
better-educated (90, 106, 110-116).    
In the United States, 30-60% of the general population use CHAs (88), and in 2007, about $14.8 
billion was spent on the purchase of non-vitamin, non-mineral, natural CHA products (109).  According 
to the 2012 National Health Interview Survey (NHIS), which included a comprehensive survey on the use 
of CHAs in the U.S., 17.7% of adults had used a dietary supplement other than vitamins and minerals in 
the past year, making these products the most commonly used CHA for which data were available (104); 
these supplements included herbal products (Image 1) Consistent with these findings, systematic reviews 
of population-based studies in U.S. adults (2001-2012) indicate 18.1% of the general population used 
herbal medicine (109, 116, 118, 137-165). Echinacea, Ginseng, Ginkgo, and Garlic were the most 
common natural products among adults in 2007 (161).  
 ‘Herbs’ (plant-derived products also known as ‘botanicals’ or ‘biologically based therapies’) are 
often sold as dietary supplements and are part of the broader CHA group of approaches called ‘Natural 
Products’, which also include (non plant-derived) vitamins and minerals. The use of herbs for potential 
health benefit is called ‘herbal medicine use’ or ‘phytomedicine’ and is part of many ‘folk medicine’ 
traditions.  Many herbs have been documented to have anti-inflammatory action (in vitro and in vivo) 
(123, 223, 225-227, 233, 241-265, 271), and anecdotal accounts demonstrate herbalists have 
recommended many herbs for the treatment of FMS and/or related symptoms such as pain (121, 179, 180, 
211, 216-219), rheumatism (121, 169, 178-180, 182, 191, 216-218), and arthritis (121, 169, 178, 179,  
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191, 212, 217, 218); others have been used for non-specific inflammation (121, 179, 180, 217, 218), sleep 
troubles (121, 169, 179), and for headache (179, 180, 217); it is not clear if these herbs continue to be 
used by those with FMS. A 2009 case-control study (FMS = 434) showed nearly half (42.9%) of those 
with FMS used herbs and other supplements; herbs used most often by those with FMS were Ginkgo 
(3.7%), Garlic (3.0%), Ginseng (3.0%), Echinacea (2.5%), Evening Primrose oil (2.3%), and Valerian 
(2.3%) (197).    
Pain-related disorders are the most commonly reported conditions for which patients use CHAs 
(86, 88, 93, 105, 106).  Those in the US most frequently use CHAs for back pain, neck pain, joint pain, 
and arthritis (161). However, investigations regarding the prevalence and correlates of herbal use in 
chronic pain populations remains limited, and even fewer studies have examined the relation of FMS to 
herbal use; one case-control study assessing this relationship combined herbal supplements with other 
natural products (197). Further, only one large study examined herbal use in a pain population receiving 
opioids (93), while UK population studies conducted over three decades ago examining similar chronic 
pain syndromes to FMS used small sample sizes (N<100).   
Further research on FMS and herbal use is clearly warranted given that FMS is poorly managed 
by current treatment options, and there is a national opioid epidemic; while previous studies suggest CHA 
use is popular, research regarding herbal use for pain remains limited, particularly before and after 
implementation of updated FMS diagnostic criteria.  We hypothesize that rates of herbal supplement use 
will differ between time points among those with FMS, and those with FMS will be more likely to use 
herbal supplements than those without FMS.    
   
Methods  
   
Data Sources  
In two nationally nationally-representative samples of 23,501 and 34,525 U.S. adults (the  
National Health Interview Surveys (NHIS), 2007 and 2012, respectively), we investigated if those with 
Fibromyalgia Syndrome (FMS) were more likely to use herbal supplements than those without FMS, and 
determined if prevalence rates for herbal supplement use among those with FMS significantly changed 
over a 5-year time period.  The NHIS is an annual national, cross-sectional household survey of the 
noninstitutionalized US population and is administered by the Centers for Disease Control and 
Prevention’s (CDC) National Center for Health Statistics.  An additional supplement (Adult Alternative 
Medicine) to the core individual, family, and household surveys in both years asked participants about 
use of a broad range of CHAs, including herbal supplements.  All questions were administered in a 
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personal interview format. Adult response rates to the NHIS were 78.3% in 2007 and 79.7% in 2012, 
respectively (309, 310).    
  The NHIS is the only national, public-use survey that includes comprehensive sets of questions 
regarding herbal and other CHA use. Both 2007 and 2012 surveys used a stratified multistage probability 
design weighted on age, sex, race/ethnicity; using 2000 and 2010 Census data for 2007 and 2012, 
respectively. Both surveys oversampled Asian, Black, and Hispanic persons, and the minority elderly 
population. Thus, each person in the covered population had a known non-zero probability of selection. 
These probabilities of selection, along with adjustments for nonresponse and post-stratification (defined 
as post-survey implementation stratification of the sample according to auxiliary information about the 
sampled population, similar to direct standardization) were reflected in the sample weights and complex 
survey procedures recommended by the CDC for our analyses.  Additional project details have been 
described elsewhere (310).  
  
Study population  
  Our analysis excluded participants who were <18 years of age, pregnant, senile, had a stroke and used a 
proxy to complete the interview, or had current cancer; those missing data on key covariates were also 
excluded, as were participants with extreme values for exercise (>6,000 minutes per week) in order to 
eliminate potential information bias; these were the only extreme values considered for exclusion. Further 
exclusion of persons with missing data on FMS and herbal use (at 30 days, 12 months, or ever using 
herbs) yielded final study samples of 20,127 and 30,672 adults for 2007 and 2012, respectively (Figure 
1).  
  
Variables  
Outcome Variables. The main outcome variables for 6 separately run analyses were (in three models for 
each of the two survey years) the use of herbal supplements within the previous 30 days, 12 months, and 
having ever used herbal supplements (all dichotomous variables); these included herbs in the form of 
pills, capsules, tablets (2007) or liquids (2012), and excluded herbal or green teas.  
Exposure Variable. Our main exposure was Fibromyalgia Syndrome (FMS) diagnosis, a dichotomous 
variable, which was self-reported as a previously diagnosed condition by a health professional.   
Covariates. Demographics lifestyle factors, health conditions, and related factors known or suspected to 
be associated with CHAs, herbal use, and/or FMS were considered a priori as potential covariates in 
multivariable models. Demographic factors assessed included age, gender, race/ethnicity, education, 
employment, income, marital status, geographic region, and place of birth. Additional related factors 
included insurance status, family out-of-pocket medical costs in the past year, and delay of care due to 
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concerns over cost. Lifestyle factors included smoking status, alcohol use, exercise, BMI (21), health 
status, and substance abuse. Health conditions included self-reported history of physician diagnosed  
diabetes (27), kidney disease (24), gastrointestinal disorder (24, 26), respiratory conditions (22),  
dyslipidemia, liver condition, Rheumatoid arthritis, Cardiovascular disease (24), hypertension, 
nonspecific arthritis (23), gout, migraines (29), mental health condition, insomnia, and previous cancer 
diagnosis.  These variables are described in greater detail below.  
Potential Effect modifiers. Gender (Male/Female) and number of health conditions (0-1/2+) were 
assessed for their potential influence on the relationship between FMS and herbal use.   
  
Statistical Analysis  
  
We conducted complete-case analyses using SAS 9.4 (Cary, NC, USA). We merged NHIS 
Family, Person, Household, Sample Adult, and Adult Alternative health files for each year, and measured 
sample characteristics, including frequencies and percentages/prevalence rates of herbal use (ever, past 12 
months, and past 30 days) for 2007 and 2012, respectively (using PROC SURVEYFREQ and PROC 
SURVEYMEANS); we extrapolated estimates to generate population frequencies using NHIS sampling 
weights. Weighted t-tests (PROC SURVEYREG) and Rao-Scott Chi-square tests were used to determine 
significant differences by herbal use status for three herbal use time points in both survey years; 
significant factors were included in final models, for which we assessed the influence of potential 
confounding factors. Weighted logistic regressions (PROC SURVEYLOGISTIC) were used to evaluate 
the independent associations of FMS diagnosis to herbal use in the last 30 days, the last 12 months, or 
ever. We also used a DOMAIN statement to keep our exclusions separate while maintaining the integrity 
of sampling weights. We used Chi-square and t-tests to determine significant changes between 2007 and 
2012 on weighted frequencies and means of all items, in addition to specific herbs used, herbal 
practitioner visits, physician disclosure of herbal use, and use of other CHAs; we considered trends 
between time points significant if there was no overlap in weighted percentage confidence intervals.  
Differences between participants missing any data were assessed using logistic regression. All p-values 
shown are two-sided at p < 0.05.  
For 2007 and 2012, we examined crude associations between FMS and herbal use at 30 days, 12 
months, and any previous use of herbs. Three additional models for each year adjusted for demographic 
and related covariates, followed by six total models additionally adjusting for lifestyle factors. Last, we 
additionally controlled for health conditions as well, in six (full) models.   
  Our models included demographic characteristics of age (evaluated as both continuous and in groups 
18-24, 25-44, 45-64, 65-74, and 75+ years), sex (Male/Female), race (defined as ‘Non-Hispanic White,’ 
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‘Non-Hispanic Black,’ ‘Hispanic,’ ‘Asian,’ and ‘Other’), education (a categorical variable defined as 
'<Some HS,’ ‘HS/GED,’ ‘Some college/AA/tech,’ and ‘Bachelor’s Degree+,’), employment (‘Employed 
for pay,’ ‘Employed but not for pay,’ and ‘Unemployed,’), income ($1 - $24,999; $25,000 -  
$44,999; $45,000 - $74,999; $75,000+; ‘Don't know’; and ‘Missing’), and geographic region  
(‘Northeast,’ ‘Midwest,’ ‘South,’ and ‘West’), and place of birth (U.S.-born/other), which were controlled 
for in a multivariate model first, as were related factors insurance status (separate categories ‘Uninsured,’  
‘Medicaid,’ ‘Medicare,’ ‘disability,’ and ‘private’), family out-of-pocket medical costs in the past year  
(aside from insurance premiums, deductibles, and/or co-pays) (‘None;’ <$500; $500-$1999; $2000- 
$2999; $3000-$4999; $5000 and over; and, ‘Don't know’), and delayed access to care because “could not 
afford” or “worried about cost” (yes/no). Marital status (evaluated as ‘married or co-habitating,’  
‘divorced/separated/ widowed,’ and ‘single’) was additionally controlled for in 2012 models. Models also 
controlled for lifestyle factors BMI (evaluated as continuous and categorical variables using the National  
Institutes of Health clinical classifications scores of <18.5 – 25 =‘Underweight or Normal weight;’ 25 –  
29.9=‘Overweight;’ 30 – 34.9=‘Obese Class 1;’ and, 35+=‘Obese Classes 2/3’) (295), tobacco use  
(defined as ‘current smoker,’ ‘former smoker,’ and ‘never smoked’), alcohol use (‘None,’ ‘Light,’ and  
‘Moderate to heavy’), substance abuse (other than tobacco or alcohol) in past year (yes/no), physical 
activity of at least 10 minutes per week (continuous and dichotomous as ‘Any’/’None’), and self-reported 
health status (‘Excellent/very good/good,’ ‘Fair,’ and ‘Poor’).    
  In our fully-adjusted models, we also evaluated the influence of both specific health conditions and total 
number of health conditions on the relation of FMS to herbal use. A comorbidity index was created from 
0-13 participant-reported conditions; these included history of 1) diabetes (27); 2) kidney disease (24); 3) 
gastrointestinal disorder (including history of ulcers, inflammatory/irritable bowel disease or constipation 
severe enough to require medication in the past year and/or (2012) abdominal pain, digestive allergy, 
and/or heartburn in the past year) (24, 26); 4) respiratory conditions (history of asthma or emphysema, 
and/or chronic bronchitis) (22); 5) dyslipidemia; 6) liver condition; 7) rheumatoid arthritis; 8) 
cardiovascular disease (coronary heart disease, angina, and/or heart attack) (24); 9) hypertension; 10) 
non-specific arthritis (23); 11) gout; 12) migraines (29); and, 13) mental health condition (depression, 
phobias, and/or often anxious in past year, and/or ever having bipolar disorder). We categorized this 
index as ‘No health conditions,’ ‘1 condition,’ 2 conditions,’ and ‘3 or more conditions’; Health 
conditions were evaluated both collectively (as continuous and categorical variables) and individually; 
insomnia in the past year or previous cancer diagnosis were also evaluated individually.    
  We assessed the potential modifying influence of gender and number of health conditions (0-1/2+) on 
the association between FMS and herbal use at each outcome time point and for each survey year; 
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interactions were assessed by including the corresponding multiplicative-interaction term in crude 
statistical models.   
  
Results   
   
Relative to participants with complete data in both survey years, those employed and with higher 
education were less likely to have missing data on key covariates (p’s ≤.0001). Those more likely to 
have missing data were underweight, older, and with poor reported health status (p’s ≤.0001); in  
2012, insured women were also more likely to have missing data (p ≤.0001). Participant age ranged from 
18 to 85 years, averaging 47.5 (SE = 0.25) and 48.5 (SE = 0.18) years for 2007 and 2012, respectively. 
In both survey years, study participants were predominantly white (72.2% and 69.5% for 2007 and 2012, 
respectively), female (53.1% and 53.5%), and insured (84.3% and 84.2%); most (56.4% and 57.9%) 
reported never smoking.  Nearly one-third of participants were overweight (mean BMI for 2007 BMI = 
27.3± 0.05; 2012 = 27.7± 0.04), and most (64% and 72.3%) reported at least one chronic health 
condition, with the number of chronic health conditions increasing from a mean of 1.5± 0.02 in 2007 to 
1.9± 0.01 in 2012.   
Demographic and lifestyle characteristics are displayed in Tables 1a (any previous use of herbs), 
2a (herbal use in past 12 months), and 3a (herbal use in past 30 days), while Tables 1b, 2b, and 3b display 
health characteristics, respectively. Those reporting herbal use (ever, and past 12 months) significantly 
decreased between 2007 and 2012 (p’s < .0001).  Those with any herbal use (ever) comprised 27.1% 
(2007 n = 5057) and 24.2% (2012 n = 7328) of population samples (Table 1a), with decreases in these 
prevalence rates for recent use of herbs (12 months: 2007 PR = 19.1%; 2012 PR =  
16.4%) (Table 2a); nearly 14% used herbs within the past 30 days (2007 PR = 13.9%; 2012 PR =  
13.9%) in both survey years (Table 3a).    
In 2012, fewer whites consumed herbs (ever, past 12 months) for health benefit compared to  
2007, while the Hispanic population increased their use (p’s = < .0001). Herbal users exercised more and 
smoked less in 2012 than in 2007 (p’s = < .0001).  Additionally, herbal use was associated with a 
significant increase in out-of-pocket costs in both survey years (p’s for trend = .0001; not shown); 
specifically, there was a significant increase in out-of-pocket costs over $3,000 among herbal users 
(ever, past 12 months) between time points. There was a significant decrease in privately-insured herbal 
users (ever), and an increase in herbal users (past 12 months) with Medicaid (p’s < .0001). All herbal 
users had significantly higher numbers of health conditions compared to non-herbal users in both 2007 
and 2012 (p’s for trend = <.0001; not shown). Rates of chronic pain conditions (including migraines, 
non-specific arthritis, gout, non-specific joint pain last greater than 3 months, and/or Rheumatoid 
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arthritis) and mental health conditions among herbal users (past 12 months, past 30 days) was also 
significantly higher in 2012 than in 2007 (p’s = <.0001) between time periods. Lastly, consumption of 
natural products increased among all herbal users between time points, while significant decreases 
occurred in those using herbs and reported ever using manipulative therapies/bodywork, as well as 
alternative medical systems (Acupuncture, Ayurveda, homeopathy, naturopathy) (p’s < .0001).  
  Prevalence of diagnosed FMS also increased significantly from 1.3% of adult participants in 2007 to 
1.7% in 2012 (p<.0001) (Table 4). However, consistent with overall trends in herbal use (Table 1a-3a), 
herbal use (ever) among adults diagnosed with FMS declined significantly from 2007 to 2012, decreasing 
from 57 to 41% (p <0.0001); however, there were no significant differences in the proportions of those 
with FMS using herbs in the past 12 months (42% to 31%) or 30 days (33% to 25%) (Table 4). There 
were no changes between time points in herbal use disclosure rates to physicians (64.6% within the past  
30 days in 2007 to 71.4% within past 12 months for “top herbal supplements used”) and number of 
different of herbal supplements taken in the past 30 days (2007 Mean = 0.99, SE = 0.20 vs. 2012 Mean =  
1.1, SE = 0.38; p = .89) among those with FMS.   
  
Relation of FMS to Herbal use. Nearly 60% of those with FMS had previous/current use of herbs 
(ever), while 42% used herbs in the past 12 months, and 33% used herbs in the past 30 days. 
Approximately 3% of herbal users (ever, past 12 months, past 30 days) had FMS in 2007 and 2012; this 
rate did not differ between time points (Table 5).  Relative to those without FMS, participants diagnosed 
with FMS were over three times as likely to use herbs for any length of time in 2007. After adjustment 
for demographic, lifestyle, and health factors, those with FMS were 2.7 times more likely to ever use 
herbs than those without FMS (Adjusted odds ratio (AOR) = 2.66, 95% confidence interval (CI): 1.85, 
3.82); this positive association remained when examining the association between FMS and recent herbal 
use as well (12 month and 30 day AOR’s = 2.25 (CI: 1.51, 3.35) and 2.34 (CI: 1.55, 3.52)). Likewise, 
FMS was significantly associated with all herbal use outcomes in 2012, although the magnitude of the 
associations were comparatively attenuated (2012 AOR’s: herbal use (all) = 1.59 (CI: 1.25, 2.03); 12 
month = 1.57 (CI: 1.21, 2.04); 30 days = 1.51 (CI: 1.15, 2.00)).   
  As illustrated in Table 6, we found evidence of a modifying effect of comorbidity only for the 
relationship between ever using herbs and FMS in 2007; the magnitude of the association of herbal use 
to FMS was significantly greater in those with 0-1 comorbid health condition than in those with 2 or 
more health conditions (OR’s, respectively= 4.67 (CI: 2.22, 9.81) vs. 2.80 (CI: 1.99, 3.92; p for 
interaction = .008); we found no evidence of a modifying effect of multiple comorbidities for either 
year, even after controlling for age. Additionally, we found no evidence for a modifying effect of 
gender on the relation between FMS and herbal use in either year.    
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Discussion   
   
Our study was the first large, population-based study to examine the relation of herbal use to 
FMS in any population, while controlling for a wide array of potential confounders and examining the 
modifying influence of comorbid conditions; it is also among the first rigorous studies to investigate the 
relation of herbal use to any chronic pain condition in a large sample. Relative to adults without FMS, 
those with FMS were significantly more likely to use herbs at 30 days, 12 months, or ever, in both 2007 
and 2012 survey years; these positive associations remained highly significant even after controlling for 
a broad array of demographic, lifestyle, and health-related factors.    
In our study, 60% of those with FMS had ever used herbs, while 42% used herbs in the past 12 
months, and 33% used herbs in the past 30 days. Studies assessing herbal use in FMS have not 
examined relationships as we did, but only reported frequencies of use; these ranged from 6.8% (in a 
large sample of Wisconsin primary care patients receiving opioids) to 78% (among 90 FMS patients in 
the UK) (93, 196, 197). However, these studies were limited by combining herbs with other natural 
products (14, 93, 196, 197, 311) in proportion estimates, and the wide variation in proportions likely 
arise from using different definitions for herbs and supplements. When examining herbal use in 
rheumatoid arthritis populations, 20% - 35% used herbal medicine; however, these small (N=78 and N 
= 94) studies were conducted over three decades ago (193-195).   
Prevalence of diagnosed FMS was significantly higher in 2012 compared to 2007 (1.7% vs. 
1.3%), which is slightly less than national estimates (1.75% of those in the U.S. (8)) but fits within 
prevalence ranges (0.5-5%) of developed countries (7); this apparent rise is likely due in part to increased 
recognition of FMS by physicians after updated 2010 ACR criteria, potentially enabling shorter patient 
waiting times to diagnoses than before.   
In contrast, we found reported herbal use among adults with FMS to decline significantly from 
2007 to 2012; this decrease may in part reflect the modest but significant reduction in overall herbal use 
observed between survey time periods. Additionally, the decrease in odds of herbal use in FMS may 
also reflect the availability of FDA-approved FMS treatments that became available in 2007, 2008, 
2009 shortly following implementation of the 2007 NHIS survey.   
It remains possible that both the increase in FMS diagnoses and the decrease in odds of herbal 
use for FMS over time are also in part perhaps the result of corporate promotion for FMS drugs, 
increased off-label use of other drugs for FMS, and potentially, increased opioid use for FMS. Between 
2007 and 2012, the mean number of different herbal supplements used by those with FMS did not 
differ, and both means (2007 mean = 0.99; 2012 mean 1.07) were lower than that of a 2009 North-
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American case-control study (FMS = 434, Control = 198) which showed those with FMS took ~ 2.8 
per person; however, this average was also combined with the use of all other natural products (197). 
Ours is the first study to document the rates of FMS in herbal users, which remained consistent at ~3% 
in both 2007 and 2012.   
The magnitude of the association between herbal use (ever) and FMS was significantly greater 
in those with 0-1 comorbid conditions in 2007 but not 2012. Although the possibility remains that this 
finding may indicate those diagnosed with FMS before 2007 were more likely to have used herbs in an 
attempt to exercise control over their health, since no FDA-approved treatments existed before 2007 
data collection (312). While it remains possible those with FMS managed their illness more successfully 
with herbs, resulting in fewer FMS comorbidities before FDA-approved treatments were made 
available, these findings should be interpreted with caution.  
Our ability to examine associations between herbal use and FMS in nationally representative 
samples that spanned two time periods comprehensive data on herbal use, as well as on many potential 
confounders, including demographic, lifestyle, health-related, and other factors, are major strengths of 
our study.  
However, there were some limitations, including inadequate capture of certain herbal products. 
No data were available on consumption of herbal teas used for health purposes or on other herbal 
products not labelled as a “dietary supplement”, including traditionally prepared herbal creams, 
tinctures/extracts, and powders, or products (with different labelling than that specified by the NHIS) 
that are sometimes recommended by herbalists over widely-available supplements due to quality and 
processing concerns. Additionally, many of the CHAs were only assessed in NHIS if they were 
administered by a practitioner (e.g., massage therapy, deep breathing only as part of other guided 
meditation practice, etc.). Our estimates for herbal use and other CHAs are likely underestimated due 
to misclassification of herbal use by the additional inclusion of non-herbal products including 
coenzyme Q-10, fiber, SAM-e, fish oil, and prebiotics/probiotics in the NHIS.  
Additionally, the 2012 questionnaire differed substantially from 2007. Based on cognitive testing 
and input from expert panels, the definitions of certain modalities were modified between years to reduce 
false-positive responses (313), which may have affected findings.  However, these changes were 
relatively minor and are unlikely to impact our estimates.  
Given the high prevalence rates of those with FMS using herbs (as indicated through positive 
associations with all herbal use outcomes), additional observational studies are needed to explore 
potential impacts of herbal use on a variety of chronic pain conditions, in order provide rationale for 
clinical trials on potential herbal therapies for other poorly-managed chronic diseases. Future 
observational research should continue to examine patterns of herbal use, and clinical research should 
also examine the safety and efficacy of herbs.  
    42  
Conclusion   
   
In this large cross-sectional study of two nationally representative samples of US adults, 
reported diagnosis of FMS was strongly and positively associated with any duration of herbal use in both 
2007 and 2012 after adjustment for demographic, lifestyle, and health factors; As a result of this study, 
we have an increased understanding of the patterns of herbal use prior to and following the 
implementation of an update to FMS diagnostic criteria and increased availability of treatments for a 
disease characterized by chronic pain. Rigorous prospective studies are needed to confirm these 
findings, to further explore the patterns and determinants of herbal use in other chronic disease 
populations.   
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CHAPTER 4: Correlates of Herbal Use and other Complementary Health Approaches among 
Appalachian Pain Patients      
Introduction   
   
Over 20% of adults eventually experience chronic pain (2, 3), and as many as 100 million 
individuals are affected in the United States alone (4).  The International Association for the Study of  
Pain (IASP) defines pain as chronic if it persists beyond normal tissue healing time of 3 months (314).  
Unrelieved pain results in decreased function, longer hospital stays, and increased rates of 
rehospitalization and outpatient visits, leading to lost employment, income, and insurance coverage (5).  
Chronic pain costs the U.S. more than $635 billion annually in medical costs and lost productivity, which 
equates to approximately $2,000 per person (3).   
The Institute of Medicine stresses the importance of increased research regarding the translation 
of effective treatments into practice and regarding the prevalence and costs associated with pain (6).  
While many pain measurement tools exist (315-324), some instruments incorporate frequency and 
intensity criteria, while others do not; this adds to variation in prevalence estimates (1-3, 325).  Recently, 
pain physicians and researchers gathered to create a more standardized measurement tool for pain 
assessment, the Global Pain Scale (GPS) which incorporates elements of existing pain measurement tools 
and measures various clinical and quality of life factors (315).    
Poor pain management frustrates patients and their caregivers; poor symptom management often 
prolongs pain treatment, and many of these treatments carry significant side effects (326).  The 
identification of superior management options for chronic pain is difficult, likely due to the multiple 
complex mechanisms and signaling pathways through which chronic pain is generated (30, 31); many 
chronic pain patients thus experience poor treatment outcomes (2). Chronic pain is challenging to 
manage, partially due to limited efficacy and negative side effects from conventional medical therapies, 
but also because some physicians are reluctant to prescribe opioids (6), while others overprescribe them  
(85).    
Over the past decade, the worrisome trend of increased prescription and utilization of opioids for 
the treatment of chronic nonmalignant pain has emerged (83), even though opioids cause physical and 
psychological dependence in users.  Additionally, there is no concrete evidence opioids are effective in 
treating some chronic pain conditions for which they are prescribed (18, 75).  Opioid pain relievers—also 
called prescription painkillers—such as Oxycodone, Hydrocodone, Fentanyl, and Hydromorphone, were 
responsible for three-fourths of all prescription drug overdose deaths in the United States in 2010 (84). 
Nationally, deaths involving opioids (using age-adjusted data) have more than quadrupled since 1999  
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(84).  However, non-opioid medications such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) carry 
significant side effects for as many as 25% of long-term users (62).     
Opioid treatment for chronic pain management presents a great challenge in the unique 
demographic of Appalachia.  In particular, West Virginia, the only state situated entirely within 
Appalachia, ranks among the highest in the nation for several health disparities, including opioid pain 
medication misuse and abuse. West Virginia’s overdose death rate has been climbing (28.9 per 100,000 
population in 2010, compared to 35.5 per 100,000 in 2014), and was more than double the national rate, 
which has also been rising over time (12.4 per 100,000 population, compared to 16.1 per 100,000, 
respectively) (86, 327).  
Understanding the patterns of usage and efficacy of other, safer forms of chronic pain treatment 
are necessary, and may include Complementary Health Approaches (CHAs) such as herbal medicine.  
Some patients choose CHAs because of concerns over the safety of conventional medicine (100); 
Painrelated disorders are the most commonly reported conditions for which patients use CHAs (86, 88, 
93, 105, 106); CHAs encompass therapeutic approaches not customarily prescribed by medical doctors to 
treat chronic pain, such as natural products (e.g., herbs, probiotics, fish oil) and Mind-body practices (e.g., 
yoga, meditation, etc.), as well as Ayurvedic medicine, Traditional Chinese Medicine, Naturopathy, 
homeopathy, and other practices.  Most people use CHAs with conventional treatments (90, 95, 96), but 
patients often do not disclose the use of CHAs to their physicians (97, 98).  CHA use is popular in the 
United States, with 30-60% of the general population estimated to use CHAs (88). In 2007, about $14.8 
billion was spent on the purchase of non-vitamin, non-mineral, natural CHA products in the United States 
(e.g., herbs, fish oil, etc.) (109).  The most comprehensive systematic review to date (28 trials meeting 
quality criteria and presenting an economic evaluation) concluded that substituting a complementary and 
integrative medicine (a.k.a. self- or practitioner-administered CHA) care component in place of usual care 
had better health outcomes and lower costs than usual care alone for a variety of chronic health conditions 
(328). However, comparative research is largely lacking, as is research regarding the overlap of CHA use 
and/or conventional treatments among those with pain conditions (329).   
Herbs (plant-derived products also known as ‘botanicals’, ‘biologically based therapies’, and 
‘herbal medicine’) are sold as food and dietary supplements in the United States. In 2012, 17.7% of U.S. 
adults had used a dietary supplement other than vitamins and minerals in the past year, making these 
products the most popular CHA (104).    
Herbal medicine is also part of many ‘folk medicine’ traditions.  Anecdotal accounts suggest that 
many herbs have been recommended by herbalists for the treatment of pain, rheumatism, and related 
symptoms (121, 179, 180, 211, 216-219).  The history of Willow (Salix spp.) and other salicin-rich plants, 
which are pre-cursors to the NSAID Aspirin, is an example of the role herbs have played in pain 
    45  
management (123).  A meta-analysis of Capsicum (a compound extracted from the fruit of Chili peppers 
C. frutecens and others) for the treatment of pain, reported that topical Capsaicin was superior to placebo 
for the treatment of chronic pain from neuropathic and musculoskeletal disorders (with trials of moderate 
to high quality); the FDA approves Capsaicin as an OTC medicine as topical cream (199). There is also 
extensive anecdotal evidence indicating widespread use of botanicals for the relief of pain. Based on 
current anecdotal evidence, plants with analgesic, anti-inflammatory and/or anti-spasmodic activities 
continue to be used as well.   
However, there are relatively few population-based studies assessing the prevalence and/or 
correlates of herbal use in pain populations.  A large cross-sectional study among Wisconsin primary care 
patients receiving opioids as a primary treatment method for chronic pain showed that 6.8% used herbs 
and supplements (93).  However, a cross-sectional study of primary care patients with chronic pain 
conducted in 12 academic medical centers demonstrated a higher prevalence rate (15%) for herbal use 
(95). Additionally, two studies indicated herbal use prevalence among U.K. Rheumatoid Arthritis patients  
varied from 20% (N=78) (193, 194) to  35% (N=94) (194, 195) of used herbal medicines, while 78% 
(N=90) (194, 196) of U.K. FMS patients used dietary supplements (including herbal supplements).   
The history of folk medicine in Southern Appalachia is much better known in some areas than 
others; more research has been conducted in western NC, eastern TN, and eastern KY.  Comparable 
research has been conducted more recently in other areas, particularly northern Georgia, southwestern 
VA, mid-TN, western KY, and northern Alabama (124).  West Virginia has a known anecdotal history of 
herbal medicine use, and some of it is specific to folk illnesses as part of Appalachian folk medicine (169, 
217); however, no epidemiological studies on herbal use have been conducted in WV pain populations. 
There are many methodological problems attending the gathering of information on the use of folk 
medicine, including small sample sizes, misclassification bias (investigators have failed to distinguish 
between past and present herbal medicine usage), and failure to account for contextual factors influencing 
use, including concurrent use of conventional medicines (124).  
In a comprehensive literature review of herbal texts and qualitative studies of herbal use in  
Appalachia (Appendix B), we found anecdotal evidence for the historical use of 101 herbs for pain relief  
(121, 179, 180, 216-219), rheumatism (121, 169, 178-180, 182, 191, 216-218), and arthritis (121, 169, 
178, 179, 191, 212, 217, 218); 12 herbs for non-specific inflammation (121, 179, 180, 217, 218); 3 for 
alleviating sleep troubles (121, 169, 179); and 4 for headache (179, 180, 217).  It is not clear if these 
herbs continue to be used for these conditions in Appalachia. Unfortunately, rigorous observational 
studies and high-quality trials regarding the use and efficacy of herbs for chronic pain syndromes remain 
sparse and little is known regarding the correlates and motivators of herbal use, including pain level and 
prescription drug use. Clearly additional research is needed, particularly in Appalachia, where  prevalence 
of chronic pain disorders (such as arthritis (330)) is high and opioid misuse is epidemic.    
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In this study, we examine potential motivators of herbal and CHA use by using a Transtheoretical  
Model-guided tool to better understand the underpinnings of short-term and long-term use. The 
Transtheoretical Model (TTM) is a behavioral theory which proposes that changes in a health behavior 
consist of movements between sequences of discrete, qualitatively distinct stages, characterized by 
distinct mindsets.  As individuals move between these stages, specific social-cognitive factors influence 
stage progression (331); stage progression occurs through 6 separate ‘Stages of Change’ (Figure 1): 
Precontemplation (a person has no intention to change a health behavior), Contemplation (they begin to 
consider changing a health behavior), Preparation (they intend to change this behavior), Action (initiation 
of the new health behavior), Maintenance (execution of the health behavior for more than 6 months) 
(332), and the newly added Termination (desired health behavior complete) (333) . The ‘Stage of  
Change’ construct is the central organizing dimension of the TTM (334); this construct has demonstrated 
success in measuring various stages of health behavior change in cross-sectional research on the topics of 
diet (335, 336), the use of health care proxies (337), exercise in pain patients (338), physical activity and 
body satisfaction (339), and measuring health-promoting behaviors for cancer prevention in a healthy 
population (340).  However, the TTM Stages of Change construct has never been applied to measure the 
health behavior of herbal use, nor other CHAs.   
Current and future public health research calls for the use of theoretical models to better 
understand motivators of health behaviors (341) such as herbal medicine use; social/biobehavioral 
underpinnings in research are critical to understanding the processes and motivators of health behavior 
change.  The use of a theoretical underpinning/conceptual framework, such as the TTM Stages of Change 
construct, in assessing the correlates of herbal medicine use (and the use of other CHAs) can help 
elucidate the reasoning and potential motivators behind an individual’s decision-making process 
regarding the use of these approaches.    
The use of herbs and other CHAs may signal a patient is actively engaged in a potentially positive 
health behavior, but may carry a risk of potentially negative interactions with other treatments. Gaps in 
existing research highlight a need to examine correlates of herbal use, as well as use of a variety of 
CHAs, to better understand if pain and other factors may influence individuals to engage in these health 
behaviors.  Additionally, gaps exist with regard to identification of herbs used in Appalachia for pain, for 
which knowledge of potentially superior pain treatments may be lost; further investigation is also needed 
regarding the relation of herbal and other CHA use to demographics, lifestyle characteristics, pain and 
other health conditions, and other health-related factors, including prescription drug use. By employing a 
new, comprehensive instrument for measuring pain and CHA use and incorporating questions regarding a 
broad range of potential correlates, this cross-sectional study was designed to help address these gaps.   
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Methods   
  
Scope of Project  
This cross-sectional survey study was conducted from June 2014 – March 2016 in a sample of 
301 English-speaking adult (>18 years) patients in four Northern West Virginia pain and rheumatology 
clinics. We conducted primary data collection using a new measurement tool, the Complementary 
Approaches for Pain Survey (CHAPS) (Appendix D), using consecutive sampling (Response rate across 
clinics = 88.0%), in order to investigate the associations between a variety of demographic, lifestyle, 
health, and pain correlates with herbal use and other CHAs for pain in an Appalachian pain patient 
population. Details regarding survey development and content, study population, and survey 
administration are given below.  
  
Survey Development   
Development. The CHAPS included 2 closed-ended items regarding past and present chronic 
pain; demographics and lifestyle (10 and 6 items, respectively); 24 health conditions (including nine 
known to cause pain) and other health factors (3 items); the Shortened-Form Global Pain Scale (SF-GPS) 
pain assessment (20 items), and, open-ended questions regarding specific herbs and other CHAs (2 
items).  Additionally, we assessed the usage of 12 separate CHAs, including Herbs/Botanicals, following 
the definition of ‘Herbs’ from the National Institutes of Health’s (NIH’s) National Center for  
Complementary and Integrative Medicine (NCCIM), which consider herbal products a CHA falling into 
the subgroup of ‘Natural products’.  Natural products listed on our survey instrument included  
‘Herbs/botanicals,’ ‘Vitamins and minerals,’ ‘Probiotics,’ and ‘Other Natural products;’ accompanying 
examples (e.g., “Herbs/Botanicals (such as Echinacea, Black Cohosh, etc.)”), were also included to 
minimize misclassification bias among users who may have been confused. These questions were asked 
how long they had used each CHA; length of time corresponded to Stage of Change (334, 341); for each  
CHA, this included: “I do not know what this is;” “No, and I do not intend to within the next 6 months 
(Precontemplation stage);” “No, but I intend to within the next 6 months (Contemplation stage);” “No, 
but I intend to within the next 30 days (Preparation stage);” “Yes, and I have for less than 6 months 
(Action stage);” “Yes, and I have for more than 6 months (Maintenance stage);” and, “If Yes, how 
effective is it in managing your pain?”. Twelve optional, nested questions regarding the efficacy of CHAs 
(if used) were also included.    
Stage of change questions were constructed based on previous surveys measuring health 
behaviors by the  TTM Stages of Change framework (334, 341). Researchers have indicated that projects 
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applying TTM should include investigation of problem severity (341). Our approach to measuring 
problem severity among this WV pain populations was through the use of the SF-GPS (315).  
The SF-GPS (315) was adapted from the pre-validated Global Pain Scale (GPS) by its original 
authors, and was used in this research; The GPS was created to meet the need for a simplified instrument 
for use by both clinicians and researchers, incorporating key elements of many existing pain assessments.  
The GPS uses a variation of the Visual Analog Scale (VAS); numbers are spaced equidistant from one 
another on a horizontal line, both ends are defined as the extreme limits of the parameter measured (pain 
severity, etc.), and orientation is from the left (best) to the right (worst), indicating the impact each 
measure has had in a participant’s life.  The SF-GPS contains 5 items each on pain, feelings, clinical 
outcomes, and activities; it addresses the ceiling, floor, and average pain over the past week, as well as 
current pain state; screens for depression, anxiety, fear, hopelessness, and energy level, while exploring 
the effect of pain on respondents’ quality of sleep, comfort, medication consumption, mood, 
independence, energy, work interference, perceived control over pain, health care utilization, and 
satisfaction with health care received.  Finally, it also assesses how pain affects respondents’ ability to 
complete a variety of activities.    
A cover page was attached to every survey, indicating that the study was open only to patients 
over the age of 18 years, ensuring anonymity, and indicating the intent of the research study (Appendix 
D); returning of the survey served as implied informed consent.  The CHAPS was designed to require no 
more than 15 minutes to complete, and the average time for survey completion among clinic patients was 
~12 minutes.   
  
Pre-testing/Pilot period. Following initial development of CHAPS and after obtaining provider 
permissions and IRB approval, we piloted the survey in a convenience sample of pain patents attending 
the WVU Medicine Pain clinic in Morgantown, WV (June 2014 – March 2015).  We visited the clinic 
waiting room in person to solicit patient participation in the survey. In addition, we also placed a stack of 
surveys, pens, and a survey drop box in the waiting room; during the following 9 months, we visited 
every 2-3 weeks to collect surveys, and ensure surveys and pens were replenished.  A total of 66 patients 
completed surveys during this period, including 28 during our in-person visit.    
A preliminary version of the CHAPS was also pre-tested in 10 patients by two independent 
investigators in order to assess comprehension, recall, identification of strong and weak points, and 
through gauging sensitive/controversial elements (342); our investigators gauged this through the 
assessment of 13 pre-determined questions. Wording of the survey was designed to be at a ninth grade 
reading level or below.  
Based on responses to and feedback on this preliminary survey, and after learning more about the 
patient experience through a 20-hour clinical immersion (accompanying a lead physician in patient rooms 
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at the WVU Medicine Pain clinic), we made minor formatting changes to the CHAPS to improve clarity, 
and included an additional question about (each) prescription use, CHA efficacy (if respondent used a 
CHA), and military status.  We then pre-tested the final survey version in 11 additional patients at the 
same clinic location.   
  
Final Version. Minor alterations were made to the final version of the CHAPS by September 2015.  This 
89-item self-administered survey required 10-12 minutes to complete.  The survey included questions 
regarding use of a variety of CHAs, including herbs, in a manner consistent with surveys utilizing a 
Stages of Change approach (335, 337-339, 343). The CHAPS also included the 20-item SF-GPS(315); 
questions regarding a variety of demographic, lifestyle, and health factors (10, 6, and 25-items, 
respectively); and, 4 open-ended questions regarding additional CHA use, diagnoses, and prescriptions 
used for pain. There were no differences in CHA/herbal use outcomes by survey version (Fisher’s p =  
.102 and .690, respectively) or (pilot) test period (Fisher’s p = .879 and .678). Based upon the similarity 
of the preliminary and final CHAPS surveys, data from these surveys were pooled in our primary 
analyses.   
  
Data Collection  
  
Target study population and Identification of Sampling Locations.  Our target study population 
comprised adult chronic pain patients attending a WV pain management or rheumatology clinic within a 
100 mile radius of Morgantown, WV. Pain and rheumatology clinics were identified by conducting an 
internet search utilizing the Bing search engine; an online White Pages directory (www.whitepages.com); 
and, online healthcare specialist directories (www.healthgrades.com; www.RA.com; and, 
www.vitals.com) with search terms “Rheumatology,” “Rheumatology clinic,” or “Pain clinic,” and 
“WV,” or “West Virginia” and (for internet specialist directories) using the ‘Physician locator’ function 
to search for rheumatologists within 100 miles of the CHAPS office (May – July 2015).    
      Of the 15 and 91 rheumatology and pain management practices identified, respectively, non-pain 
specializing physicians were excluded, as were multidisciplinary practices that included specialties other 
than pain or rheumatology (Figure 2); also excluded were eye doctors, podiatrists, neurosurgeons, 
chiropractors, acupuncturists, and weight centers, leaving 9 and 30 eligible rheumatology and pain 
clinics, respectively.  After exclusion of duplicates and those not meeting location criteria, we made 
phone calls to all remaining clinics (6 and 9, respectively) to verify address and purpose of the business, 
asking “Is this a rheumatology/pain management clinic, and do a majority of patients seek care in your 
facility for pain?”.  Following a positive response from rheumatology and pain clinic personnel, we 
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engaged clinic managers or lead physicians from each facility in an effort to describe the study and secure 
permission to administer the survey to their patients.  When clinic managers were not available to speak 
by phone or email, we attempted to follow up 3 times. A total of 4 eligible clinics (1 rheumatology and 3 
pain management) located in 4 different WV counties agreed to participate. Managers from each 
participating clinic signed a consent form which: briefly described the study purpose, stated that study 
investigators would neither disrupt clinic practice nor provide any medical advice; and, provided the IRB 
number and the primary contact information for the CHAPS study coordinator. Our resources allowed 24 
total clinic visits throughout the study.  
  
Clinic visits. Although our presence was not specifically advertised in clinics, we chose our seating in 
strategic areas of clinic waiting rooms (corners and/or areas located close to the entrance) so that we 
could utilize table space to hold our equipment (a number of clipboards, pens, and a stack of surveys). 
While we dressed nicely (i.e., no jeans or sneakers), we omitted the use of uniforms or formal business 
attire because we did not want to draw attention to our non-patient status.  During clinic visits, a member 
of our team consecutively approached every patient (with the exception of one, who was on a stretcher 
with his face covered) by (in order) verifying patient status, giving a self-introduction and description of 
the study purpose, and asking for their participation as an anonymous respondent. When approaching 
someone in obvious pain, we added "I understand if you are in too much pain, or if you are not interested 
in filling out a survey." If they agreed to participate, we handed them a clipboard, survey, and pen; we 
thanked them regardless of decision. All surveys were self-administered with the exception of 14 (4.7%), 
which were completed by a proxy; we also assisted with personal interview format requests (n =6, 2.0%). 
Upon submission to a CHAPS team member, all surveys were marked with date and clinic location, 
folded to conceal any written information, and placed in a bag beneath our sitting area for delivery to the 
CHAPS office for analysis.  All surveys were placed in a locked filing cabinet in our research 
coordinator’s office when not in use by the CHAPS team. All data entry and compilation of a master 
codebook was completed by TF; data were checked periodically for data entry errors by visual 
examination, assessment of the distribution of each variable, and by examining the consistency of related  
variables.  
During all phases of CHAPS research, we also engaged with clinic administrative staff, ensuring 
they were familiar with our study objectives; this enabled the return delivery of surveys taken back into 
the patient rooms. We used phones and other technology only minimally in waiting rooms, engaged in 
dialogue with patients when prompted, and kept a record of distance traveled and participant refusals.  
Public notification was not given for this study.  
No participant incentives were used for this research study.  Approval for the study was obtained 
from West Virginia University Institutional Review Board (IRB# 1403248198).  
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Variables  
Outcome Variables. The main, dichotomous outcome variables for these analyses are  1) Current herbal 
use for pain (defined as ‘Action [<6 months] or Maintenance [>6 months] stage of herbal use’ or ‘Does 
not use herbs’); and, 2) Current use of other CHAs for pain (defined as the ‘Action or Maintenance stage 
of CHA use’ or ‘Does not use CHAs’), which included the use of vitamins and/or minerals, probiotics, 
other natural products (excluding herbs), acupuncture, massage therapy, spinal 
manipulation/Chiropractic, Tai Chi, yoga, meditation, other relaxation practices, and/or movement 
therapies.   
Independent Variables. We examined relationships between the outcomes with a variety of 
demographic, lifestyle, and health exposure variables in separately run models for each exposure.  
Demographics: variables included age, gender, race/ethnicity, education, marital status, household 
Income, body mass index, and employment status.  
Lifestyle factors: Smoking status, alcohol use in past year, and exercise were included as lifestyle factors. 
Health factors: The SF-GPS score was our overall indicator variable for pain. Additionally, twenty-three 
comorbidities were assessed, as was past/current prescription medication use for pain management. 
Covariates. We adjusted for education, age, exercise, SF-GPS, and health conditions in models, when 
sample sizes allowed.   
  
 
  
Statistical Analysis  
  
We conducted analyses using SAS 9.4 (Cary, NC), and measured means/frequencies of sample 
characteristics, including outcomes CHA/herbal use by each length of time used (Stage of Change). We 
manually coded the answers to open-ended questions describing specific herbs used for pain and 
generated frequencies for each. Next, we examined relationships between CHA/herbal use and a variety 
of demographic, lifestyle, and health factors among pain patients; we also assessed the potential influence 
of education and other significantly associated covariates from crude, individual models on CHA/herbal 
use for pain.    
Demographic variables included age (continuous and 18-49/50+ years), gender (Male/Female), 
race/ethnicity (Non-Hispanic White/Other Race), education (‘<HS/GED;’ ‘Some College/Associate/ 
Technical training;’ ‘>Bachelor’s degree’), marital status (‘Single;’ ‘Divorced/Separated/Widowed;’  
    52  
‘Married/Cohabitating’), and household Income (ordinal and in categories ‘<$50,000’/‘$50,001+’). 
Additionally, Body Mass Index (BMI, calculated as weight (pounds) x 703/height in inches2) was 
evaluated as continuous and categorical, using the National Institutes of Health clinical classifications  
(BMI scores of <25 = “Underweight or Normal weight;” 25 – 29.9 = “Overweight;” 30 – 34.9 = “Obese 
Class 1;” and, 35+ = “Obese Classes 2/3”) (295), as was employment status (a categorical variable 
defined as ‘employed,’ ‘not employed and not disabled,’ ‘disabled,’ and ‘retired’). Lifestyle factors 
included smoking status (defined as Current/former/Never), alcohol use in past year (None/any), and 
exercise (categorical as None/Any, and continuous, in 30-minutes per week increments).   
Health factors included SF-GPS score, as well as comorbidities. The total SF-GPS score was our 
overall indicator variable for pain. As stated before, the SF-GPS contains 5 items each on pain, feelings, 
clinical outcomes, and activities; the total score is the sum of these subscales, and ranges from 0 -100, 
where 0 = pain generally doesn’t affect life and 100 = pain causes great distress in life) (315). 
Additionally, twenty-three comorbidities (a continuous index from 0-23, in addition to dichotomous 
variables: ‘Pain syndromes,’ which incorporated diagnoses of spine/back/neck pain, migraines, tension 
headaches, rheumatoid arthritis, osteoarthritis, temporomandibular jaw disorder, non-specific knee pain, 
fibromyalgia, and/or gout; ‘Mental Health conditions,’ including depression and/or anxiety; ‘Injury,’ 
including broken bones and/or musculoskeletal injury/tissue trauma; and, ‘Other conditions,’ for which 
hypertension, heart disease, irritable bowel disorder, renal disorder, asthma, chronic bronchitis, diabetes, 
cancer, stroke, and/or chronic fatigue syndrome were included). Past and current prescription medication 
use for pain management was manually recoded (None/any Rx) and examined as an exposure variable as 
well.   
Additionally, we assessed the association of herbal use to concurrent use of other CHAs. Thus, 
we examined as independent variables CHA use (Current user of any CHA except herbs/None), Dietary 
supplement use (current use of Vitamins/Minerals, Probiotics, and/or other natural products excluding 
herbs/None), Mind and Body practices use (current use of Meditation, Relaxation, Yoga, and/or Tai 
Chi/Qi Gong/None), and, use of Acupuncture, Manipulative treatments, Massage, and/or Movement 
therapies (current user/None) in separate models.  All CHA exposures were further examined in separate 
models by Action (short-term use, defined as <6 months) and Maintenance (long-term use, defined as >6 
months) Stages of Change for each respective CHA.  
All multivariable models were adjusted for demographic and lifestyle factors that did not have a 
substantial proportion of missing values (>10%) and were associated (p < .10) with herbal/CHA use in 
the unadjusted analyses, such as education, chosen due to its established associations with herbal (144) 
and CHA use (95, 144). Additionally, we controlled for variables significantly associated with either 
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respective outcome in crude models; these variables included age, exercise, SF-GPS, and health 
conditions, when adequate sample sizes for power allowed.    
  
Sensitivity Analysis of Missing Data  
  
As we had over 10% missing data on certain variables, including CHA use, herbal use, BMI, 
alcohol consumption, and income, we conducted additional sensitivity analyses using the fully 
conditional specification (FCS) method of multiple imputation (PROC MI/MIANALYZE); FCS was 
chosen because it allowed us to incorporate both dichotomous outcomes and all categorical/continuous 
predictors (with missing values ranging from 5.0% – 53.5%, for SF-GPS and those missing any of the 11 
other CHA use questions, respectively) using a total of 250 imputed datasets. Prior to performing multiple 
imputation analyses, we first verified that data were missing at random by conducting regression tests on 
missing data for all variables of interest, followed by an assessment of missing data patterns to further 
verify data were missing at random  (PROC MI). After imputation, we compared the unadjusted odds 
ratios between our imputed and original datasets; because no differences were detected, we have 
presented the results from our original dataset in the Results section.   
    
Results   
  
Response rates were high overall (88% ± 4.1%) ranging from 84 to 94%. Common reasons for 
refusal to participate included hand pain, visual impairment (e.g., forgot glasses), or a reluctance to fill 
out paperwork. The average one-way travel time for patients across all locations was 74 minutes (ranging 
from 34 to and 129 minutes for pain clinics in Elkins and Morgantown, respectively). Results from our 
preliminary survey indicated very high internal consistency for the SF-GPS (Cronbach’s alpha = .919); 
the internal reliability of each (5-question) subscale was also high (Cronbach’s alpha for the Pain subscale 
= .888; Feelings subscale = .874; Clinical Outcomes subscale = .804; Activities subscale = .904).   
Coefficients for the total sample were similar, likewise indicating high internal reliability of the SF-GPS  
(Cronbach’s alpha overall= .931; Pain subscale= .892; Clinical outcomes subscale = .830; Activities 
subscale= .908 Feelings subscale = .865).   
Relative to participants with complete data, those missing data on any survey item were more 
likely to be older (Odds Ratio (OR) for age = 1.04, 95% CI 1.02, 1.07), prescribed opioids (OR = 3.41, CI 
1.39, 8.38), and have a lower SF-GPS score (OR for lowest vs. highest SF-GPS quartile = 3.46, CI 1.62,  
7.39). Those missing data on outcome variables CHA/herbal use were also older (OR = 1.04, CI 1.02, 
1.06 and OR = 1.04, CI 1.01, 1.07, respectively) and more likely to use opioids (OR = 2.59, CI 1.24, 5.42 
and OR = 5.42, CI 1.92, 15.30) over no drugs.  Although there was no difference in herbal use by clinic 
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location (Fisher’s p = .656), there was a borderline significant difference in CHA use by location 
(Fisher’s p = .05), with the lowest use of CHAs (other than herbs) found among rheumatology clinic 
patients in our sample (4.0%), compared to the highest proportion of other CHA use in the Morgantown 
pain clinic (78.5%).  There was no difference between those using a proxy/personal interview vs. 
selfadministered format (Fisher’s p = .857) by herbal use; however, there was a difference in survey 
format by CHA use (Fisher’s p = .034), with a lower CHA use proportion among those using a proxy or 
personal interview format (4.0%) compared to those self-administering surveys (96.1%).   
Demographic and lifestyle characteristics are displayed in Table 1. Study participants were 
predominantly white (92.0%), female (56.9%), and married or cohabitating (57.5%). Participant age 
ranged from 22 to 88 years, averaging 55.6 (SD = 13.6) years. Over 40% of participants were disabled 
(43%) and/or obese (44%, mean BMI=33.4±31.5), and over 55% reported no exercise during the last 
month.  Nearly half did not consume alcohol within the past year (46.8%).   
Health characteristics are displayed in Table 2. As expected, the majority of study participants 
were experiencing chronic pain (93.4%). Average GPS scores were high (mean=50.9 ±20.6), with 44% of 
participants reporting opioid use for pain management.  The mean number of pain syndromes/conditions 
was 2.3 (SD = 1.6), and prevalence of comorbidity was high, with 93% reporting at least 2 health 
conditions (mean=5.4±3.1).  
  
Herbal Use  
Table 3 displays frequencies for the use of CHAs, including herbal use. Eight percent of 
participants (n = 24) used herbs for pain, with the majority using herbs for 6 months or more  
(Maintenance stage) (4.3% of sample).  Nineteen specific herbs used for pain management were reported; 
of these, the most commonly reported were ginger (41.7%), lavender (33.3%), peppermint (29.2%), black 
cohosh (16.7%), marijuana (12.5%), and turmeric/curcumin (12.5%). The mean age for those using herbs 
was 49.5 (SD = 12.2) years, with nearly half of herbal users reporting at least a Bachelor’s degree (45.8%).  
Those using herbs had a mean of 6.1 health conditions (SD = 3.5) and a SF-GPS score of 56.9 (SD = 18.2). 
Eighty-four percent of herbal users were using or had used prescriptions for pain; 63.2% of herbal users 
had used opioids (not shown). Nearly all herbal users were also using other CHAs (95.8%), with the highest 
proportion using other dietary supplements (91.7%). Over half of herbal users also reported using 
Acupuncture, Manipulative treatments, and/or Movement therapies (60.9%), as well as Mind - Body 
practices (56.5%).  
  
Relation of herbal use to demographic, lifestyle, and health factors (including other CHAs). Age 
showed a marginally significant inverse association with herbal use which persisted after adjustment for 
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education (adjusted odds ratio (AOR) = 0.97, 95% confidence interval (CI) 0.94, 1.01). After adjustment 
for age, those with the highest education level were approximately five times as likely to use herbs than 
those with the lowest education level (AOR = 4.94, CI 1.59, 15.29) (Table 4).  While herbal use was 
significantly and positively related to household income in the unadjusted model (OR = 1.59, CI 1.07, 
2.37 per $25,000-unit income increase), this association was eliminated after adjustment for age and 
education (AOR = 1.25, CI 0.81, 1.93). There were no significant differences in herbal use by other 
demographic or lifestyle factors.    
Although there was no difference in herbal use by prescription medication, those using CHAs 
other than herbs were 11.5 times more likely to concomitantly use herbs compared to those not using 
CHAs (AOR = 11.46, CI 1.49, 87.93); specifically, in order of decreasing magnitude, those more likely to 
consume herbs included those using: Dietary supplements (OR = 12.26, CI 2.82, 53.38), Acupuncture, 
manipulative treatments, massage, and/or movement therapies (OR = 5.15, CI 2.11, 12.60), followed by 
Mind-body practices (OR = 3.83, CI 1.59, 9.23). Adjustment for age and education only modestly 
attenuated these associations (Dietary supplements AOR = 10.25, CI 2.31, 45.47; Acupuncture, 
manipulative treatments, massage, and/or movement therapies AOR = 3.99, CI 1.55, 10.23; and, Mind- 
Body practices AOR = 2.44, CI 0.94, 6.30).  Short-term (<6 months) dietary supplement users were 4.7 
times more likely to use herbs than those not using dietary products for under 6 months (AOR = 4.46, CI 
1.76, 11.32); long-term (> 6 months) dietary supplement use was not associated with concomitant herbal 
use (AOR = 1.83, CI 0.75, 4.49) (not shown). Additionally, short-term users of Acupuncture, 
manipulative treatments, massage, and/or movement therapies were 3 times as likely to use herbs (AOR = 
2.97, CI, 1.09, 8.07), although long-term use of these CHAs was not associated with concomitant herbal 
use (AOR = 2.38, CI 0.84, 6.70) (not shown). Conversely, longer-term users of Mind-Body practices  
were over 3 times more likely to use herbs than those not using mind and body practices long-term (AOR 
= 3.21, CI 1.23, 8.37), while no significant association existed between short-term use of Mind-Body 
practices with herbal use (AOR = 0.50, CI 0.10, 2.45) (not shown).  
  
Other CHA use  
CHAs other than herbs were used by the majority of survey participants (58.8%, n= 177), with 
47% of survey participants in the long-term/Maintenance (>6 months) stage of use; an additional 32% of 
participants were in the Contemplation or Preparation stage (i.e., had an intention to use within 6 months). 
Most commonly reported CHAs used were dietary supplements (53.6% of participants), followed by 
Mind -Body practices (28.9%) and Acupuncture, manipulative treatments, massage, and/or movement 
therapies (28.1%).    
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Relation of CHA use (excluding herbs) to demographic, lifestyle, and health factors. Relative to 
participants with a high school diploma or less, those with higher education levels were significantly 
more likely to use CHAs other than herbs than those with the lowest education levels (Crude OR’s for  
>Bachelor’s degree and some college/Associate’s degree/tech training = 2.55 (CI 1.21, 5.40) and  2.11 
(CI 1.17, 3.79), respectively); adjustment for age, exercise, health conditions, and GPS strengthened these 
associations (AOR for the highest vs lowest education level = 2.68, CI 1.13, 6.39).  CHA use was 
significantly and inversely associated with age (OR = 0.98, CI 0.96, 0.99) in the unadjusted model, 
although adjustment for education and exercise eliminated this association (AOR = 0.99, CI 0.96, 1.01).   
(Table 5).   
Exercise was strongly associated with CHA use in both crude and adjusted models, with a 14% 
increase in the odds of CHA use per 30-minute increase in exercise per week, after adjustment for age, 
education, GPS, and health conditions (AOR = 1.14, CI 1.01, 1.29).  Relative to those reporting no 
exercise, participants indicating engagement in physical activity were over twice as likely to use CHAs 
(fully adjusted OR =2.34, CI 1.29, 4.22). Reported SF-GPS, which includes pain severity, was also 
positively related to CHA use (OR adjusted for age, education, exercise, and health conditions=1.02 (CI  
1.00, 1,03) per unit GPS increase).   
  
Sensitivity Analyses. Missing data was unrelated to specific patient characteristics, suggesting that 
missing data likely occurred due to inability to complete the survey while with a physician, or the 
wording/layout of the CHAPS, rather than a patient misunderstanding of what specific CHAs were. In 
addition, risk estimates for herbal/CHA use calculated using imputed data did not differ appreciably on 
any variable from those derived using the original CHAPS data set, suggesting that missing data are 
unlikely to account for our findings. Further, exclusion of participants in the pilot phase did not 
appreciably alter our findings.  
  
Relation of specific CHA groups (excluding herbs) to demographic, lifestyle, and health factors. We 
examined the relationships between all covariates and: dietary supplements (other than herbs) (Table 6); 
Mind-body practices (Table 7); and Acupuncture and other approaches (Table 8).  After controlling for 
demographic, lifestyle, and health factors, education level remained significantly and positively 
associated with all CHA categories, with Mind-body practices showing the strongest relationship   (AOR 
for Bachelor’s degree or higher= 6.45, CI 2.71, 15.37).  In addition, exercise remained significantly 
associated with dietary supplements (AOR = 2.42, CI = 1.41, 4.14) and Mind-body practices (AOR = 
2.31, CI 1.22, 4.39) after adjustment for other covariates, while associations with age were largely 
eliminated (Mind and body practices AOR = 0.98 (CI 0.95, 1.00); Acupuncture and other approaches  
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AOR = 0.98 (CI 0.96, 1.01)).  Those who were morbidly obese (BMI >35) were 70% less likely to use 
Acupuncture, manipulative treatments, massage, and/or movement therapies relative to normal or 
underweight individuals (AOR = 0.32, CI 0.12, 0.82) (Table 8); likewise, morbid obesity showed an 
inverse, although more modest association with use of dietary supplements other than herbs (AOR = 0.40, 
CI 0.16, 1.02) (Table 6).  
Concomitant use of other CHAs was significantly and positively associated with all CHA 
categories; these associations persisted after adjustment for demographic, lifestyle, and health factors, 
with AORs ranging from 2.5 (1.2, 5.2) for dietary supplements (Table 6) to 3.3 (1.6, 6.7) for Acupuncture 
(and other manipulative/bodywork/movement approaches) (Table 8). Dietary supplement use was 
positively related to the number of health conditions (OR for total number of health conditions adjusted 
for demographic and lifestyle factors= 1.1, CI 1.01, 1.22) and specifically to pain syndromes and injuries  
(partially adjusted OR’s = 1.25 (CI 1.04, 1.51) and 1.52 (CI 0.99, 2.34), respectively); these associations 
were modestly attenuated by the addition of SF-GPS to the model (Table 6).   
  
  
Discussion   
  
This was the first study to examine correlates of herbal use and other CHAs specifically used for 
pain in a chronic pain population, and among one of the first to examine correlates of herbal use and other 
CHAs in an Appalachian population, while controlling for a variety of potential confounders. To our 
knowledge, correlates of overall herbal use have only been assessed in the general population; unadjusted 
bivariate comparisons are seen more often in the literature, and many do not separate herbs from other 
natural products.   
A wide variety of herbs were reported as having been used for pain management, some of which 
have at least preliminary evidence of benefit for pain, and/or have been anecdotally used for pain 
symptoms in Appalachian herbal texts and qualitative literature.  Herbal users (and those using all other  
CHAs) had higher education levels, and were significantly more likely to concomitantly use a variety of 
CHAs; the strongest association was found between herbal use and short-term use of other dietary 
supplements. Other CHAs were used by almost 60% of participants; dietary supplements (excluding 
herbs) were the most commonly used CHA, followed by an approximately equal proportion of those 
using either Acupuncture (including manipulative or movement therapies, and/or massage), or, Mind and 
body practices. Additionally, CHA use was marginally associated with increased SF-GPS scores.  
Exercise was associated with the use of all individual CHAs, with the exception of herbal use.     The 
8% prevalence of herbal use in our study was higher than that reported in a recent study of primary care 
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patients using opioids for pain management (93) and another U.S. study of chronic pain patients (95), but 
substantially lower than that reported in prior European (193-195).  However, these differences may be 
due to the differing classification of our outcome of herbal use specifically for pain, rather than herbs 
used for a variety of purposes. The lower rates of herbal use reported in our study population may reflect 
the modest decline in the national use of herbs over the last decade (125), and/or differences in 
methodology, time period, and/or study population.  For example, in their cross-sectional study of 463 
chronic pain primary care patients sampled from multiple U.S. academic medical centers, Rosenberg et 
al. used an open-ended item administered with a personal interview format to assess herbal use; this may 
have allowed a broader capture of herbs and herbal preparations in their study (35). Two of the three 
European investigations assessing use of herbs for pain conditions were conducted 3 decades ago; 
including two U.K investigations indicating 20 (193, 194) to 35% (194, 195) of Rheumatoid Arthritis 
patients used herbal medicines; one more recent (1996) survey study in another U.K. population 
suggested high prevalence of herbal use in FMS patients (194, 196, 197), although the authors did not 
distinguish herbal from other dietary supplements, rendering comparisons with our findings challenging.   
Only two prevalence studies have assessed herbal use in non-pain Appalachian populations, including a 
2003 prevalence study on 578 WV pregnant women which showed that 45.2% used herbs (184); 
however, this included soft drinks, cocoa butter for external use, and other products not counted as herbs 
in our study, while in 1999-2004, 19.3% of 2523 rural NC adults over 45 years of age used herbs and 
other natural products, with garlic (4.9%) and cayenne (1.8%) the most widely reported (141).  
In contrast, the reported prevalence of CHA use other than herbs was higher in our sample  
(58.8%) than that reported in prior studies of U.S. chronic pain populations (93). For example, in a large 
sample of Wisconsin primary care patients using opioids for chronic pain, participants reported lower 
usage of several CHAs; the most striking contrast was the difference between supplement use in our 
sample (53.6%) compared to that of the Wisconsin sample (6.8% for herbs/supplements) (93, 95).  
Likewise, observed CHA use in our population also higher than that of reported by a sample of chronic 
pain primary care patients from academic medical centers in the US, although differences were more 
modest (58.8% vs. 52%) (95).  
Our preliminary systematic review on herbal prevalence among the general U.S. population 
(Appendix C) showed the majority of large cross-sectional studies frequently lumped herbs and dietary 
supplements together, resulting in uncertainty regarding true herbal prevalence rates; this was often due to 
misclassification of herbal use with other natural products (such as fish oil, etc.) in national surveys 
(primarily, the NHIS, which was used for a majority of these studies). Many studies assessing potential 
correlates of herbal use have used inconsistent definitions as well, often combining herbs with other 
dietary supplements (141, 143, 144, 146, 147, 155, 156, 159, 161, 165, 344) or other approaches (139,  
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145, 152, 154); few have kept the outcome herbal use separate from other CHAs (138, 157, 160, 162, 
345); our study separately classified herbal products from other dietary supplements.   
Two herbs used in the Appalachian region and for which both evidence of anti-inflammatory and 
pain management exist were also reported in our sample; these were Ginger (223, 232, 233, 257-261) and  
Peppermint (223, 234, 235, 243) (41.7% and 29.2% of herbal users, respectively).  Although not for pain, 
18% of 578 WV pregnant women used peppermint in a 2003 study (184). Lavender has at least 
preliminary evidence of efficacy for pain management (346-348), and anti-inflammatory (272) effects as 
well; our study is the first to report its use in an Appalachian sample. Herbs used most often by a 
U.S./Canadian sample of 434 with Fibromyalgia syndrome (FMS) were Ginkgo (3.7%), Garlic (3.0%), 
Ginseng (3.0%), Echinacea (2.5%), Evening Primrose oil (2.3%), and Valerian (2.3%) (197). With the 
exception of Ginkgo and Ginger, these were not reported by our participants; however, this was due to a 
difference in the assessment of herbal use for management of pain (in our sample) vs. herbal use for a 
variety of conditions.   
Compared with nonusers, CHA users in the general population tend to be women, white, middle 
aged, better-educated, and of higher income (90, 106, 110-116).  CHA use was not associated with female 
gender or race, and a borderline association between CHA use and (younger) age was eliminated when 
controlling for education, exercise, SF-GPS, and health conditions. Similarly, a study of 463 primary care 
patients with chronic pain also found no association between female gender, race, and age, after 
controlling for a variety of factors.  It is plausible the demographic makeup and likelihood of CHA use 
differs in populations experiencing pain, compared to populations with a greater variety of health 
characteristics.  Other CHA use was significantly associated with higher levels of education in our sample 
of pain patients, particularly mind and body practices; herbal use was as well.   
Both CHA and herbal use in our sample were significantly and positively associated with higher 
education levels, consistent with previous studies, including two large 2002 studies which found those 
with a higher education were more likely to use CHAs (95, 144) and natural products (144).After 
adjustment for other factors, income was not associated with herbal use or other CHAs, unlike a study of 
over 900 chronic pain patients using opioids (93). Although an income effect (349) may influence CHA 
use (i.e., higher-wage individuals are more likely to invest in health because they perceive higher benefits 
associated with improved health, including an increase in productive days and less sickness-related 
income loss), Bhargava et al. recently proposed that a substitution effect may also be present among those 
with higher incomes (i.e., higher wages may also increase the opportunity cost of time used for producing 
health, thus discouraging time spent on health care) (116). This may, perhaps, apply to CHAs use among 
those with higher incomes in pain populations; alternately, the impact of pain may influence individuals 
(regardless of income) to try approaches outside of or alongside conventional medicine. However, neither 
of our outcomes was associated the SF-GPS subscale, which incorporated pain severity as a component, 
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even after controlling for income and other factors; this contrasts a cross-sectional study which found an 
adjusted (age, gender, race, pain sites, and illicit drug use) association between CHA use and pain 
severity without the use of the SF-GPS (93).  
Overall, CHA users had higher odds of exercise and a marginal inverse association with higher  
BMI, associations of BMI and exercise were particularly pronounced with dietary supplement and 
Acupuncture (and manipulative/movement approaches) users. These findings are consistent with those 
from a study using 2012 NHIS data which indicated a significant, positive association of exercise to use 
of Chiropractic, Massage, herbs, and yoga (116).  Herbal and CHA use was not associated with specific 
health conditions (such as both neck/upper back and multiple sites of pain), in contrast to findings 
reported in previous studies, including a larger study also controlling for demographic, health, and 
lifestyle factors similar to ours (93). Neither CHA nor herbal use was associated with prescription drug 
use in the CHAPS, similar to a large sample of primary care patients with chronic pain using opioids (95).   
In addition, CHA use differed by those using a proxy or personal interview format, while no 
difference was found for herbal use. Thus, there may be a possibility that those lacking skills to complete 
the survey on their own may have limitations, perhaps disability and/or cognitive impairment, preventing 
them from using CHAs which require either physical movement or frequent practitioner visits – however, 
this may not prevent them from engaging in self-administered CHAs such as herbal use. Only one study 
has compared differences between self- and practitioner-administered CHA use, for which 
disability/cognitive impairment factors were not assessed (116).   
This the first study to assess correlates of both herbal use and other CHAs in an Appalachian pain 
patient population. We pilot-tested and employed a newly developed survey instrument, the CHAPS.  
Incorporating pain items adapted from a previously validated pain measurement tool (315), the CHAPS 
included comprehensive information on a range of factors and constructs, yet required only 12 minutes to 
complete, and may thus be appropriate for use in future population- and clinic-based survey studies of 
pain populations. Survey response rates were high and we exceeded our target sample size, despite 
limited resources and other challenges including clinic lockdown, suspension of physician licensure, and 
inclement weather.  In addition, our high reliability estimates for the SF-GPS also support further use of 
this measurement tool in pain populations.   
Despite these strengths, there were also some limitations.  Due to limited data regarding the use 
of CHAs in an Appalachian population with pain, we powered our study based on herbal prevalence 
rates reported in the literature for the general population (18%); given that CHA use is known to be 
further elevated in chronic pain populations, we assumed that herbal use would be at least as high in our 
sample of Appalachian chronic pain patients. However, due to the lower than expected rates of herbal 
use in survey participants, we did not have sufficient power to examine associations by specific Stages 
of Change regarding herbal use, or to determine with confidence the prevalence of use of specific herbs.   
    61  
Many of our confidence intervals were wide, suggesting estimates should be interpreted with caution.   
Notably, some factors had relatively high rates of missing data, including the outcome herbal use 
(18.3%), BMI (11.6%), alcohol use (11%), and income (12.3%). However, we used multiple imputation 
procedures to account for missing data in order to obtain appropriate estimates of uncertainty associated 
with missing variables, assess for and minimize potential bias, and maximize the use of available 
information in our CHAPS dataset,; notably, estimates using imputed data did not differ appreciably 
from those derived from the original data, suggesting that missing data are unlikely to account for our 
findings. As there were no systematic patterns associated with missing data, and risk estimates did not 
appreciably change, we have confidence that estimates obtained from our data provided reasonably 
reliable measurements regarding the correlates of CHAs, including herbal use, in northern WV pain 
patients.   
As in many studies using self-report data, there is a possibility of recall bias. While the 
misclassification of outcomes was unlikely, specific herbs or prescriptions listed in open-ended items 
may have suffered from misclassification bias, potentially resulting in underascertainment.  For example, 
we overheard a proxy interviewer ask a respondent, "Do you want to list your prescriptions?” to which 
the respondent replied, "No, it would take too long.".  Additionally, we did not incorporate specific 
questions about marijuana due to concerns regarding the sensitivity of this issue. Nonetheless, marijuana 
use for pain was still reported by 12.5% of herbal users in our open-ended item, a figure that likely 
substantially underestimates true prevalence.   
Selection bias may have been present since this study utilized a convenience sample.  However, 
our consecutive sampling approach minimized this possibility; in addition, response rates were very 
high, reducing the likelihood of non-response bias.  Researchers wishing to implement the CHAPS or 
similar surveys should explore barriers to survey implementation present at specific clinics, including 
the physical space made available to them; one clinic was gracious enough to offer our coordinator a 
workstation behind their check-in window during data collection days, and although all patients were 
solicited for participation, this site had the lowest overall response rate (84.1%) of all clinics.  
Additionally, much remains unknown about the health behavior habits of opioid users with regard 
to CHA use. Our measurement of CHAs, particularly herbal use, was hindered by a high proportion of 
missing responses among those using opioids, which comprised nearly half of our population, potentially 
leading to an underestimate for herbal use. Other issues surrounding the use of our survey instrument 
include a lack of data on specific reasoning to use herbs and other CHAs. This was the result of our 
decision to keep the CHAPS as brief as possible; however, future studies may wish to incorporate more 
contextual elements of herbal use and CHAs, including specific reasons for use, concomitant use of 
medications, spirituality and/or prayer, access to CHAs, and disclosure of CHA use to physicians.  
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Additional considerations should be made for the capture of information in future iterations of the 
CHAPS, or for similar surveys. These include additional questions regarding e-cigarettes and other 
forms of tobacco, capture of previous use of CHAs beyond the 6-month time point assessed in our study, 
and reformatting CHA questions with equally-spaced bins on multiple pages with adequate visual cues 
and space for nested efficacy questions.   
  
Conclusion   
  
   Our study was the first to assess concomitant CHA use in a pain population and to document specific 
herbs used within this population. Although the majority of patients in our sample did not use herbs for 
pain, their use was reported 8% of the time and through the use of 19 unique herbs, and was strongly and 
positively associated with the use of other CHAs. The majority of our sample used at least one CHA for 
pain. Investigation of factors associated with herbal medicine, other CHAs, and their concomitant use in 
pain populations will help inform physicians concerned about potential interactions. Additional studies 
are needed to further explore the patterns and determinants of herbal and other CHA use in chronic pain 
populations, to assess perceived efficacy of these approaches, and to lay the foundation for future clinical 
efficacy studies on herbal and other CHA approaches for managing chronic pain.  
  
  
   
CHAPTER 5: Discussion    
Summary of Key Findings   
  
Inflammation is often a component of chronic pain, yet its potential role in fibromyalgia 
syndrome (FMS) remains inconclusive. FMS is a complex chronic pain condition affecting ~2% of the 
population; management is challenging and treatment options remain limited. Many herbs contain anti-
inflammatory properties, and herbs indicated for analgesia and rheumatic conditions have traditionally 
been used in Appalachia. Despite the popularity of herbs in the US, determinants and patterns of herbal 
use in FMS and other chronic pain populations have not been well studied, particularly in Appalachia, 
where prevalence of chronic pain and related comorbid conditions is high.  Likewise, prevalence, patterns 
and correlates of other CHA use remain little studied in Appalachian chronic pain populations, or in 
adults with certain pain conditions, including FMS. This series of 3 studies are designed to help fill these 
knowledge gaps; the overall objectives of these investigations were to investigate: 1) the association of 
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FMS to a marker of inflammation, serum C-reactive protein (CRP) in a large Appalachian population; 2) 
the demographic, lifestyle, and health-related correlates of herbs and other complementary health 
approaches (CHAs) used for pain in a sample of WV chronic pain patients, using a newly developed 
survey instrument; and, 3) the relation of herbal supplement use to FMS in two nationally representative 
samples of U.S. adults (NHIS 2007 and 2012), as well as trends in patterns of herbal use over time.   
  Although we found herbal use was associated with concurrent use of other CHAs in WV pain 
patients, it was not associated with pain level, the use of prescription medications, or the number of pain 
conditions. Results of these studies suggest the following 1) FMS is positively associated with serum 
CRP; this association was largely explained by obesity and comorbidity, suggesting the role of 
inflammation in FMS may be complex 2) CHA use in chronic pain patients in northern WV is high, 
although reported use of herbs for pain appears low. Herbal use for pain was strongly associated with use 
of other CHAs, but was unrelated to pain severity or use of prescription medications.  3) Use of herbs and 
other CHAs is strongly and positively associated with FMS diagnosis in U.S adults.   
  
Strengths of the Dissertation   
All studies had high response rates and population-based designs.  Sample sizes for two of the 
three studies were large. The C8 Health Project, from which we drew data for Chapter 2, was the largest 
comprehensive community study conducted to date in the Appalachian region; Chapter 3 was conducted 
using two nationally representative samples of US adults. Chapter 4, the CHAPS, was the first to assess 
correlates of CHAs and herbal use in an Appalachian pain population and to employ a newly developed 
comprehensive survey instrument for measuring herbal and other CHA use, pain severity, and a wide 
range of demographic, lifestyle, and health-related factors (see below). With the exception of analyses 
regarding correlates of herbal use in the CHAPS, we were also able to control for a broad array of 
potential confounders, including health conditions, which diminished the possibility of unmeasured 
confounding. We were also able to assess the influence of a variety of potential mediators and/or effect 
modifiers in our analyses.  
In Chapter 4, we employed our newly developed survey instrument, the CHAPS, in over 300 pain 
patients, utilizing independent investigators to conduct quality assessment, and incorporating pain items 
adapted from a previously-validated pain measurement tool (315). Although allowing for capture of 
information on a wide array of health-related information, the CHAPS required only 10-12 minutes to 
complete; reliability of the CHAPS was also excellent overall, indicating high internal reliability 
estimates and further supporting the use of this instrument for observational research in chronic pain 
populations. We exceeded our target sample size, even though we faced significant obstacles to data 
collection including clinic lockdown, inclement mountain weather, and temporary withdrawal of 
physician licensure which limited our access to patients.  In addition, we conducted a sensitivity analysis 
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using imputation procedures to verify our estimates against those without missing data, which enabled us 
to interpret our findings with confidence.   
  
Limitations of the Dissertation   
Although our studies had many strengths, there were several limitations. Most important 
conclusions regarding causality cannot be drawn due to the lack of a temporal component in our 
crosssectional study designs. Two of our studies targeted populations of predominantly white 
Appalachian adults, potentially limiting the generalizability of findings to other populations. Moreover, 
our original study in a sample of WV chronic pain patients was underpowered to assess herbal use based 
on the TTM Stages of Change as originally envisioned. Given the often poor recognition of FMS in the 
medical community, particularly prior to 2010, misclassification is also possible and may have led to 
underascertainment.  Nearly all health conditions, and all herbal/CHA use measurements in our studies 
were based on self-report, possibly leading to response or misclassification bias.   
Additionally, neither NHIS dataset captured the use of herbal products other than supplements, 
likely leading to underestimates of herbal use. Likewise, many of the CHAs were only assessed in the 
NHIS if they were administered by a practitioner, likely resulting in underestimates, which may have 
impacted our ability to measure concurrent CHA and herbal use accurately. Additionally, we were 
unable to incorporate an additional year of the NHIS (2002) due to a lack of specific information 
regarding FMS diagnosis.   
  
Potential Public Health Implications and Future Recommendations  
  
  FMS, a disease with largely unknown etiology, has higher odds of comorbid conditions compared to 
non-FMS populations; this includes inflammatory-mediated diseases such as autoimmune disease (22). 
However, the potential shared role of inflammatory markers between FMS and specific comorbidities 
remains largely unexplored by population studies. Because we were only able to assess the role of CRP as 
an overall measure of systemic inflammation, however, we remain unaware of specific dynamics 
regarding inflammatory response, or interplay, between other cytokines (and related markers) in those 
with FMS, in the presence of obesity and comorbidities such as autoimmune disease.   
Although it is possible inflammation is not associated with FMS, given the results of our first 
study, further large, population-based research is still needed to replicate our findings while assessing for 
a variety of inflammatory markers while controlling for a variety of factors and assessing potential 
mediators as we did; based on established knowledge of the anti-inflammatory effects of some herbs 
(123, 223, 225-227, 233, 241-268, 270-272), and, given FMS was positively associated with herbal use in 
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our second study, future research should also compare a variety of inflammatory measures among those 
using herbs (ideally, with known anti-inflammatory benefit) by FMS status; based on sensitivity analysis 
results from our second study as well, the role of comorbidities in research on herbal use in FMS 
populations should be further explored.   
As a result of our second study, we have a better understanding of the patterns of herbal use 
prior to and following the implementation of updated FMS diagnostic criteria and increased 
availability of FDA-approved treatments for FMS. It remains possible that both the increase in FMS 
diagnoses and the decrease in odds of herbal use for FMS over time are also in part perhaps the result 
of corporate promotion for FMS drugs, increased off-label use of other drugs, and, opioid use for 
FMS. Additional research should continue to monitor FMS trends, in addition to herbal use trends over 
time for a variety of diseases; all trend studies should continue to consider changes in diagnostic 
criteria as well as the changing availability of treatments for respective diseases.  
  Whether opioids can be reduced by introducing herbal products remains to be examined. Our second 
and third studies offer information regarding the patterns and correlates of complementary health 
practices in specific chronic pain populations in WV and nationally. Although efficacy studies for such 
approaches, including herbs, are largely lacking, our research may encourage a more open dialogue 
between physicians and patients about potential opioid alternatives at a time when there is a public 
health epidemic of opioid misuse and abuse (86). However, studies regarding perceived or 
demonstrated efficacy of herbs for FMS and other pain syndromes remain sparse; unfortunately, we 
were unable to adequately measure efficacy on a number of CHAs due to low sample size. 
Nonetheless, clinical studies should ideally examine aspects of CHA and herbal efficacy in pain 
populations rather than observational research; with the inclusion of a larger sample size, the CHAPS 
will be a useful tool in identification of potential herbs and other CHAs of interest. Future observational 
and clinical studies should, however, capture concurrent dietary supplements and medication intakes, 
including opioids, to enable assessment of potential herb-drug interactions in populations with disease.   
Neither CHAs nor herbal use were strongly associated with the SF-GPS subscale in our third 
study; however, 8% of pain patients still reported using herbs specifically for pain. Due to lack of a 
standard definition for herbal products, true herbal prevalence rates for pain are unknown. Moving toward 
an international consensus regarding a widely-used definition for herbal products will only improve the 
quality of research by enabling a greater degree of comparison between studies. Other CHAs were used 
by 58.8% of participants in our sample; again, the comparability of our results to other studies is greatly 
hampered by the lack of standardized CHA definitions.   
  Herbs reported as used for pain management in our third study included ginger and peppermint, which 
have at least preliminary evidence of benefit for pain and/or inflammation, and have been anecdotally 
used for pain in Appalachian herbal texts and qualitative literature (223, 232-235). Our study was the first 
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to report pain patient use of lavender, an herb for which some evidence of anti-inflammatory mechanism 
exists (272); lavender was used specifically for pain in our sample. While ethnobotanical studies are 
important in documenting herbal preparations in a variety of populations for health purposes, our 
epidemiological approach to quantifying the use of herbs is also useful; this approach lays the foundation 
for understanding differences regarding a variety of factors associated with herbal use in subpopulations, 
while enabling our ability to draw estimates for measures of association. Replication of the CHAPS in a 
larger population may yield additional information about the correlates of specific herbs; these future 
studies may inform differences in herbal use by a variety of demographic, lifestyle, and health factors, to 
lay the foundation for clinical studies or when clinical studies are not feasible.   
  
  
Conclusion   
   
Our studies, collectively, demonstrate a need for further clarification regarding the relationships 
between herbal use, FMS, and inflammation.  Our main findings suggest that: inflammation in FMS may 
be partially accounted for by factors including BMI, comorbidities, and other factors; those with FMS are 
significantly more likely to use herbs; and, although herbal use (specifically) for pain may be strongly 
associated with concurrent use of other CHAs for pain, their use may not be associated with pain level, 
but other factors.  Future observational and longitudinal studies must replicate our studies with specific 
improvements: correct classification of herbal use as plant-based products consumed in a variety of 
formats; multiple, concurrent, inflammatory marker measurement; ascertainment of FMS diagnosis 
timing; and, for CHAPS, larger samples to obtain more precise estimates regarding correlates of herbal 
use for pain.   
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Table 1: Characteristics of an Appalachian adult population by Fibromyalgia (FMS) status,   
Adjusted for Demographic and Lifestyle factors, C8 Health Project, 2005-2006  
Characteristic  Total Population          FMS      Non-FMS  Adjusted Odds Ratioa  
                                       N (%) / Mean (SD)          OR (CI), p-value  
Total  52535      1125 (2.1%)  51410 (97.9%)  ---  
Age (years)  45.25  (16.14)       51.14  (11.58)    45.12 (16.20)  1.02 (1.02-1.03), <.0001*  
Age           
      18-24 (ref)  6540 (12.5%)   16   (1.4%)    6524 (12.7%)  ---  
      25-44   20178 (38.4%)  300 (26.7%)    19879 (38.7%)  3.89 (2.30-6.56), <.0001*  
      45-64  19098 (36.4%)       689 (61.2%)   18409 (35.8%)  8.28 (4.91-13.95), <.0001*  
      65+    6719 (12.8%)       120 (10.7%)     6599 (12.8%)  4.37 (2.50-7.64), <.0001*  
Gender          
      Male (ref)    25002 (47.6%)            90 (8.0%)   24912 (48.5%)  ---  
      Female     27533 (52.4%)     1035 (92.0%)   26498 (51.5%)  10.68 (8.53-13.37), <.0001*  
Race/Ethnicity           
       Non-Hispanic White     51092 (97.2%)     1098 (97.6%)   49994 (97.2%)  1.09 (0.73-1.62), .683  
       Other Race (ref)      1443   (2.8%)           27 (2.4%)       1416 (2.8%)        ---  
Education          
      <12th grade (ref)         6261 (11.9%)         106 (9.4%)    6155 (12.0%)                                 ---  
       HS/GED          22353 (42.6%)         445 (39.6%)  21908 (42.6%)        1.57 (1.25-1.96), .0001*  
      Some College         17081 (32.5%)         442 (39.3%)  16639 (32.4%)      2.22 (1.75-2.82), <.0001*  
      Bachelor’s degree+           6840 (13.0%)         132 (11.7%)    6708 (13.1%)       1.91 (1.42-2.56), <.0001*  
Employment          
   Employed/Student(ref)  33682 (64.1%)  482 (42.8%)  33200 (64.6%)  ---  
   Retired/Unemployed  9057 (17.2%)         144 (12.8%)    8913 (17.3%)  1.44 (1.16-1.79), .0008*  
      Disabled  3357 (6.4%)  252 (22.4)     3105 (6.0%)  5.70 (4.73-6.87), <.0001*  
      Homemaker           5979 (11.4%)         233 (20.7%)   5746 (11.2%)  1.50 (1.26-1.78), <.0001*  
      Other      460 (0.88%)             14 (1.2%)       446 (0.9%)  2.23 (1.28-3.88), .004*  
Marital Status          
      Married/Cohabitating (ref)   36198 (68.9%)         836 (74.3%)   35362 (68.8%)  ---  
      Single  8729 (16.6%)  60   (5.3%)     8669 (16.9%)  0.63 (0.47-0.84), .002*  
      Divorced/Sep/Widow  7608 (14.5%)  229 (20.4%)   7379 (14.4%)  0.85 (0.71-1.01), .058  
Household Income          
       Don’t know/Missing  5335   (10.2%)           92   (8.2%)    5243 (10.2%)  0.85 (0.66-1.10), .217  
        <$20,000 (ref)      12308 (23.4%)         288 (25.6%)  12020 (23.4%)  ---  
       $20,000-40,000      14326 (27.3%)         301 (26.8%)  14025 (27.3%)  1.03 (0.86-1.24), .759  
       $40,001-70,000      13559 (25.8%)         291 (25.9%)  13268 (25.8%)  1.05 (0.86-1.29), .619  
       $70,000+       7007 (13.3%)         153 (13.6%)    6854 (13.3%)  1.09 (0.85-1.39), .514  
Alcohol          
      Don’t drink (ref)    26847 (51.1%)         722 (64.2%)  26125 (50.8%)  ---  
     Currently Drink    25688 (48.9%)         403 (35.8%)   25285 (49.2%)  0.86 (0.75-0.98), .023*  
Tobacco User          
      Never (ref)         22859(43.5%)         567 (50.4%)  22292 (43.4%)  ---  
    104  
       Current  16691 (31.8%)         274 (24.4%)  16417 (31.9%)  0.91 (0.78-1.07), .243  
       Former  12985 (24.7%)         284 (25.2%)  12701 (24.7%)  1.06 (0.91-1.23), .441  
Exercise Program          
       No regularity (ref)  36113 (68.7%)         762 (67.7%)  35351 (68.8%)  ---  
       Regular exercise   16422 (31.3%)         363 (32.3%)  16059 (31.2%)  ---  
Menopause occurred  10526 (38.2%)  631 (61.0%)     9895 (37.3%)  1.82 (1.49, 2.21), <.0001*  
Note: Column Percentages shown a Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, 
White Race, and Household Income; Also adjusted for lifestyle covariates Tobacco Use and Current Alcohol consumption  
  
  
Table 2: Health Characteristics of an Appalachian adult population by   
Fibromyalgia (FMS) status, Adjusted for Demographic and Lifestyle factors,   
C8 Health Project, 2005-2006  
Characteristic  Total 
Population   
       FMS  Non-FMS  Adjusted Odds Ratioa  
                                         N (%) / Mean (SD)          OR (CI), p-value  
BMI+   28.53  (6.31)  30.47  (7.22)   28.49 (6.28)  1.02 (1.01-1.03), .001*   
       < 24.99 (ref)      16258 (31.0%)  279 (24.8%)  15979 (31.1%)  ---  
        25.5-29.99      18200 (34.6%)  320 (28.4%)  17880 (34.8%)  1.11 (.932-1.31), .248  
       30 – 34.9      10704 (20.4%)  251 (22.3%)   10453 (20.3%)  1.24 (1.02-1.49), .028*  
       35+      7373 (14.0%)      275 (24.4%)  7098 (13.8%)  1.43 (1.18-1.74), .0003*  
Number of 
Comorbidities  
1.29 (1.27)  2.78 (1.59)  1.25 (1.24)  1.60 (1.54-1.67), <.0001*  
Comorbidity Index          
            None (ref)  16778 (31.9%)  58   (5.2%)  16720 (32.5%)  ---  
            1  16999 (32.4%)      177 (15.7%)  16822 (32.7%)  2.38 (1.77-3.21), <.0001*  
            2  10535 (20.1%)      301 (26.8%)  10234 (19.9%)  5.16 (3.88-6.86), <.0001*  
            3+  8223 (15.7%)       589 (52.4%)  7634 (14.9%)  10.46 (7.90-13.84), <.0001*  
Autoimmune disorder  2192   (4.2%)  220 (19.6%)  1972 (3.8%)  3.43 (2.89-4.06), <.0001*  
Osteoarthritis  4093 (7.7%)  411 (35.5%)  3782 (7.1%)  3.86 (3.34-4.45), <.0001*  
Allergies or Chronic 
Sinusitis  
24470 (46.6%)  893 (79.4%)  23577 (45.9%)   2.91 (2.51-3.38), <.0001*  
Kidney disorder  5202   (9.9%)  226 (20.1%)  4976 (9.7%)  1.72 (1.47-2.01), <.0001*  
Respiratory disease  7385 (14.1%)  342 (30.4%)  7043 (13.7%)  1.89 (1.64-2.17), <.0001*  
Cardiovascular 
disease   
4661   (8.9%)  148 (13.2%)  4513 (8.9%)  1.25 (1.03-1.51), .027*  
Liver disease                 684   (1.3%)   38   (3.4%)   646 (1.3%)  1.51 (1.06-2.16), .022*  
Endocrine Disorder  4083 (7.8%)  264 (23.5%)  3819 (7.4%)  1.82 (1.57-2.12), <.0001*  
Diabetes  4778 (9.1%)   157 (14.0%)  4621 (9.0%)  .978 (.813-1.18), .810  
Frequent Headache  10105 (19.2%)  439 (39.0%)  9666 (18.8%)  2.03 (1.78-2.31), <.0001*  
Sleep Impairment  
Scores  
4.00 (3.56)  7.32 (3.29)  3.93 (3.53)  1.23 (1.21-1.25), <.0001*  
Mood Disturbance  
Scorem  
4.59 (3.70)  7.25 (3.40)  4.53 (3.68)  1.19 (1.17-1.21), <.0001*  
 
Note: Column Percentages shown  
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a Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household Income;       
Also adjusted for lifestyle covariates Tobacco Use and Current Alcohol consumption  
S Sleep impairment derived from responses to four individual questions regarding the frequency of short sleep, fitful sleep, insomnia and/or 
daytime somnolence; higher   
    score indicates increased frequency of impairment m Mood disturbance derived from responses to four individual questions regarding 
frequent mood swings, irritability, fatigue and/or inability to  
concentrate; higher       
   score indicates increased frequency of disturbance  
  
  
  
Table 3: Model Statistics assessing the association between Fibromyalgia (FMS) and blood serum  C-
reactive Protein (CRP) quartile adjusting for BMI and Comorbidity index in an Appalachian adult 
population, 2005-2006 (N=52,535)  
  
  Characteristic  
  
  
   Total   
  
  
FMS  
  
NonFMS  
  
Models  
Odds Ratio (CI) (p-value)  
 
  
N (%) / Mean (SD)  
Crudee  Adjusted for  
Demographic 
and Lifestyle 
Factors  
(Model 1)f  
Model 1 + 
BMIg  
Model 1 + 
comorbiditiesh  
Model 1 +  
BMI & 
comorbiditiesr  
CRP level (mg/L)  3.79  (7.22)   5.54 (9.77)  3.75 (7.15)  1.02 (1.011.02)  
(<.0001*)  
1.01 (1.00- 
1.01) (.004*)  
1.01 (1.00- 
1.01) (.059)  
1.00 (.997-1.01) 
(.267)  
1.00 (.997-1.01) 
(.279)  
CRP   Quartile 1a  
(ref)         
14516  
(27.6%)  
192  
(17.1%)  
14324  
(27.9%)  
                ---                 ---                  ---                  ---                  ---  
          Quartile 2b          12221 
(23.3%)  
214 (19.0%)  12007  
(23.4%)  
1.33 (1.09-1.62) 
(.004*)  
1.13 (0.92-1.38) 
(.243)  
1.07 (0.88- 
1.32) (.473)  
1.04 (0.85-1.28) 
(.686)  
1.03 (0.84-1.27) 
(.750)  
          Quartile 3c          12755 (24.3% 297 (26.4%)  12458 (24.2% 1.78 (1.48-2.14) 
(<.0001*)  
1.23 (1.02-1.48) 
(.032*)  
1.12 (0.92- 
1.37) (.244)  
1.08 (0.89-1.30) 
(.452)  
1.06 (0.87-1.29) 
(.576)  
          Quartile 4d  
Wald X2, p for trendt  
13043  
(24.8%)  
422 (37.5%)  12621  
(24.6%)  
2.50 (2.10-2.97)  
(<.0001*)  
118.42,  
(<.0001*)  
1.35 (1.13-1.62)  
(.0009*)  
17.48,  
(<.0001*)  
1.17 (0.961.42) 
(.120)  
4.02, (.045*)  
1.10 (0.92-1.32)  
(.310)  
3.44, (.064)  
1.07 (0.88-1.30)  
(.510)  
1.23, (.269)        
a C-reactive protein .15-.80  mg/L b 
C-reactive protein .81-1.80 mg/L c 
C-reactive protein 1.81-4.20 mg/L d 
C-reactive protein 4.21-250.6 mg/L  
t Linear trend e (R2==.003) f  Full Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household 
Income; Also adjusted for  
lifestyle covariates Tobacco Use and Current Alcohol consumption (R2= .031)  
g (R2=.031)  
h Model adjusted for Comorbidity index; index included diabetes, other endocrine disorders (thyroid, Addison’s, and Cushing’s disease), kidney 
disease, respiratory  
conditions (asthma, emphysema, chronic obstructive pulmonary disorder, bronchitis), osteoarthritis, heart disease, liver disease, autoimmune disorders (defined as having 
any diagnoses of immune disease, lupus, or rheumatoid arthritis), sleep apnea, irritable bowel syndrome,  allergies or frequent sinusitis, or frequent recurrent headache  
(R2=.041) 
r (R2=.041)  
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Table 4: Model Statistics assessing the association between Fibromyalgia (FMS) and blood serum   
C-reactive Protein (CRP) quartile adjusting for Sleep impairment and Mood disturbance  in 
an Appalachian adult population, 2005-2006 (N=52,535)  
                      Models  
Odds Ratio (CI) (p-value)  
 
Crudee  Adjusted for  
Demographic and 
Lifestyle Factors  
(Model 1)f  
Model 1 + Moodg  Model 1 + Sleeph  Model 1 + 
Mood & Sleepr  
CRP level (mg/L)  1.02 (1.01-1.02) 
(<.0001*)  
1.01 (1.00-1.01) (.004*)  1.01 (1.00-1.01) (.021*)  1.01 (1.00-1.01) (.035*)  1.01 (1.00-1.01) 
(.031*)  
CRP   Quartile 1a  
(ref)         
                ---                  ---                  ---                  ---                  ---  
          Quartile 2b         1.33 (1.09-1.62) (.004*)  1.13 (0.92-1.38) (.243)  1.12 (0.91-1.36) (.287)  1.10 (0.90-1.35) (.357)  1.10 (0.90-1.34) 
(.363)  
          Quartile 3c          1.78 (1.48-2.14) (<.0001*)  1.23 (1.02-1.48) (.032*)  1.20 (1.00-1.45) (.056)  1.18 (0.98-1.43) (.083)  1.18 (0.97-1.42) 
(.093)  
          Quartile 4d  2.50 (2.10-2.97) (<.0001*)  1.35 (1.13-1.62) (.0009*)  1.28 (1.07-1.53) (.007*)  1.26 (1.05-1.51) (.011*)  1.24 (1.03-1.48) 
(.021*)  
Wald X2, p for trendt  118.42, (<.0001*)  17.48, (<.0001*)  11.06, (.0009*)  10.40, (.001*)  8.25, (.004*)  
a C-reactive protein .15-.80  mg/L b 
C-reactive protein .81-1.80 mg/L c 
C-reactive protein 1.81-4.20 mg/L  
d C-reactive protein 4.21-250.6 mg/L  
         t  Linear trend e (R2==.003) f  Full Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household 
Income; Also adjusted for lifestyle covariates Tobacco Use and Current Alcohol consumption (R2= .031)  
g Mood disturbance derived from responses to four individual questions regarding frequent mood swings, irritability, fatigue and/or inability to concentrate (R2=.035) 
h Sleep impairment derived from responses to four individual questions regarding the frequency of short sleep, fitful sleep, insomnia and/or daytime somnolence  
(R2=.037) 
r (R2=.038)  
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Table 1a: Demographic and Lifestyle Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by Herbal use (previous or current use of herbal products) 
 
 Yes  No Yes  No 
 Weighted   Weighted   
 Characteristic N (%)  95% CI population  N (%)  N (%)  95% CI population  N (%)  
 estimate* estimate** 
Total 
Age in years  
       18-24 
       25-44  
       45-64 
       65-75 
       75+ 
       Mean (SE) 
Gender 
       Male  
       Female  
Race/Ethnicity  
       Non-Hispanic White  
       Non-Hispanic Black 
       Hispanic  
       Asian 
       Other Race/ethnicity   
Education 
        <12th grade 
        HS/GED 
        Tech Training/some College 
        >Bachelor’s degree 
Employment 
       Employed for pay 
       Employed but not for pay 
       Unemployed 
Income  
$1 - $24,999 
       $25,000 - $44,999 
       $45,000 - $74,999 
       $75,000 and over 
       Don't know 
       Missing 
Marital Status  
       Married/Cohabitating 
Never married 
Divorced/Sep/Widow 
Insurance status 
Uninsured  
Medicaid 
Medicare 
Disability 
Private insurance 
Out of pocket costs, past year$ 
        None 
        <$500 
        $500-$1999 
        $2000-$2999 
        $3000-$4999 
        $5000+ 
        Don't know 
Delayed Care because could not  
afford/worried about cost 
Geographic location 
         Northeast 
         Midwest 
         South 
         West 
Place of birth 
         US born 
Physical ActivityR 
        NoneS 
        Low/Moderate  
        High  
           Mean (SE)  (weekly)(min)  
Tobacco Use  
     Never 
     Former 
       Current 
Alcohol Use 
       None 
       Light 
       Moderate to heavy 
Substance Abuse  
Use of other Complementary  
Health Approachest 
        Other Natural Productsa 
        Mind-bodyb 
        Manipulative/Bodyworkc 
        Energy healing/Reiki 
        Spiritual practicesd 
        Alternative medical systemse 
5057 (27.1) (26.2, 27.9) 23057602 15070 (72.9) 
 
7238 (24.2) (23.5, 25.0) 21914809 23434 (75.8) 
 
<.0001 
  
<.0001 
    
<.0001 <.0001 
397 (8.4) (7.2, 9.7) 1943145 1756 (12.0) 
 
507 (7.3) (6.4, 8.2) 1600475 2521 (11.5) 
  
1700 (33.5) (31.9, 35.0) 7717572 5664 (36.2) 
 
2400 (32.5) (31.0, 33.9) 7112702 8254 (34.1) 
  
1992 (39.4) (37.8, 41.0) 9088019 4736 (31.7) 
 
2846 (39.5) (38.1, 40.9) 8653969 7695 (32.5) 
  
591 (11.3) (10.3, 12.3) 2597876 1470 (9.6) 
 
953 (13.7) (12.8, 14.6) 3002082 2565 (11.3) 
  
377 (7.4) (6.6, 8.3) 1710990 1444 (10.5) 
 
532 (7.1) (6.3, 7.8) 1545581 2399 (10.6) 
  
48.35 (0.33) (47.71, 48.99) 
 
47.14 (0.28) 0.0009 49.44 (0.28) (48.90, 50.00) 
 
48.2 (0.20) 0.001 0.0158 
    
<.0001 
    
<.0001 <.0001 
2187 (44.0) (42.4, 45.6) 10145502 6992 (48.0) 
 
3136 (43.4) (41.9, 44.9) 9516692 10770 (47.5) 
  
2870 (56.0) (54.4, 57.6) 12912100 8078 (52.0) 
 
4102 (56.6) (55.1, 58.1) 12398117 12664 (52.5) 
  
    
<.0001 
    
<.0001 <.0001 
3771 (82.0) (80.9, 83.2) 18915344 8364 (68.5) 
 
5226 (78.5)  (77.4, 79.7) 17213880 13390 (66.6) 
  
523 (7.7) (6.9, 8.6) 1782620 2618 (13.9) 
 
681 (7.7) (7.0, 8.5) 1697535 3890 (13.7) 
  
516 (6.8) (6.1, 7.5) 1567155 3202 (13.4) 
 
839 (8.9) (8.2, 9.7) 1961358 4579 (14.8) 
  
141 (1.8) (1.5, 2.2) 426139 505 (2.3) 
 
266 (2.7) (2.3, 3.1) 593743 905 (2.9) 
  
106 (1.6) (1.3, 1.9) 366344 381 (1.9) 
 
226 (2.0) (1.7, 2.3) 448293 670 (2.1) 
  
    
<.0001 
    
<.0001 <.0001 
411 (7.3) (6.5, 8.1) 1687140 3168 (17.4) 
 
576 (6.6) (5.9, 7.4) 1456473 4261 (15.7) 
  
1147 (22.3) (20.9, 23.6) 5138228 4491 (30.4) 
 
1409 (19.0) (17.9, 20.1) 4161460 6494 (27.2) 
  
1682 (33.3) (31.8, 34.9) 7680535 4030 (28.0) 
 
2547 (35.4) (33.9, 36.9) 7764858 6925 (30.3) 
  
1817 (37.1) (35.5, 38.7) 8551699 3381 (24.2) 
 
2706 (38.9) (37.4, 40.5) 8532018 5754 (26.8) 
  
    
<.0001 
    
<.0001 <.0001 
3125 (62.3) (60.7, 63.9) 14359042 8882 (59.0) 
 
4287 (59.3) (57.8, 60.8) 12989605 12871 (55.3) 
  
211 (4.6) (3.9, 5.3) 1056194 416 (3.0) 
 
309 (4.5) (3.8, 5.1) 979184 621 (2.8) 
  
1721 (33.1) (31.6, 34.6) 7642366 5772 (38.0) 
 
2642 (36.3) (34.8, 37.7) 7946020 9942 (41.9) 
  
    
<.0001 
    
<.0001 <.0001 
1170 (23.4) (22.0, 24.8) 5392332 3360 (22.1) 
 
1608 (21.8) (20.6, 22.9) 4772787 5248 (21.4) 
  
                               Herbal use P                             Herbal use P       Overall P W 
  2007 (N = 20,127)                        2012 
  
( N = 30 , 672 ) 
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831 (16.8) (15.6, 18.0) 3878888 2290 (15.5) 
 
1185 (16.4) (15.3, 17.5) 3586770 3384 (14.4) 
  
678 (13.5) (12.3, 14.7) 3115599 1443 (10.3) 
 
1038 (14.6) (13.6, 15.6) 3192245 2492 (11.4) 
  
455 (9.4) (8.4, 10.4) 2163806 744 (5.4) 
 
741 (11.0) (10.1, 11.9) 2412850 1525 (7.4) 
  
192 (3.7) (3.1, 4.2) 843187 881 (5.4) 
 
230 (2.9) (2.5, 3.4) 646373 1062 (4.5) 
  
1731 (33.2) (31.5, 35.0) 7663790 6352 (41.3) 
 
2436 (33.3) (31.9, 34.7) 7303784 9723 (41.0) 
  
    
0.118 
    
0.0002 <.0001 
2699 (52.4) (50.7, 54.2) 12086329 7711 (51.1) 
 
3780 (52.1) (50.5, 53.7) 11421411 11439 (49.1) 
  
1030 (21.4) (19.9, 22.9) 4937934 3480 (23.1) 
 
1577 (22.4) (21.1, 23.8) 4915172 5813 (25.0) 
  
1328 (26.2) (24.8, 27.6) 6033339 3879 (25.7) 
 
1881 (25.5) (24.2, 26.7) 5578226 6182 (25.9) 
  
           
716 (13.5) (12.6, 14.4) 3108438 2788 (16.5) <.0001 1089 (13.8) (12.9, 14.7) 3025400 4406 (16.5) <.0001 <.0001 
237 (4.2) (3.6, 4.8) 971775 1428 (7.8) <.0001 412 (4.7) (4.1, 5.2) 1021071 2611 (9.6) <.0001 <.0001 
1061 (20.6) (19.2, 22.0) 4749125 3191 (22.1) 0.058 1654 (22.9) (21.6, 24.1) 5011748 5545 (24.1) 0.1 <.0001 
86 (1.9) (1.3, 2.4) 426800 142 (0.89) <.0001 130 (1.8) (1.4, 2.2) 394974 239 (1.0) <.0001 <.0001 
3572 (72.5) (71.1, 73.9) 16717518 9176 (64.6) <.0001 4826 (69.0) (67.5, 70.4) 15115629 13148 (59.9) <.0001 <.0001 
    
<.0001 
    
<.0001 <.0001 
424 (8.0) (7.1, 8.9) 1842858 2017 (12.0) 
 
674 (8.6) (7.8, 9.4) 1879476 3620 (14.2) 
  
1763 (34.6) (33.1, 36.1) 7972887 6205 (40.2) 
 
2406 (31.9) (30.6, 33.2) 6989608 8967 (37.5) 
  
1739 (34.4) (33.0, 35.9) 7935523 4252 (28.9) 
 
2340 (33.2) (32.0, 34.4) 7272642 6407 (28.1) 
  
467 (9.4) (8.4, 10.3) 2165805 1017 (7.4) 
 
722 (10.3) (9.5, 11.2) 2267715 1857 (8.6) 
  
296  (5.9) (5.2, 6.7) 1368788 612 (4.4) 
 
528 (7.9) (7.3, 8.6) 1737660 1129 (5.0) 
  
305 (6.3) (5.7, 7.0) 1460678 552 (3.9) 
 
501 (7.1) (6.4, 7.8) 1557788 1075 (5.0) 
  
63 (1.3) (0.91, 1.8) 311063 415 (3.1) 
 
67 (0.96) (0.70, 1.2) 209920 379 (1.6) 
  
856 (17.3) (16.1, 18.5) 3991358 1712 (11.5) <.0001 1273 (16.9) (15.9, 17.9) 3703456 3169 (12.9) <.0001 <.0001 
    
<.0001 
    
<.0001 <.0001 
763 (15.6) (14.1, 17.2) 3600700 2561 (17.6) 
 
993 (13.8) (12.5, 15.1) 3029506 4094 (18.7) 
  
1213 (26.0) (23.6, 28.4) 5992975 3279 (24.8) 
 
1610 (26.0) (24.2, 27.7) 5690774 4793 (23.1) 
  
1703 (32.5) (30.2, 34.8) 7491580 5824 (38.3) 
 
2033 (29.7) (27.6, 31.7) 6503257 9156 (39.5) 
  
1378 (25.9) (24.0, 27.8) 5972347 3406 (19.3) 
 
2602 (30.5) (28.8, 32.3) 6691272 5391 (18.8) 
  
          
<.0001 
4472 (91.1) (90.3, 91.9) 21012787 11808 (84.7) <.0001 6287 (89.3) (88.5, 90.2) 19578199 18616 (83.2) <.0001 
 
           
1371 (25.9) (24.4, 27.4) 5970320 6972 (43.7) <.0001 1552 (20.5) (19.4, 21.7) 4500886 8662 (35.5) <.0001 <.0001 
3155 (63.7) (62.0, 65.4) 14689791 6647 (46.1) <.0001 4971 (69.9) 
3705 (52.7) 
(68.6, 71.2) 
(51.2, 54.2) 
15313768 
11550005 
12295 (53.9) <.0001 <.0001 
2240 (45.9) (44.1, 47.7) 10581806 4537 (32.7) <.0001 9036 (40.1) <.0001 <.0001 
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275.56 (8.87) (258.10, 293.02) 
 
192.0 (6.28) <.0001 310.63 (8.6) (293.79, 327.47) 
 
237.8 (4.8) <.0001  0.0046 
    
<.0001 
    
<.0001 <.0001 
2696 (51.8) (50.2, 53.5) 11951861 9175 (58.0) 
 
4087 (56.0) (54.7, 57.4) 12277432 13966 (58.6) 
  
1438 (28.5) (27.1, 29.9) 6570756 2921 (20.9) 
 
1974 (28.0) (26.8, 29.3) 6141595 4846 (21.7) 
  
923 (19.7) (18.2, 21.1) 4534985 2974 (21.0) 
 
1177 (16.0) (14.9, 17.0) 3495782 4622 (19.7) 
  
    
<.0001 
    
<.0001 <.0001 
1405 (26.4) (24.9, 27.9) 6088296 6559 (40.9) 
 
1974 (25.0) (23.7, 26.3) 5471701 9377 (37.2) 
  
2438 (47.6) (46.0, 49.2) 10973974 5911 (40.4) 
 
3477 (48.8) (47.4, 50.3) 10701511 9611 (42.4) 
  
1214 (26.0) (24.5, 27.5) 5995332 2600 (19.1) 
 
1787 (26.2) (24.9, 27.5) 5741597 4446 (20.3) 
  
39 (0.80) (0.52, 1.1) 182916 87 (0.60) 0.189 78 (1.2) (0.85, 1.5) 252648 148 (0.65) 0.0008 <.0001 
4990 (98.8) (98.5, 99.1) 22775084 12699 (84.8) <.0001 6996 (97.0) (96.6, 97.4) 21258408 16050 (70.4) <.0001 <.0001 
4672 (92.8) (91.9, 93.6) 21394190 8902 (61.5) <.0001 6747 (93.8) (93.1, 94.4) 20545840 14274 (62.8) <.0001 <.0001 
2577 (52.0) (50.5, 53.5) 11983152 2914 (20.8) <.0001 2646 (37.9) (36.5, 39.4) 8310751 2738 (12.5) <.0001 <.0001 
2730 (55.3) (53.7, 56.9) 12753689 3448 (24.8) <.0001 3584 (50.4) (49.0, 51.9) 11051380 5274 (23.7) <.0001 <.0001 
260 (5.3) (4.6, 6.1) 1230209 95 (0.61) <.0001 286 (4.1) (3.6, 4.6) 894463 77 (0.32) <.0001 <.0001 
3267 (63.7) (62.0, 65.4) 14681433 8704 (56.0) <.0001 813 (11.9) (11.0, 12.7) 2603754 548 (2.4) <.0001 <.0001 
1094 (21.6) (20.2, 23.0) 4972413 900 (5.9) <.0001 1281 (17.8) (16.8, 18.9) 3910655 987 (4.2) <.0001 <.0001 
 Note: Column Percentages shown * Adjusted for age, sex, race/ethnicity  **Adjusted for age, sex,  
based on 2000 Census data race/ethnicity based on 2010 Census data 
a. Supplements other than herbs, including Vitamins/Minerals,  probiotics (past 30 days), fish oil (past 30 days), chelation therapies 
b. Tai Chi/Qi Gong, Yoga, guided imagery, progressive relaxation, deep breathing exercises, Meditation (for which singular term "meditation" is used in 2007; was expanded in 2012 to include mantra, and mindfulness meditation), 
Stress-management class and support group (2007), mindfulness meditation: including  mindfulness-base stress reduction and congitive therapy (2012)  Biofeedback, hypnosis c. (Ever) Practitioner-based massage, 
chiropractic/osteopathic manipulation, Sobador visit 
d. Prayed for one's own health (2007) or centering prayer/contemplative meditation (2012); and/or, visit with espiritista (2007 only), cuarandero, shaman, and/or Native American healer e. Acupuncture, 
Ayurveda, homeopathy, naturopathy  
$ family costs aside from deductibles, premiums, copays 
R. Defined as >10 min per week 
 W. p-values obtained by comparing weighted estimates   
Table 1b: Health Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by ever using herbal products 
 
 Weighted   Weighted   
 N (%)  95% CI population  N (%)  N (%)  95% CI population  N (%)  
 estimate* estimate** 
Body Mass Index (BMI)  
        <24.9 
        25-29.9 
        30-35 
        35+ 
           Mean (SE) 
Comorbidity Indexa  
0 
1 
2 
3+ 
           Mean (SE) 
Chronic Health Conditions 
     Diabetes 
     Kidney disease 
     GI diseaseaa 
     Chronic Respiratory     
conditionsb  
     CVDc 
     Hypertension 
     Dyslipidemia 
     Liver disease 
     Chronic pain conditionsd 
     Mental health conditionse 
     Insomnia 
     History of Cancer  
Perceived health status 
   Excellent/very good/good 
          Fair 
          Poor 
    
0.125 
    
0.158 <.0001 
1929 (38.6) (37.0, 40.1) 8889846 5698 (38.8) 
 2663 (37.6) (36.3, 39.0) 8244907 
8433 (36.5) 
  
1739 (34.2) (32.8, 35.6) 7883150 5382 (35.6) 
 
2524 (34.5) (33.2, 35.8) 7562183 8109 (34.8) 
  
871 (17.1) (15.9, 18.4) 3944736 2474 (16.0) 
 
1209 (16.6) (15.6, 17.6) 3633769 4119 (17.3) 
  
518 (10.1) (9.1, 11.2) 2339870 1516 (9.6) 
 
842 (11.3) (10.5, 12.1) 2473950 2773 (11.4) 
  
27.47 (0.10) (27.27, 27.67) 
 
27.31 (0.06) 0.182 27.70 (0.08) (27.55, 27.86) 
 
27.73 (0.05) 0.735 0.0743 
    
<.0001 
    
<.0001 <.0001 
1331 (26.3) (24.9, 27.7) 6056905 6119 (39.6) 
 
1372 (18.7) (17.7, 19.7) 4095224 7251 (30.6) 
  
1268 (25.6) (24.3, 27.0) 5911165 3490 (23.5) 
 
1614 (22.2) (21.1, 23.4) 4873381 5321 (22.9) 
  
919 (18.2) (17.0, 19.4) 4199183 2231 (15.2) 
 
1405 (19.5) (18.5, 20.5) 4265489 3921 (17.1) 
  
1539 (29.9) (28.5, 31.3) 6890349 3230 (21.6) 
 
2847 (39.6) (38.2, 41.0) 8680715 6941 (29.4) 
  
1.82 (0.03) (1.76, 1.88) 
 
1.42 (0.02) <.0001 2.25 (0.03) (2.20, 2.31) 
 
1.80 (0.02) <.0001 <.0001 
                            Herbal use P                            Herbal use P     Overall P W 
Yes  No Yes  No 
2007 ( N  = 20,127)                      2012 
  
( N  = 
  
30 , 672 ) 
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442 (8.2) (7.3, 9.0) 1885710 1505 (9.5) 0.007 806 (10.7) (9.8, 11.5) 2337648 2755 (11.1) 0.388 <.0001 
85 (1.8) (1.3, 2.1) 397934 261 (1.6) 0.621 126 (1.6) (1.3, 1.9) 352738 471 (1.9) 0.128 <.0001 
830 (16.7) (15.5, 17.9) 3848711 1456 (10.1) <.0001 2907 (40.8) (39.4, 42.1) 8936761 6747 (29.0) <.0001 <.0001 
875 (17.2) (16.0, 18.4) 3957352 1884 (12.9) <.0001 1331 (18.3) (17.2, 19.4) 4015034 3416 (14.8) <.0001 <.0001 
359 (6.9) (6.1, 7.7) 1597503 976 (6.8) 0.09 517 (7.2) (6.5, 7.8) 1569346 1705 (7.3) 0.674 <.0001 
1594 (30.8) (29.3, 32.3) 7107125 4306 (28.5) 0.01 2439 (33.5) (32.2, 34.8) 7336612 7585 (32.1) 0.067 <.0001 
1608 (31.5) (30.1, 33.0) 7274054 3528 (24.0) <.0001 2468 (33.8) (32.4, 35.2) 7408479 6041 (26.2) <.0001 <.0001 
74 (1.5) (1.1, 1.9) 345579 178 (1.1) 0.06 123 (1.6) (1.3, 1.9) 345528 316 (1.3) 0.135 <.0001 
2561 (50.8) (49.2, 52.4) 11715342 5215 (35.6) <.0001 3928 (55.0) (53.6, 56.4) 12047659 9033 (38.9) <.0001 <.0001 
1189 (23.9) (22.4, 25.3) 5506796 2266 (15.1) <.0001 2249 (30.8) (29.6, 32.1) 6758368 5279 (22.2) <.0001 <.0001 
1331 (26.4) (24.9, 27.8) 6082197 2502 (17.0) <.0001 1957 (26.8) (25.6, 28.0) 5874097 4259 (18.1) <.0001 <.0001 
488 (9.8) (8.9,10.7) 2258274 968 (7.2) <.0001 740 (10.5) (9.6, 11.3) 2293335 1868 (8.6) <.0001 <.0001 
    
0.002 
    
<.0001 <.0001 
4402 (87.5) (86.5, 88.5) 20170533 12893 (86.2) 
 
6335 (88.6) (87.8, 89.5) 19423622 19897 (86.2) 
  
520 (10.0) (9.1, 10.9) 2305743 1624 (10.2) 
 
713 (9.0) (8.2, 9.7) 1962675 2734 (10.6) 
  
135 (2.5) (2.0, 3.0) 581326 553 (3.7) 
 
190 (2.4) (2.0, 2.8) 528512 803 (3.2) 
  
**Adjusted for age, sex,  
* Adjusted for age, sex, race/ethnicity  
 Note: Column Percentages shown race/ethnicity based on 2010  
based on 2000 Census data 
Census data 
a. Includes diabetes, kidney disease, Gastrointestinal disorder (including ulcer and/or abdominal pain, digestive allergy, heartburn), respiratory conditions (Asthma, emphesema, and.or chronic bronchitis), dyslipidemia, liver condition, Rheumatoid 
Arthritis, CVD, hypertension, non-specific arthritis, gout, migraines, mental health condition  
aa. Includes: bowel conditions and ulcers (2007); past 12 month abdominal pain, digestive allergy, heartburn, and ever having ulcer (2012) b. Asthma, 
emphysema, and/or chronic bronchitis 
c. Myocardial Infarction, Heart Disease, Angina pectoris 
d. Migraines (past 3 months), nonspecific arthritis, gout, non-specific joint pain for 3+ months, Rheumatoid Arthritis 
e. Depression, bipolar disorder, phobias, often anxious in past year 
 W. p-values obtained by comparing weighted estimates          
  
Table 2a: Demographic and Lifestyle Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by herbal use in the last 12 months 
 
 Characteristic Yes  No Yes  No 
 Weighted   Weighted   
 N (%)  95% CI population  N (%)  N (%)  95% CI population  N (%)  
 estimate* estimate** 
Total 
Age in years  
       18-24 
       25-44  
       45-64 
       65-75 
       75+ 
       Mean (SE) 
Gender 
       Male  
       Female  
Race/Ethnicity  
       Non-Hispanic White  
       Non-Hispanic Black 
       Hispanic  
       Asian 
       Other Race/ethnicity   
Education 
        <12th grade 
        HS/GED 
        Tech Training/some  
College 
        >Bachelor’s degree 
Employment 
       Employed for pay 
       Employed but not for pay 
       Unemployed 
Income  
       $1 - $24,999 
       $25,000 - $44,999 
       $45,000 - $74,999 
       $75,000 and over 
       Don't know 
       Missing 
Marital Status  
       Married/Cohabitating        
Never married 
       Divorced/Sep/Widow 
Insurance status 
3582 (19.1) (18.4, 19.8) 16270972 16545 (80.9) 
 
5490 (16.4) (15.8, 17.1) 16713004 25182 (72.4) 
 
<.0001 
  
<.0001 
    
<.0001 <.0001 
269 (8.2) (6.8, 9.6) 1332833 1884 (11.7) 
 
391 (7.4) (6.3, 8.4) 1231081 2637 (11.1) 
  
1169 (31.9) (30.1, 33.7) 5193487 6195 (36.3) 
 
1775 (32.1) (30.4, 33.7) 5358304 8879 (34.1) 
  
1414 (39.8) (37.9, 41.7) 6476821 5314 (32.3) 
 
2162 (39.1) (37.5, 40.8) 6542615 8379 (33.1) 
  
462 (12.6) (11.4, 13.7) 2044193 1599 (9.5) 
 
741 (14.0) (12.8, 15.1) 2332396 2777 (11.4)  
  
268 (7.5) (6.5, 8.5) 1223638 1553 (10.2) 
 
421 (7.5) (6.6, 8.4) 1248608 2510 (10.3) 
  
49.06 (0.35) (48.38, 49.75) 
 
47.09 (0.27) <.0001 49.58 (0.33) (48.93, 50.23) 
 
48.24 (0.19) <.0001 0.2794 
    
0.0001 
    
<.0001 <.0001 
1535 (43.2) (41.3, 45.1) 7028291 7644 (47.8) 
 2341 (42.8) (41.1, 44.5) 7153927 11565 (47.3)   
2047 (56.8) (54.9, 58.7) 9242681 8901 (52.2) 
 3149 (57.2) (55.5, 58.9) 9559077 13617 (52.7)   
    
<.0001 
    
<.0001 <.0001 
2716 (82.9) (81.7, 84.1) 13487880 9419 (69.6) 
 
3979 (78.8) (77.5, 80.1) 13163299 14637(67.4) 
  
                             Herbal use P                               Herbal use P     Overall P W 
2007 ( N  = 20,127)                           2012 
  
( N = 30 , 672 ) 
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       Uninsured  
       Medicaid 
       Medicare 
       Disability 
       Private insurance 
Out of pocket costs, past  
year$ 
        None 
        <$500 
        $500-$1999 
        $2000-$2999 
        $3000-$4999 
        $5000+ 
        Don't know 
Delayed Care because could 
not afford/worried about cost 
Geographic location 
         Northeast 
         Midwest 
         South 
         West 
Place of birth 
         US born 
Physical ActivityR 
        None 
        Low/Moderate  
        High  
           Mean (SE)  (weekly)(min)  
Tobacco Use  
        Never 
        Former 
        Current 
Alcohol Use 
        None 
        Light 
        Moderate to heavy 
Substance Abuse  
Use of other Complementary  
Health Approachest 
        Other Natural Productsa 
        Mind-bodyb 
        Manipulative/Bodyworkc 
        Energy healing/Reiki 
        Spiritual practicesd         
Alternative medical 
systemse 
329 (6.9) (6.0, 7.8) 1121133 2812 (13.5) 
 
513 (7.6) (6.7, 8.4) 1266927 4058 (13.3) 
  
360 (6.7) (5.9, 7.5) 1091895 3358 (12.8) 
 
622 (9.0) (8.1, 9.8) 1496127 4796 (14.4) 
  
99 (1.8) (1.4, 2.2) 297318 547 (2.3) 
 
196 (2.6) (2.2, 3.0) 438850 975 (2.9) 
  
78 (1.7) (1.3, 2.0) 272746 409 (1.8) 
 
180 (2.1) (1.7, 2.4) 347801 716 (2.1) 
  
    
<.0001 
    
<.0001 <.0001 
272 (7.0) (6.1, 7.8) 1131795 3307 (16.5) 
 
417 (6.4) (5.7, 7.2) 1076502 4420 (15.1) 
  
808 (22.3) (20.7, 23.8) 3624376 4830 (29.6) 
 
1043(18.4) (17.2, 19.6) 3078409 6860 (26.8) 
  
1185 (33.4) (31.6, 35.2) 5436406 4527 28.5) 
 
1924 (35.3) (33.6, 36.9) 5896361 7548 (30.7) 
  
1317 (37.4) (35.4, 39.3) 6078395 3881 (25.4) 
 
2106 (39.9) (38.1, 41.6) 6661732 6354 (27.4) 
  
    
<.0001 
    
<.0001 <.0001 
2189 (61.6) (59.8, 63.3) 10016152 9818 (59.5) 
 
3301 (60.2) (58.5, 61.9) 10065089 13857(55.4) 
  
162 (4.8) (4.0, 5.6) 784425 465 (3.1) 
 
227 (4.3) (3.7, 5.0) 725979 703(3.0) 
  
1231 (33.6) (31.9, 35.3) 5470395 6262 (37.4) 
 
1962 (35.4) (33.7, 37.1) 5921936 10622 (41.7) 
  
    
<.0001 
    
<.0001 <.0001 
820 (23.4) (21.8, 25.1) 3809168 3710 (22.2) 
 
1186 (21.0) (19.8, 22.3) 3512363 5670 (21.6) 
  
576 (15.7) (14.3, 17.1) 2553714 2545 (15.9) 
 
894 (16.3) (15.1, 17.5) 2727946 3675 (14.5) 
  
478 (13.5) (12.2, 14.9) 2203952 1643 (10.6) 
 
803 (14.9) (13.7, 16.0) 2490180 2727 (11.5) 
  
341 (10.0) (8.8, 11.1) 1622926 858 (5.6) 
 
583 (11.4) (10.4, 12.5) 1912903 1683 (7.5) 
  
129 (3.6) (3.0, 4.2) 578665 944 (5.3) 
 
189 (3.2) (2.6, 3.8) 538020 1103 4.3) 
  
1238 (33.8) (31.9, 35.7) 5502547 6845 (40.4) 
 
1835 (33.1) (31.6, 34.6) 5531592 10324 (40.5) 
  
    
0.088 
    
0.009 <.0001 
1903 (52.0) (50.0, 53.9) 8453944 8507 (51.4) 
 
2865 (52.1) (50.2, 53.9) 8703339 12354 (49.4) 
  
710 (21.0) (19.2, 22.7) 3411156 3800 (23.1) 
 
1206 (22.8) (21.2, 24.4) 3813588 6184 (24.7) 
  
969 (27.1) (25.5, 28.7) 4405872 4238 (25.6) 
 
1419 (25.1) (23.7, 26.5) 4196077 6644 (25.9) 
  
           
505 (13.4) (12.4, 14.5) 2185136 2999 (16.2) <.0001 790 (13.0) (12.0, 13.9) 2168607 4705 (16.5) <.0001 <.0001 
155 (4.0) (3.3, 4.6) 645744 1510 (7.6) <.0001 287 (4.4) (5.2, 10.5) 735478 2736 (9.3) <.0001 <.0001 
786 (21.6) (20.0, 23.2) 3519561 3466 (21.7) 0.623 1277 (23.3)  (21.8, 24.8) 3892141 5922 (23.9) 0.451 <.0001 
63 (2.0) (1.3, 2.7) 321398 165 (0.96) <.0001 111 (2.1) (1.7, 2.5) 346117 258 (1.1) <.0001 <.0001 
2537 (72.6) (70.9, 74.3) 11813273 10211 (65.3) <.0001 3736 (70.2) (68.7, 71.8) 11739270 14238 (60.2) <.0001 <.0001 
    
<.0001 
    
<.0001 
<.0001 
286 (7.8) (6.8, 8.8) 1272433 2155 (11.7) 
 
483 (8.1) (7.3, 9.0) 1358939 3811 (13.9) 
  
1249 (35.0) (33.3, 36.8) 5700791 6719 (39.6) 
 
1780 (31.3) (29.7, 32.9) 5230362 9593 (37.3) 
  
1236 (34.1) (32.4, 35.8) 5549126 4755 (29.5) 
 
1809 (33.8) (32.4, 35.1) 5641914 6938 (28.3) 
  
    112  
333 (9.3) (8.3, 10.3) 1512573 1151 (7.7) 
 
554 (10.3) (9.3, 11.3) 1717635 2025 (8.7) 
  
217 (6.2) (5.3, 7.1) 1008834 691 (4.5) 
 
420 (8.3) (7.5, 9.1) 1391128 1237 (5.1) 
  
222 (6.4) (5.6, 7.2) 1039327 635 (4.1) 
 
396 (7.3) (6.5, 8.1) 1219938 1180 (5.1) 
  
39 (1.2) (0.74, 1.6) 187888 439 (2.9) 
 
48 (0.9) (0.63, 1.2) 153088 398 (1.6) 
  
621 (17.6) (16.2, 19.0) 2867318 1947 (12.0) <.0001 964 (16.7) (15.6, 17.9) 2794500 3478 (13.2) <.0001 <.0001 
    
<.0001 
    
<.0001 <.0001 
541 (15.5) (13.8, 17.2) 2526830 2783 (17.4) 
 
762 (13.9) (12.5, 15.3) 2324064 4325 (18.3) 
  
850 (25.6) (23.1, 28.1) 4161206 3642 (25.0) 
 
1230 (26.2) (24.2, 28.1) 4374539 5173 (23.3) 
  
1190 (32.2) (29.7, 34.7) 5232720 6337 (37.8) 
 
1506 (29.2) (26.8, 31.7) 4886374 9683 (38.9) 
  
1001 (26.7) (24.6, 28.9) 4350216 3783 (19.8) 
 
1992 (30.7) (28.6, 32.7) 5128027 6001 (19.6) 
  
          
<.0001 
3164 (91.0) (90.1, 91.9) 14807161 13116 (85.4) <.0001 4791 (89.8) (88.9, 90.7) 15010846 20112 (83.5) <.0001 
 
           
915 (24.6) (22.9, 26.3) 4001744 7428 (42.2) <.0001 1078 (18.9) (17.7, 20.1) 3158655 9136 (34.8) <.0001 <.0001 
2298 (65.3) (63.3, 67.3) 10629710 7504 (47.5) <.0001 3837 (70.8) 
2924 (54.7) 
(69.5, 72.2) 
(53.0, 56.3) 
11841154 
9136857 
13429 
(54.8) 
9817 
(40.6) 
<.0001 <.0001 
1613 (46.5) (44.5, 48.5) 7571196 5164 (33.8) <.0001 <.0001 <.0001 
283.09 (10.23) (262.96, 
303.22)  
198.45 (6.00) <.0001 325.00 (9.77) (305.77, 344.24) 
 
239.65 (4.63) <.0001 0.003 
    
<.0001 
    
<.0001 <.0001 
1894 (51.2) (49.2, 53.2) 8330263 9977 (57.6) 
 
3114 (56.3) (54.8, 57.9) 9413789 14939 (58.3) 
  
1067 (30.3) (28.7, 31.9) 4930987 3292 (21.2) 
 
1539 (28.6) (27.3, 30.0) 4788193 5281 (22.0) 
  
621 (18.5) (16.7, 20.3) 3009722 3276 (21.2) 
 
837 (15.0) (13.8, 16.2) 2511022 4962 (19.6) 
  
    
<.0001 
    
<.0001 <.0001 
1006 (26.7) (25.1, 28.4) 4349888 6958 (39.0) 
 
1454 (24.0) (22.5, 25.5) 4012831 9897 (36.6) 
  
1740 (47.9) (46.1, 49.7) 7794610 6609 (41.0) 
 
2662 (49.6) (48.0, 51.3) 8292892 10426 (42.7) 
  
836 (25.4) (23.6, 27.1) 4126474 2978 (19.9) 
 
1374 (26.4) (24.9, 27.9) 15263475 4859 (20.7) 
  
30 (0.81) (0.52, 1.1) 132414 96 (0.62) 0.157 62 (1.3) (0.89, 1.6) 210988 164 (0.66) 0.0003 <.0001 
3539 (98.9) (98.6, 99.3) 16094998 14150 (86.2) <.0001 5357 (97.9) (97.5, 98.4) 16369136 
17689 (72.1) 
<.0001 
<.0001 
3331 (93.4) (92.4, 94.4) 15192940 10243 (64.4) <.0001 5215 (95.5) (94.9, 96.2) 15965914 15806 (64.5) <.0001 <.0001 
1870 (53.2) (51.5, 55.0) 8659604 3621 (23.6) <.0001 2094 (39.7) (38.0, 41.4) 6633294 3290 (13.9) <.0001 <.0001 
2034 (58.4) (56.5, 60.3) 9496114 4144 (27.1) <.0001 2783 (51.7) (50.0, 53.4) 8634942 6075 (25.3) <.0001 <.0001 
218 (6.1) (5.2, 7.0) 997157 137 (0.89) <.0001 240 (4.5) (3.8, 5.1) 747014 123 (0.47) <.0001 <.0001 
2334 (64.6) (62.7, 66.5) 10512222 9637 (56.5) <.0001 643 (12.5) (11.4, 13.5) 2081886 718 (2.9) <.0001 <.0001 
858 (23.8) (22.1, 25.5) 3867268 1136 (6.9) <.0001 1037 (19.0) (17.8, 20.2) 3180077 
1231 (4.9) 
<.0001 
<.0001 
**Adjusted for age, sex,  
 Note: Column Percentages  * Adjusted for age, sex, race/ethnicity  
race/ethnicity based on 2010  
 shown based on 2000 Census data 
Census data 
a. Supplements other than herbs, including Vitamins/Minerals,  probiotics (past 30 days), fish oil (past 30 days), chelation therapies 
b. Tai Chi/Qi Gong, Yoga, guided imagery, progressive relaxation, deep breathing exercises, Meditation (for which singular term "meditation" is used in 2007; was expanded in 2012 to include mantra, and mindfulness meditation), 
Stress-management class and support group (2007), mindfulness meditation: including  mindfulness-base stress reduction and congitive therapy (2012)  Biofeedback, hypnosis c. (Ever) Practitioner-based massage, 
chiropractic/osteopathic manipulation, Sobador visit 
d. Prayed for one's own health (2007) or centering prayer/contemplative meditation (2012); and/or, visit with espiritista (2007 only), cuarandero, shaman, and/or Native American healer e. 
Acupuncture, Ayurveda, homeopathy, naturopathy 
$ family costs aside from deductibles, premiums, copays 
R. Defined as >10 min increments 
Table 2b: Health Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by herbal use in the last 12 months 
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 Weighted   Weighted   
 Characteristic N (%)  95% CI population  N (%)  N (%)  95% CI population  N (%)  
 estimate* estimate** 
Body Mass Index (BMI)  
        <24.9 
        25-29.9 
        30-35 
        35+ 
            Mean (SE) 
Comorbidity Indexa  
0 
1 
2 
3+ 
             Mean (SE) 
Chronic Health Conditions 
     Diabetes 
     Kidney disease 
     GI diseaseaa 
     Chronic Respiratory 
conditionsc 
b  
     CVD 
     Hypertension      
Dyslipidemia 
     Liver disease 
     Chronic pain conditionsd 
     Mental health conditionse 
     Insomnia 
     History of Cancer  
Perceived health status    
Excellent/very  
          Fair 
          Poor 
    
0.016 
    
0.031 <.0001 
1384 (39.0) (37.3, 40.8) 6348273 6243 (38.7) 
 
2057 (38.6) (37.0, 40.1) 6448785 9039 (36.3) 
  
1246 (34.5) (32.7, 36.2) 5605830 5875 (35.4) 
 
1916 (34.4) (32.9, 36.0) 5757553 8717 (34.8) 
  
614 (17.2) (15.8, 18.6) 2793014 2731 (16.1) 
 
903 (16.3) (15.1, 17.4) 2718245 4425 (17.3) 
  
338 (9.4) (8.3, 10.5) 1523855 1696 (9.9) 
 
614 (10.7) (9.8, 11.6) 1788421 3001 (11.6) 
  
27.37 (0.11) (27.15, 27.60) 
 
27.35 (0.56) 0.887 27.54 (0.09) (27.36, 27.72) 
 
27.77 (0.05) 0.024 0.2305 
    
<.0001 
    
<.0001 0.0001 
918 (25.6) (23.9, 27.3) 4164042 6532 (38.4) 
 
1035 (18.7) (17.5, 19.8) 3117059 7588 (29.8) 
  
912 (26.0) (24.4, 27.5) 4225414 3846 (23.7) 
 
1218 (22.3) (20.9, 23.6) 3721577 5717 (22.9) 
  
662 (18.4) (16.9, 19.8) 2987313 2488 (15.5) 
 
1083 (19.6) (18.4, 20.8) 3272605 4243 (17.2) 
  
1090 (30.1) (28.4, 31.7) 4894203 3679 (22.4) 
 
2154 (39.5) (37.8, 41.2) 6601763 7634 (30.2) 
  
1.83 (0.03) (1.77, 1.90) 
 
1.45 (0.02) <.0001 2.23 (0.03) (2.17, 2.29) 
 
1.84 (0.02) <.0001 <.0001 
           
314 (8.2) (7.2, 9.1) 1331587 1633 (9.4) 0.021 596 (10.2) (9.3, 11.2) 1709992 2965 (11.2) 0.106 <.0001 
57 (1.6)  (1.2, 2.1) 263373 289 (1.6) 0.713 91 (1.5) (1.2, 1.8) 250872 506 (1.9) 0.047 <.0001 
590 (16.9) (15.5, 18.3) 2752405 1696 (10.8) <.0001 2186 (40.4) (38.9, 41.9) 6744109 7468 (29.9) <.0001 <.0001 
615 (16.9) (15.6, 18.2) 2745606 2144 (13.4) <.0001 985 (18.0) (16.8, 19.3) 3015703 3762 (15.1) <.0001 <.0001 
257 (7.0) (6.1, 7.9) 1142025 1078 (6.8) 0.607 393 (7.1) (6.3, 7.9) 1186819 1829 (7.3) 0.621 <.0001 
1136 (31.1) (29.4, 32.9) 5064154 4764 (28.7) 0.017 1856 (33.4) (31.8, 35.0) 5582424 8168 (32.2) 0.165 <.0001 
1159 (32.2) (30.5, 34.0) 5246236 3977 (24.6) <.0001 1881 (33.9) (32.2, 35.6) 5659527 6628 (26.8) <.0001 <.0001 
54 (1.5) (1.1, 1.9) 244387 198 (1.2) 0.138 91 (1.6) (1.2, 2.0) 271510 348 (1.3) 0.146 <.0001 
1836 (51.6) (49.8, 53.3) 8390744 5940 (36.9) <.0001 3018 (55.2) (53.9, 56.9) 9263106 9943 (39.9) <.0001 <.0001 
832 (23.8) (22.1, 25.6) 3874783 2623 (16.0) <.0001 1674 (30.4) (28.9, 31.9) 5084683 5854 (22.9) <.0001 <.0001 
948 (26.9)  (25.2, 28.7) 4383811 2885 (17.8) <.0001 1488 (26.8) (25.4, 28.2) 4472612 4728 (18.8) <.0001 <.0001 
355 (10.1) (9.0, 11.2) 1638188 1101 (7.4) <.0001 569 (10.7) (9.7, 11.7) 1792043 2039 (8.6) <.0001 <.0001 
    
0.001 
    
0.001 <.0001 
3133 (87.7) (86.6, 88.9) 14272846 14162 (86.3) 
 
4849 (89.7) (88.8, 90.6) 14987051 21383 (86.2) 
  
363 (10.0) (9.0, 11.1) 1632026 1781 (10.1) 
 
505 (8.1) (7.3, 8.9) 1347889 2942 (10.7) 
  
86 (2.3) (1.7, 2.8) 366100 602 (3.6) 
 
136 (14.0) (1.8, 2.7) 378064 857 (86.0) 
  
 
 * Adjusted for age, sex, race/ethnicity  **Adjusted for age, sex, race/ethnicity  
Note: Column Percentages show based on 2000 Census data based on 2010 Census 
data 
a. Includes diabetes, kidney disease, Gastrointestinal disorder (including ulcer and/or abdominal pain, digestive allergy, heartburn), respiratory conditions (Asthma, emphesema, and.or chronic bronchitis), dyslipidemia, liver condition, 
Rheumatoid Arthritis, CVD, hypertension, non-specific arthritis, gout, migraines, mental health condition  
aa. Includes: bowel conditions and ulcers (2007); past 12 month abdominal pain, digestive allergy, heartburn, and ever having ulcer (2012) 
b. Asthma, emphysema, and/or chronic bronchitis 
c. Myocardial Infarction, Heart Disease, Angina pectoris 
d. Migraines (past 3 months), nonspecific arthritis, gout, non-specific joint pain for 3+ months, Rheumatoid Arthritis 
e. Depression, bipolar disorder, phobias, often anxious in past year 
 W. p-values obtained by comparing weighted estimates    
                              Herbal use P                            Herbal use P    Overall P W 
Yes  No Yes  No 
2007 ( N  = 20,127)                      2012 
  
( N  = 
  
30 , 672 ) 
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Table 3a: Demographic and Lifestyle Characteristics of two National U.S. samples (NHIS 2007 & 2012), stratified by herbal use in past 30 days 
 
 Yes  No Yes  No 
 Characteristic Weighted   Weighted   
 N (%)   95% CI population  N (%)  N (%)   95% CI population  N (%)  
 estimate* estimate** 
Total 
Age in years 
       18-24 
       25-44  
       45-64 
       65-75 
       75+ 
       Mean (SE) 
Gender 
       Male  
       Female  
Race/Ethnicity  
       Non-Hispanic White  
       Non-Hispanic Black 
       Hispanic  
       Asian 
       Other Race/ethnicity   
Education 
        <12th grade 
        HS/GED 
        Tech Training/some College 
        >Bachelor’s degree 
Employment 
       Employed for pay 
       Employed but not for pay 
       Unemployed 
Income  
       $1 - $24,999 
       $25,000 - $44,999 
       $45,000 - $74,999 
       $75,000 and over 
       Don't know 
       Missing 
Marital Status  
       Married/Cohabitating        
Never married 
       Divorced/Sep/Widow 
Insurance status 
       Uninsured  
       Medicaid 
       Medicare 
       Disability 
       Private insurance 
Out of pocket costs, past year$ 
        None 
        <$500 
        $500-$1999 
        $2000-$2999 
        $3000-$4999 
        $5000+ 
        Don't know 
Delayed Care because could not  
afford/worried about cost 
Geographic location 
         Northeast 
         Midwest 
         South 
         West 
Place of birth 
         US born 
Physical ActivityR 
        None 
        Low/Moderate  
        High  
         Mean (SE)  (weekly)(min)  
Tobacco Use  
        Never 
        Former 
        Current 
Alcohol Use         
None 
        Light 
        Moderate to heavy 
Substance Abuse  
Use of other Complementary Health 
Approache 
        Other Natural Productsa 
        Mind-bodyb 
        Manipulative/Bodyworkc 
        Energy healing/Reiki 
        Spiritual practicesd 
2623 (13.9) (13.3, 14.6) 11859568 17504 (86.1) 
 
4120 (13.9) (13.4, 14.5) 12603256 26552 (86.1) 
 
<.0001 
 
<.0001 
   
<.0001 <.0001 
155 (6.7) (5.2, 8.1) 790687 1998 (11.7) 
 
208 (5.2) (4.2, 6.2) 658449 2820 (11.3) 
  
754 (28.2) (26.1, 30.2) 3340364 6610 (36.6) 
 
1165 (28.0) (26.2, 29.8) 3529186 9489 (34.6) 
  
1100 (42.3) (40.1, 44.5) 5014017 5628 (32.4) 
 
1717 (41.3) (39.5, 43.1) 5207028 8824 (33.1) 
  
392 (14.3) (12.9, 15.8) 1697704 1669 (9.4) 
 
661 (16.8) (15.4, 18.1) 2111431 2857 (11.1) 
  
222 (8.6) (7.4, 9.8) 1016796 1599 (9.9) 
 
369 (8.7) (7.6, 9.8) 1097162 2562 (9.9) 
  
51.05 (0.39) (50.29, 51.82) 
 
46.90 (0.26) <.0001 52.06 (0.36) (51.35, 52.76) 
 
47.91 (0.19) <.0001 0.0592 
    
0.022 
    
<.0001 <.0001 
1154 (44.6) (42.5, 46.8) 5291066 8025 (47.3) 
 
1731 (42.1) (40.2, 44.1) 5311074 12175 (47.2) 
  
1469 (55.4) (53.2, 57.5) 6568502 9479 (52.7) 
 
2389 (57.9) (55.9, 59.8) 7292182 14377 (52.8) 
  
    
<.0001 
    
<.0001 <.0001 
2020 (83.8) (82.4, 85.3) 9939278 10115 (70.3) 
 
3065 (80.4) (79.1, 81.8) 10135774 15551 (67.7) 
  
218 (6.1) (5.1, 7.1) 725090 2923 (13.2) 
 
351 (6.9) (6.0, 7.8) 871677 4220 (13.1) 
  
258 (6.6) (5.7, 7.5) 787286 3460 (12.4) 
 
419 (8.1) (7.3, 8.9) 1017455 4999 (14.2) 
  
76 (1.9) (1.4, 2.5) 229743 570 (2.3) 
 
139 (2.4) (1.9, 2.8) 302167 1032 (2.9) 
  
51 (1.5) (1.1, 1.9) 178171 436 (1.8) 
 
146 (2.2) (1.7, 2.7) 276183 750 (2.0) 
  
    
<.0001 
    
<.0001 <.0001 
193 (6.6) (5.7, 7.5) 783942 3386 (16.0) 
 
315 (6.5) (5.6, 7.4) 814077 4522 (14.7) 
  
602 (22.8) (21.1, 24.6) 2706476 5036 (29.1) 
 
801 (18.7) (17.3, 20.2) 2362123 7102 (26.3) 
  
837 (31.9) (29.8, 34.0) 3780874 4875 (29.0) 
 
1403 (34.5) (32.6, 36.4) 4348552 8069 (31.1) 
  
991 (38.7) (36.4, 41.0) 4588276 4207 (25.9) 
 
1601 (40.3) (38.4, 42.2) 5078504 6859 (28.0) 
  
    
0.002 
    
0.0005 <.0001 
1546 (59.7) (57.6, 61.8) 7078796 10461 (60.0) 
 
2384 (57.9) (56.0, 59.7) 7291127 14774 (56.0) 
  
121 (4.7) (3.8, 5.6) 553445 506 (3.2) 
 
168 (4.1) (3.4, 4.9) 521755 762 (3.1) 
  
956 (35.7) (33.6, 37.7) 4227327 6537 (36.8) 
 
1568 (38.0) (36.1, 39.9) 4790374 11016 (40.9) 
  
    
<.0001 
    
<.0001 <.0001 
                                 Herbal use P                                       Herbal use P     Overall P W 
2007 ( N  = 20,127)                                  2012 
  
( N = 30 , 672 ) 
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        Alternative medical systemse 548 (21.3) (19.5, 23.1) 2521574 3982 (22.6) 
 
834 (19.5) (18.1, 20.9) 2458527 6022 (21.8) 
  
412 (15.4) (13.8, 16.9) 1823695 2709 (16.0) 
 
640 (15.3) (14.0, 16.6) 1930363 3929 (14.8) 
  
348 (13.4) (11.8, 14.9) 1586462 1773 (10.8) 
 
572 (14.03) (12.8, 15.2) 1768090 2958 (11.8) 
  
256 (10.3) (8.9, 11.7) 1225529 943 (5.8) 
 
454 (11.9) (10.6, 13.2) 1503329 1812 (7.7) 
  
86 (3.3) (2.6, 4.0) 388584 987 (5.2) 
 
131 (3.0) (2.4, 3.6) 379531 1161 (4.3) 
  
973 (36.4) (34.1, 38.6) 4313724 7110 (39.6) 
 
1489 (36.2) (34.5, 38.0) 4563416 10670 (39.6) 
  
    
0.0003 
    
<.0001 <.0001 
1403 (52.4) (50.0, 54.7) 6210153 9007 (51.3) 
 
2160 (52.2) (50.3, 54.2) 6582911 13059 (49.5) 
  
477 (19.4) (17.6, 21.3) 2302205 4033 (23.2) 
 
807 (20.3) (18.6, 21.9) 2552328 6583 (25.1) 
  
743 (28.2) (26.3, 30.2) 3347210 4464 (25.5) 
 
1153 (27.5) (25.9, 29.2) 3468017 6910 (25.5) 
  
           
334 (12.2) (11.1, 13.3) 1442171 3170 (16.2) <.0001 535 (11.4) (10.5, 12.4) 1440406 4960 (16.6) <.0001 <.0001 
100 (3.2) (2.5, 3.9) 382615 1565 (7.5) <.0001 199 (4.0) (3.3, 4.6) 498246 2824 (9.1) <.0001 0.008 
655 (24.5) (22.5, 26.4) 2902188 3597 (21.2) 0.0003 1117 (27.3) (25.5, 29.1) 3444310 6082 (23.2) <.0001 <.0001 
41 (1.9) (1.1, 2.8) 228975 187 (1.0) 0.008 88 (2.2) (1.7, 2.7) 273708 281 (1.1) <.0001 <.0001 
1885 (73.9) (72.0, 75.7) 8761977 10863 (65.6) <.0001 2834 (71.0) (69.3, 72.7) 8950546 15140 (60.6) <.0001 <.0001 
    
<.0001 
    
<.0001 <.0001 
197 (7.3) (6.1, 8.4) 861372 2244 (11.5) 
 
330 (7.2) (6.2, 8.1) 902927 3964 (13.8) 
  
907 (34.5) (32.5, 36.6) 4095033 7061 (39.4) 
 
1322 (30.9) (29.1, 32.7) 3894734 10051 (37.0) 
  
910 (34.4) (32.5, 36.3) 4078211 5081 (29.8) 
 
1388 (35.0) (33.4, 36.6) 4410820 7359 (28.4) 
  
242 (9.3) (8.1, 10.5) 1104356 1242 (7.8) 
 
440 (10.7) (9.6, 11.7) 1343206 2139 (8.8) 
  
173 (6.8) (5.7, 7.9) 810726 735 (4.5) 
 
304 (8.0) (7.0, 8.9) 1002071 1353 (5.4) 
  
168 (6.7) (5.7, 7.7) 792257 689 (4.2) 
 
298 (7.3) (6.4, 8.3) 923040 1278 (5.2) 
  
26 (0.99) (0.57, 1.4) 117613 452 (2.9) 
 
38 (1.0) (0.63, 1.4) 126458 408 (1.5) 
  
425 (16.5) (14.9, 18.2) 1957497 
2143 (12.5) <.0001 
700 (16.1) (14.8, 17.4) 2025158 3742 (13.5) <.0001 <.0001 
    
<.0001 
    
<.0001 <.0001 
386 (15.2) (13.4, 17.0) 1799932 2938 (17.3) 
 
599 (14.7) (13.1, 16.2) 1850077 4488 (17.9) 
  
631 (25.7) (23.1, 28.4) 3051859 3861 (25.0) 
 
917 (26.0) (24.1, 27.9) 3280781 5486 (23.4) 
  
875 (32.8) (30.0, 35.5) 3885028 6652 (37.4) 
 
1127 (29.0) (26.6, 31.4) 3653277 10062 (38.4) 
  
731 (26.3) (23.9, 28.8) 3122749 4053 (20.2) 
 
1477 (30.3) (28.3, 32.3) 3819121 6516 (20.2) 
  
          
<.0001 
2324 (91.1) (90.1, 92.2) 10805693 13956 (85.7) <.0001 3614 (90.2) (89.2, 91.1) 11362696 21289 (83.8) <.0001 
 
          
663 (23.9) (21.9, 25.9) 2831382 7680 (41.3) <.0001 841 (19.6) (18.2, 21.1) 2475988 9373 (33.8) <.0001 <.0001 
1696 (66.1) (63.8, 68.4) 7838030 8106 (48.4) <.0001 2856 (70.4) 14410 (55.7) <.0001 <.0001 
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1179 (46.8) (44.5, 49.2) 5554793 5598 (34.6) <.0001 2145 (53.4) (68.8, 71.9) 
(51.4, 55.4) 
8869651 
6729515 
10596 (41.5) <.0001 <.0001 
291.87 (11.8) (268.59, 315.14) 
 
202.10 (5.9) <.0001 328.76 (11.7) (305.82, 351.69) 
 
243.55 (4.6) <.0001 
 
    
<.0001 
    
<.0001 <.0001 
1378 (51.2) (49.0, 53.4) 6071327 10493 (57.2) 
 
2304 (55.7) (53.9, 57.5) 7018240 15749 (58.3) 
  
823 (31.7) (29.8, 33.5) 3755974 3536 (21.6) 
 
1228 (30.4) (28.8, 32.1) 3834185 5592 (22.1) 
  
422 (17.1) (15.1, 19.2) 2032267 3475 (21.2) 
 
588 (13.9) (12.6, 15.1) 1750831 5211 (19.6) 
  
    
<.0001 
    
<.0001 <.0001 
756 (27.7) (25.7, 29.6) 3283147 7208 (38.1) 
 
1146 (25.4) (23.6, 27.2) 3203003 10205 (35.7) 
  
1249 (46.6) (44.4, 48.8) 5526656 7100 (41.7) 
 
1975 (49.3) (47.5, 51.2) 6221233 11113 (43.1) 
  
618 (25.7) (23.8, 27.7) 3049765 3196 (20.2) 
 
999 (25.2) (23.6, 26.8) 3179020 5234 (21.2) 
  
16 (0.62) (0.32, 0.93) 73924 110 (0.66) 0.832 38 (0.94) (0.54, 1.3) 118622 188 (0.74) 0.324 <.0001 
2592 (98.9) (98.5, 99.3) 11728276 15097 (86.9) <.0001 4045 (98.4) (98.0, 98.8) 12400511 19001 (73.3) <.0001 <.0001 
2460 (94.1) (93.0, 95.2) 11157170 11114 (66.1) <.0001 3972 (96.7) (96.1, 97.4) 12191074 17049 (66.0) <.0001 <.0001 
1337 (51.9) (49.8, 54.1) 6158756 4154 (25.5) <.0001 1575 (39.6) (37.7, 41.6) 4997184 3809 (15.3) <.0001 <.0001 
1520 (59.4) (57.2, 61.6) 7044988 4658 (28.8) <.0001 2144 (53.0) (51.1, 54.8) 6674207 6714 (26.5) <.0001 <.0001 
173 (6.5) (5.5, 7.6) 775716 182 (1.1) <.0001 196 (4.8) (4.0, 5.6) 608722 167 (0.65) <.0001 <.0001 
1691 (64.2) (61.9, 66.5) 7610988 10280 (57.1) <.0001 504 (12.8) (11.5, 14.1) 1615648 857 (3.3) <.0001 <.0001 
661 (25.1) (23.1, 27.1) 2975378 1333 (7.7) <.0001 815 (19.9) (18.4, 21.4) 2510445 1453 (5.5) <.0001 <.0001 
 * Adjusted for age, sex,  **Adjusted for age, sex,  
 Note: Column Percentages shown race/ethnicity based on 2000  race/ethnicity based on 2010  
 Census data Census data 
a. Supplements other than herbs, including Vitamins/Minerals,  probiotics (past 30 days), fish oil (past 30 days), chelation therapies 
b. Tai Chi/Qi Gong, Yoga, guided imagery, progressive relaxation, deep breathing exercises, Meditation (for which singular term "meditation" is used in 2007; was expanded in 2012 to include mantra, and mindfulness meditation), Stress-
management class and support group (2007), mindfulness meditation: including  mindfulness-base stress reduction and congitive therapy (2012)  Biofeedback, hypnosis c. (Ever) Practitioner-based massage, chiropractic/osteopathic 
manipulation, Sobador visit 
d. Prayed for one's own health (2007) or centering prayer/contemplative meditation (2012); and/or, visit with espiritista (2007 only), cuarandero, shaman, and/or Native American healer e. 
Acupuncture, Ayurveda, homeopathy, naturopathy 
$ family costs aside from deductibles, premiums, copays 
R. Defined as >10 min increments 
 W. p-values obtained by comparing weighted estimates    
Table 3b: Health Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by herbal use in past 30 days 
 
 Characteristic Weighted   Weighted   
 N (%)   95% CI population  N (%)  N (%)   95% CI population  N (%)  
 estimate* estimate** 
Body Mass Index (BMI)  
        <24.9 
        25-29.9 
        30-35 
        35+ 
           Mean (SE) 
Comorbidity Indexa  
0 
1 
2 
3+ 
           Mean (SE) 
Chronic Health Conditions 
     Diabetes 
     Kidney disease 
     GI diseaseaa 
     Chronic Respiratory conditionsb  
     CVDc 
     Hypertension 
     Dyslipidemia 
     Liver disease 
     Chronic pain conditionsd 
     Mental health conditionse 
     Insomnia 
     History of Cancer  
Perceived health status 
   Excellent/very good/good 
          Fair 
          Poor 
  
0.56 
1506 (37.6) (35.7, 39.5) 4737825 9590 (36.6) 
0.102 <.0001 
1012 (39.2) (37.1, 41.4) 4651169 6615 (38.6)    
932 (35.0) (33.1, 36.9) 4151454 6189 (35.2)  1474 (35.6) (33.8, 37.4 4484736 9159 (34.6)   
440 (16.7) (15.1,18.2) 1975771 2905 (16.2)  679 (16.2) (14.8, 17.6) 2043500 4649 (17.3)   
239 (9.1) (8.0,10.3) 1081174 1795 (9.9)  461 (10.6) (9.6, 11.7) 1337195 3154 (11.5)   
27.26 (0.12) (27.02, 27.51) 
 
27.40 (0.06) 0.434 27.56 (0.10) (27.37, 27.76) 
 
27.75 (0.05) 0.088 0.0945 
  
<.0001 
    
<.0001 <.0001 
631 (24.0) (22.1, 25.9) 2844176 6819 (37.9)  735 (17.6) (16.2, 19.0) 2216922 7888 (29.3)   
662 (25.7) (24.0, 27.5) 3051748 4096 (23.9)  890 (21.5) (20.1, 22.9) 2711153 6045 (23.0)   
497 (18.8) (17.0, 20.5) 2224006 2653 (15.6)  798 (19.2) (17.9, 20.5) 2417833 4528 (17.4)   
833 (31.5) (29.7, 33.4) 3739638 3936 (22.6)  1697 (41.7) (39.9, 43.5) 5257348 8091 (30.3)   
                                 Herbal use P                                         Herbal use P     Overall P W 
Yes  No Yes  No 
  2007 (N = 20,127)                                   2012 
  
( N  = 
  
30 , 672 ) 
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1.88 (0.04) (1.81, 1.95) 
 
1.46 (0.02) <.0001 2.31 (0.03) (2.24, 2.38) 
 
1.84 (0.02) <.0001 0.0001 
           
246 (8.8) (7.7, 10.0) 1046551 1701 (9.2) 0.547 485 (11.1) (9.9, 12.3) 1401593 3076 (11.0) 0.048 <.0001 
45 (1.8) (1.2, 2.4) 212862 301 (1.6) 0.558 68 (1.6) (1.1, 2.0) 195466 529 (1.9) 0.173 <.0001 
441 (17.4) (15.7, 19.1) 2061656 1845 (11.0) <.0001 1637 (40.4) (38.6, 42.1) 5089779 8017 (30.5) <.0001 <.0001 
434 (16.2) (14.8, 17.7) 1923974 2325 (13.7) 0.0009 750 (18.4) (17.0, 19.8) 2322524 3997 (15.2) <.0001 <.0001 
206 (7.7) (6.6, 8.7) 911835 1129 (6.7) 0.071 318 (7.7) (6.8, 8.7) 973750 1904 (7.2) 0.314 <.0001 
877 (32.4) (30.3, 34.4) 3836843 5023 (28.6) 0.0003 1508 (36.4) (34.7, 38.2) 4589502 8516 (31.8) <.0001 <.0001 
925 (35.1) (33.2, 37.1) 4166974 4211 (24.5) <.0001 1510 (36.6) (34.6, 38.5) 4607481 6999 (26.7) <.0001 <.0001 
38 (1.4) (0.94, 1.9) 169692 214 (1.2) 0.329 72 (1.7) (1.2, 2.1) 209745 367 (1.4) 0.146 <.0001 
1378 (52.8) (50.8, 54.8) 6259209 6398 (37.6) <.0001 2347 (57.5) (55.7, 59.3) 7245512 10614 
(40.4) 
<.0001 <.0001 
583 (23.2) (21.1, 25.4) 2753361 2872 (16.6) <.0001 1196 (28.9) (27.3, 30.6) 3645993 6332 (23.6) <.0001 <.0001 
679 (26.8) (24.8, 28.9) 3179543 3154 (18.3) <.0001 1133 (27.1) (25.5, 28.7) 3416688 5083 (19.1) <.0001 <.0001 
282 (10.7) (9.4, 12.1) 1272814 1174 (7.5) <.0001 477 (11.9) (10.7, 13.0) 1495165 2131 (8.6) <.0001 <.0001 
    
0.005 
    
0.0001 <.0001 
2296 (87.7) (86.3, 89.1) 10400152 14999 (86.4)  3613 (89.1) (88.0, 90.2) 11230927 22619 
(86.4)   
268 (10.1) (8.8, 11.4) 1201167 1876 (10.1)  404 (8.6) (7.7, 9.5) 1084958 3043 (10.5)   
59 (2.2) (1.6, 2.8) 258249 629 (3.5)  103 (2.3) (1.7, 2.8) 287371 890 (3.1)   
* Adjusted for age, sex,  
**Adjusted for age, sex, race/ethnicity  
Note: Column Percentages shown race/ethnicity based on 2000 based on 2010 Census data Census data 
a. Includes diabetes, kidney disease, Gastrointestinal disorder (including ulcer and/or abdominal pain, digestive allergy, heartburn), respiratory conditions (Asthma, emphesema, and.or chronic bronchitis), dyslipidemia, liver condition, Rheumatoid Arthritis, CVD, 
hypertension, non-specific arthritis, gout, migraines, mental health condition  
aa. Includes: bowel conditions and ulcers (2007); past 12 month abdominal pain, digestive allergy, heartburn, and ever having ulcer (2012) b. Asthma, 
emphysema, and/or chronic bronchitis 
c. Myocardial Infarction, Heart Disease, Angina pectoris 
d. Migraines (past 3 months), nonspecific arthritis, gout, non-specific joint pain for 3+ months, Rheumatoid Arthritis 
e. Depression, bipolar disorder, phobias, often anxious in past year 
 W. p-values obtained by comparing weighted estimates       
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Image 1: Current harvesting of medicinal plants in West Virginia             
  
                                                (Photo taken by author July 10, 2014 near Hookersville, WV)  
  
Chapter 3  
Image 1: Percentage of adults who used nonvitamin, nonmineral dietary supplements in the past 12 months, by 
region: United States, 2012  
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   Figures  
Chapter 1  
Figure 1: Taxonomy of Folk Illnesses in Appalachia  
 
                                                                                 (Matthews et al 1992)    
Figure 2: Evolution of Folk Medicine in Appalachia  
                                                                                                 
(Amjad 2006)   
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Figure 3: Information Flow Pathways of Efficacy Research for use of Herbal Product vs. 
Prescription Drug  
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Figure 4. Conceptual Model of  the Rela tionships between Chronic Pain, Inflammation, and Herbal Medicine  
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Chapter 3  
  
          Figure 1. Study Flow for two NHIS datasets  
  
Chapter 4  
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Figure 1. The Transtheoretical Model’s Six Stages of Change  
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Figure 2. Flow diagram for the CHAPS 2014-2016  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Response Rate = 88% 
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Additional Files   
  
Appendix A. 
Search Results for Cochrane Reviews on Herbal Medicine and  
FMS/CFS/Chronic Pain   
Results: 206; search performed 10/10/14 using search terms "herb" "herbal" 
"botanical" "fibromyalgia" in Cochrane Summaries   
GUIDE  
Relevant studies to non-cancerous chronic pain relating to fibromyalgia or 
chronic fatigue and herbs manually pulled: 22  
herbs mentioned   
treatment  
       non-herbal 
therapies  
as treatment  
Description  Type of herb or 
intervention  
Results  N (if clear)  
Traditional Chinese medicinal herbs 
for the treatment of idiopathic 
chronic fatigue and chronic fatigue 
syndrome;"Traditional Chinese 
medicinal herbs for chronic 
fatigue";CD006348;http://su 
mmaries.cochrane.org/CD006 
348/DEPRESSN_traditionalchinese-
medicinal-herbs-forchronic-fatigue  
No studies met 
inclusion criteria 
and specific herbs 
used were not 
specified  
      
Anticonvulsants for 
fibromyalgia;"Anticonvulsant s for  
fibromyalgia";CD010782;http 
://summaries.cochrane.org/C 
D010782/MUSKEL_anticonv 
ulsants-for-fibromyalgia  
anti-epileptic drug  reliable conclusions  
for pregabalin only  
This is an  original 
review which was 
withdrawn in 2009 
and replaced by the 
same group's 
"Antiepileptic 
drugs for 
neuropathic pain 
and fibromyalgia" 
in  
2013  
Exercise for treating fibromyalgia 
syndrome;"Exercise for 
fibromyalgia";CD003786;http 
://summaries.cochrane.org/C 
D003786/MUSKEL_exercise 
-for-fibromyalgia  
exercise  There is 'gold' level 
evidence  
(www.cochranemsk.o 
rg) that supervised 
aerobic exercise 
training has beneficial 
effects on physical 
capacity and FM 
symptoms. Strength 
training may also  
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  have benefits on some FM 
symptoms.  
Further studies on muscle 
strengthening and flexibility 
are needed. Research on the 
long-term benefit of exercise 
for FM is needed. - See more 
at:  
http://summaries.coch 
rane.org/CD003786/ 
MUSKEL_exercise- 
forfibromyalgia#sthash. 
BzwierwV.dpuf  
 
Resistance exercise training 
for fibromyalgia;"Resistance 
training (such as 
weightlifting) for  
fibromyalgia";CD010884;http 
://summaries.cochrane.org/C 
D010884/MUSKEL_resistanc 
e-training-such-as-
weightlifting-for-fibromyalgia  
resistance training  For women with 
fibromyalgia, resistance 
training for 16 to 21 weeks 
likely improves  
- ability to do normal 
activities  
- pain, tenderness, 
muscle strength and overall 
well-being. Quality of the 
evidence -Because so few 
studies have been done so far, 
more research is likely to 
change these results.  
- See more at:  
http://summaries.coch 
rane.org/CD010884/ 
MUSKEL_resistancetraining-
such-asweight-lifting-
forfibromyalgia#sthash. 
76OJ4uGl.dpuf  
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Acupuncture for treating 
fibromyalgia;"Acupuncture 
for  
fibromyalgia";CD007070;http 
://summaries.cochrane.org/C 
D007070/MUSKEL_acupunc 
ture-for-fibromyalgia  
electric acupuncture  
and manual 
acupuncture  
There is low to 
moderate-level 
evidence that 
compared with no 
treatment and 
standard therapy, 
acupuncture improves 
pain and stiffness in 
people with 
fibromyalgia. There is 
moderate-level 
evidence that the 
effect of acupuncture 
does not differ from 
sham acupuncture in 
reducing pain or 
fatigue, or improving 
sleep or global 
wellbeing. EA is 
probably better than 
MA for pain and 
stiffness reduction 
and improvement of 
global well-being, 
sleep and fatigue. The 
effect lasts up to one 
month, but is not 
maintained at six 
months follow-up. 
MA probably does 
not improve pain or 
physical functioning. 
Acupuncture appears 
safe. People with 
fibromyalgia may 
consider using EA 
alone or with exercise 
and medication. The 
small sample size, 
scarcity of studies for 
each comparison, lack 
of an ideal sham 
acupuncture weaken 
the level of evidence 
and its clinical 
implications. Larger 
studies are warranted.  
- See more at:  
http://summaries.coch 
rane.org/CD007070/ 
MUSKEL_acupunctu 
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  re-
forfibromyalgia#sthash. 
ZhGfzRsC.dpuf  
 
Cognitive behavioural 
therapies for 
fibromyalgia;"Cognitive 
behavioural therapies for 
fibromyalgia 
syndrome";CD009796;http://s 
ummaries.cochrane.org/CD00 
9796/cognitive-
behaviouraltherapies-for-
fibromyalgiasyndrome  
CBT  CBTs provided a small 
incremental benefit 
over control 
interventions in 
reducing pain, negative 
mood and disability at 
the end of treatment 
and at long-term 
follow-up.  
23 studies with up 
to 2031 people  
Phenytoin for neuropathic 
pain and fibromyalgia in 
adults;"Phenytoin for 
neuropathic pain and 
fibromyalgia in 
adults";CD009485;http://sum 
maries.cochrane.org/CD0094 
85/SYMPT_phenytoin-
forneuropathic-pain-
andfibromyalgia-in-adults  
phenytoin is for  
neuropathic pain and 
fibromyalgia. - See 
more at: 
http://summaries.coc 
hrane.org/CD00948 
5/SYMPT_phenytoi 
n-for-
neuropathicpain-
andfibromyalgia-
inadults#sthash.BniKq 
Zkm.dpuf  
No studies met 
inclusion criteria  
   
Multidisciplinary 
rehabilitation for 
fibromyalgia and 
musculoskeletal pain in 
working age  
adults;"Multidisciplinary  
rehabilitation for 
fibromyalgia and 
musculoskeletal pain in  
working age 
adults";CD001984;http://sum 
maries.cochrane.org/CD0019 
84/MUSKEL_multidisciplina 
the combo of  
psychological, 
behavioral and 
educational 
interventions 
practiced in pain 
clinics and  
rehabilitation centers  
little scientific evidence 
for the effectiveness of 
multidisciplinary 
rehabilitation for these 
musculoskeletal 
disorders  
 1808 abstracts, and 
the references of 65 
reviews, we found 
only seven relevant 
studies (1050 
patients)  
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ry-rehabilitation-
forfibromyalgia-
andmusculoskeletal-pain-
inworking-age-adults  
   
Clonazepam for neuropathic 
pain and fibromyalgia in 
adults;"Clonazepam for 
neuropathic pain and 
fibromyalgia in  
adults";CD009486;http://sum 
maries.cochrane.org/CD0094 
86/SYMPT_clonazepam-
forneuropathic-pain-
andfibromyalgia-in-adults  
Some antiepileptic 
medications can help 
neuropathic pain. 
Clonazepam is an 
antiepileptic 
medication   
no good quality  
studies  
   
Gabapentin for chronic 
neuropathic pain and 
fibromyalgia in 
adults;"Gabapentin for chronic 
neuropathic pain and 
fibromyalgia in 
adults";CD007938;http://sum 
maries.cochrane.org/CD0079 
38/SYMPT_gabapentin-
forchronic-neuropathic-
painand-fibromyalgia-in-
adults  
Medicines like 
paracetamol or 
ibuprofen are not 
effective in 
neuropathic pain, 
while medicines that 
are sometimes used 
to treat depression or 
epilepsy can be very 
effective in some 
people with 
neuropathic pain. 
Our understanding of 
fibromyalgia (a 
condition of 
persistent, 
widespread pain and 
tenderness, sleep 
problems, and 
fatigue) is poor, but 
fibromyalgia can 
respond to the same 
medicines as 
neuropathic pain.  
  
Gabapentin was 
developed to treat 
epilepsy, but it is 
now used to treat 
various forms of 
chronic pain.  
There were 
insufficient data for 
direct comparisons 
with other active 
treatments, and only 
third tier evidence for 
other painful 
conditions.  
Seven new studies 
with 1919 participants 
were added in this 
third update.  
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Milnacipran for neuropathic 
pain and fibromyalgia in 
adults;"Milnacipran for 
chronic neuropathic pain and 
fibromyalgia in 
adults";CD008244;http://sum 
maries.cochrane.org/CD0082 
44/SYMPT_milnacipran-
forchronic-neuropathic-
painand-fibromyalgia-in-
adults  
milnacipran is for  
treating chronic 
neuropathic pain or 
fibromyalgia. We 
identified no studies 
using milnacipran in 
neuropathic pain, but 
five studies in 
fibromyalgia satisfied 
the inclusion criteria. 
- See more at:  
http://summaries.coc 
hrane.org/CD00824 
4/SYMPT_milnacipr 
an-for-
chronicneuropathic-
painand-fibromyalgia-
inadults#sthash.sszfV2 
Ug.dpuf  
Milnacipran has shown 
modest effects in a 
minority of participants 
with fibromyalgia, and 
several technical issues 
indicate that even this 
modest effect may 
overstate effectiveness 
in clinical practice The 
drug may be a useful 
option if first-line 
treatments fail. - See 
more at: 
http://summaries.coch 
rane.org/CD008244/S 
YMPT_milnacipranfor-
chronicneuropathic-
pain-andfibromyalgia-
inadults#sthash.sszfV2 
Ug.dpuf  
4000 participants 
treated with 
milnacipran 100 mg or 
200 mg, or placebo, for 
eight to 24 weeks at the 
target dose. - See more 
at: 
http://summaries.coch 
rane.org/CD008244/S 
YMPT_milnacipranfor-
chronicneuropathic-
pain-andfibromyalgia-
inadults#sthash.sszfV2 
Ug.dpuf  
Amitriptyline for neuropathic 
pain and fibromyalgia in 
adults;"Amitriptyline for 
neuropathic pain and 
fibromyalgia in 
adults";CD008242;http://sum 
maries.cochrane.org/CD0082 
42/SYMPT_amitriptyline-
forneuropathic-pain-
andfibromyalgia-in-adults  
Amitriptyline is a 
tricyclic 
antidepressant that is 
widely used to treat 
chronic neuropathic 
pain (pain due to 
nerve damage) and 
fibromyalgia, and is 
recommended in many 
guidelines.  
There was no top-tier 
evidence for 
amitriptyline in treating 
neuropathic pain or 
fibromyalgia. Second-
tier evidence indicated 
some evidence of effect 
in painful diabetic 
neuropathy (PDN), 
mixed neuropathic  
pain, and fibromyalgia. 
Amitriptyline has been 
a first-line treatment 
for neuropathic pain for 
many years. The fact 
that there is no 
supportive unbiased 
evidence for a 
beneficial effect is 
disappointing, but has 
to be balanced against 
decades of successful 
treatment in many 
patients with 
neuropathic pain or  
Twenty-one studies 
(1437 participants) 
were included; they 
individually involved 
between 15 and 235 
participants, only four 
involved over 100 
participants, and the 
median study size was 
44 participants. The 
median duration was 
six weeks. Ten studies 
had a crossover design. 
Doses of amitriptyline 
were generally 
between 25 mg and 
125 mg, and dose 
escalation was 
common.  
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  fibromyalgia. There is 
no good evidence of a 
lack of effect; rather 
our concern should be 
of overestimation of 
treatment effect. 
Amitriptyline should 
continue to be used as 
part of the treatment 
of neuropathic pain or 
fibromyalgia, but 
only a minority of 
patients will achieve 
satisfactory pain 
relief.  
 
Duloxetine for treating painful 
neuropathy, chronic pain or 
fibromyalgia;"Duloxetine for 
treating chronic pain or 
fibromyalgia";CD007115;http 
://summaries.cochrane.org/C 
D007115/NEUROMUSC_dul 
oxetine-for-treating-
painfulneuropathy-chronic-
pain-orfibromyalgia painful 
neuropathy  
Duloxetine is a 
balanced serotonin 
and noradrenaline 
reuptake inhibitor 
licensed for the 
treatment of major 
depressive disorders, 
urinary stress 
incontinence and the 
management of 
neuropathic pain 
associated with 
diabetic peripheral 
neuropathy.   
There are adequate 
amounts of moderate 
quality evidence from  
eight studies 
performed by the 
manufacturers of 
duloxetine that doses 
of 60 mg and 120 mg 
daily are efficacious 
for treating pain in 
diabetic peripheral 
neuropathy but lower 
daily doses are not. 
Further trials are not 
required. In 
fibromyalgia, there is 
lower quality 
evidence that 
duloxetine is effective 
at similar doses to 
those used in diabetic 
peripheral neuropathy 
and with a similar 
magnitude of effect. 
The effect in 
fibromyalgia may be 
achieved through a 
greater improvement 
in mental symptoms 
than in somatic 
physical pain. There is 
low to moderate 
quality evidence that 
pain relief is also 
achieved in pain  
18 trials, which 
included 6407 
participants. We 
found 12 of these 
studies in the 
literature search for 
this update. Eight 
studies included a 
total of 2728 
participants with 
painful diabetic 
neuropathy and six 
studies involved 2249 
participants with 
fibromyalgia. Three 
studies included 
participants with 
depression and painful 
physical symptoms 
and one included 
participants with 
central neuropathic 
pain.   
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  associated with 
depressive symptoms, 
but the NNTB of 8 in 
fibromyalgia and 
depression is not an 
indication of 
substantial efficacy.   
 
Lacosamide for neuropathic 
pain and fibromyalgia in 
adults;"Lacosamide for 
neuropathic pain and 
fibromyalgia in 
adults";CD009318;http://sum 
maries.cochrane.org/CD0093 
18/NEUROMUSC_lacosamid 
e-for-neuropathic-pain-
andfibromyalgia-in-adults  
Antiepileptic drugs 
like lacosamide  
In people with painful 
diabetic neuropathy, 
lacosamide had only a 
modest effect, with a 
specific effect due to 
its use in 1 person in 
10. This is a minor 
effect and may be an 
over-estimate due to 
use of the last 
observation carried 
forward method for 
analysis. There was  
insufficient 
information in 
fibromyalgia to draw 
any conclusions about  
the effect of 
lacosamide. - See more 
at:  
http://summaries.coch 
rane.org/CD009318/ 
NEUROMUSC_lacos 
amide-for- 
neuropathic-pain-
andfibromyalgia-
inadults#sthash.6W9bIi 
Q5.dpuf  
five studies in painful  
diabetic neuropathy 
(1863 participants) and 
one in fibromyalgia 
(159 participants). - 
See more at: 
http://summaries.coch 
rane.org/CD009318/ 
NEUROMUSC_lacos 
amide-forneuropathic-
pain-andfibromyalgia-
inadults#sthash.6W9bIi 
Q5.dpuf  
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Topiramate for neuropathic pain 
and fibromyalgia in 
adults;"Topiramate for treating 
neuropathic pain or 
fibromyalgia";CD008314;http 
://summaries.cochrane.org/C 
D008314/NEUROMUSC_top 
iramate-for-treatingneuropathic-
pain-orfibromyalgia  
Topiramate is a 
medicine used to 
treat epilepsy, 
and so it might 
be a useful 
medicine for 
neuropathic pain 
or fibromyalgia.  
Topiramate did not help 
the pain and was no 
different from placebo 
except in causing more 
sideeffects, which made 
many more people 
withdraw from the 
studies early. About 3 
people in 10 withdrew 
because of side-effects 
with topiramate 
compared with 1 in 10 
with placebo.  
Topiramate has not been 
shown to work as a pain 
medicine in diabetic 
neuropathy.  
four studies of  
reasonable quality that 
tested topiramate 
against placebo for a 
number of weeks. 
Almost all of the 1684 
people in the studies 
had painful limbs 
because of damaged 
nerves caused by 
diabetes. - See more 
at:  
http://summaries.coch 
rane.org/CD008314/ 
NEUROMUSC_topir 
amate-for-
treatingneuropathic-
pain-
orfibromyalgia#sthash. 
9txXjI9A.dpuf  
Monoamine oxidase inhibitors 
(MAOIs) for fibromyalgia 
syndrome;"Monoamine oxidase 
inhibitors (MAOIs) for  
fibromyalgia";CD009807;http 
://summaries.cochrane.org/C 
D009807/monoamine- 
oxidase-inhibitors-maois-
forfibromyalgia  
MAOIs may 
slightly improve 
pain and tender 
points in the 
short term 
compared to 
placebo. Of the 
MAOIs studied, 
pirlindole seems 
more effective 
than 
moclobemide.  
Pirlindole showed 
statistically  
significant results 
compared with placebo 
for several outcomes 
(pain, tender points and 
overall assessment by 
the patient and the 
physician), whereas 
moclobemide did not 
show statistically 
significant differences 
between groups.  
 two studies of  
inconsistent risk of 
bias with a total of 230 
patients diagnosed 
with FM. We 
evaluated two MAOIs: 
pirlindole and 
moclobemide.  
Valproic acid and sodium 
valproate for neuropathic pain 
and fibromyalgia in 
adults;"Valproic acid and 
sodium valproate for 
neuropathic pain and 
fibromyalgia";CD009183;http 
://summaries.cochrane.org/C 
D009183/SYMPT_valproicacid-
and-sodium-valproatefor-
neuropathic-pain-
andfibromyalgia  
Valproic acid 
and its sodium 
salt (sodium 
valproate) are 
antiepileptic 
drugs that are 
sometimes used 
to treat chronic 
neuropathic pain 
and 
fibromyalgia, 
although they 
are not licensed 
for this use.  
There is insufficient 
evidence to support the 
use of valproic acid or 
sodium valproate as a 
firstline treatment for 
neuropathic pain. - See 
more at:  
http://summaries.coch 
rane.org/CD009183/S 
YMPT_valproic-
acidand-
sodiumvalproate-
forneuropathic-pain-
andfibromyalgia#sthash. 
xiAvcyI1.dpuf  
 three studies, two in  
diabetic neuropathy 
(42 participants 
treated with valproate, 
42 with placebo), and 
one in post-herpetic 
neuralgia (23 treated 
with divalproex 
sodium, 22 with 
placebo). Study 
duration was eight or 
12 weeks. No studies 
were found in 
fibromyalgia.  
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Oxycodone for neuropathic 
pain and fibromyalgia in 
adults;"Oxycodone for 
neuropathic pain and 
fibromyalgia in 
adults";CD010692;http://sum 
maries.cochrane.org/CD0106 
92/SYMPT_oxycodone-
forneuropathic-pain-
andfibromyalgia-in-adults  
Oxycodone is used to 
treat acute and some 
forms of chronic pain, 
and so might be a 
useful medicine for 
neuropathic pain or 
fibromyalgia. - See 
more at:  
http://summaries.coc 
hrane.org/CD01069 
2/SYMPT_oxycodo 
ne-for-
neuropathicpain-
andfibromyalgia-
inadults#sthash.VtfS5l 
3z.dpuf  
Oxycodone was not 
convincingly shown 
to help relieve the 
pain (very low quality 
evidence). Compared 
with placebo, fewer 
people stopped taking  
oxycodone because 
they felt it was not 
effective, but more 
people experienced 
adverse effects (very 
low quality 
evidence).  
Oxycodone has not 
been shown to work 
as a pain medicine in 
diabetic neuropathy 
or postherpetic 
neuralgia.  
three studies of  
modest quality that 
tested oxycodone 
against placebo for 
several weeks. 
Almost all of the 254 
people in the studies 
had painful limbs 
because of damaged 
nerves caused by 
diabetes. No studies 
have examined its use 
in other types of 
neuropathic pain, or 
in fibromyalgia.   
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Antiepileptic drugs for 
neuropathic pain and  
fibromyalgia - an overview of 
Cochrane  
reviews;"Antiepileptic drugs to 
treat neuropathic pain or 
fibromyalgia- an overview of 
Cochrane 
reviews";CD010567;http://su 
mmaries.cochrane.org/CD010 
567/SYMPT_antiepilepticdrugs-
to-treat-neuropathicpain-or-
fibromyalgia-anoverview-of-
cochranereviews  
Antiepileptic drugs 
(previously called 
anticonvulsants) are 
used for treating 
epilepsy, but have 
also been used for 
treating neuropathic 
pain and 
fibromyalgia. Many 
of the drugs have 
been the subject of 
individual Cochrane 
reviews. In August 
2013 we collected 
all these Cochrane 
reviews on 
antiepileptic drugs 
together to provide 
an overview. 
Individual 
antiepileptic drugs 
work in different 
ways, and there is no 
expectation that they 
are equally effective.  
- See more at: 
http://summaries.coc 
hrane.org/CD01056 
7/SYMPT_antiepile 
ptic-drugs-to-
treatneuropathic-
pain-orfibromyalgia-
anoverview-
ofcochrane- 
reviews#sthash.xqm 
OPsy4.dpuf  
No studies reported 
top tier results. We 
found that only for 
gabapentin and 
pregabalin was there 
some evidence that 
they worked in 
longterm nerve pain 
with diabetes (painful 
diabetic neuropathy) 
and pain after 
shingles (postherpetic 
neuralgia). 
Pregabalin also had 
evidence of efficacy 
in central neuropathic 
pain (typically pain 
after stroke) and in 
fibromyalgia. The 
drugs work very well 
in some people with 
these painful 
conditions, with pain 
reduced by half. 
However, only 
between 1 in 10 and 1 
in 4 people will get 
this level of benefit, 
depending on the 
pain condition and 
the drug. Most people 
will get no pain 
relief.  
  
The antiepileptic 
drugs produced side 
effects in most 
people taking them, 
and for about 1 in 4 
these could not be 
tolerated so they 
stopped taking the 
drug. Serious side 
effects were no more 
common with  
antiepileptic drugs 
than with a harmless 
placebo.  
  
The evidence we 
found did not meet 
current best  
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  standards, and as a 
result it may 
overestimate benefit. 
The biggest concern is 
a lack of any evidence 
for most drugs in 
most types of 
neuropathic pain and 
fibromyalgia. For 
lacosamide and 
lamotrigine there is 
evidence of a lack of 
effect; for other 
antiepileptic drugs  
(including 
carbamazepine, 
clonazepam, 
phenytoin, valproate) 
there is no evidence of 
effect or insufficient 
evidence of effect.  
 
Serotonin and noradrenaline 
reuptake inhibitors (SNRIs) 
for fibromyalgia 
syndrome;"Serotonin and 
noradrenaline reuptake  
inhibitors for  
fibromyalgia";CD010292;http 
://summaries.cochrane.org/C 
D010292/serotonin-
andnoradrenaline-
reuptakeinhibitors-for-
fibromyalgia  
 serotonin and  
noradrenaline 
reuptake inhibitors  
(SNRIs)  
The SNRIs duloxetine 
and milnacipran 
provided a small 
incremental benefit 
over placebo in 
reducing pain. The 
superiority of 
duloxetine and 
milnacipran over 
placebo in reducing 
fatigue and limitations 
of QOL was not 
substantial. 
Duloxetine and 
milnacipran were not 
superior to placebo in 
reducing sleep 
problems. The 
dropout rates due to  
Ten studies were 
included with a total 
of 6038 participants. 
Five studies 
investigated 
duloxetine against 
placebo, and five 
investigated 
milnacipran against 
placebo. A total of 
3611 participants were 
included into 
duloxetine or 
milnacipran groups 
and 2427 participants 
into placebo groups. 
The studies had a low  
risk of bias in general.  
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  adverse events were 
higher for duloxetine 
and milnacipran than 
for placebo.   
 
Lamotrigine for chronic 
neuropathic pain and 
fibromyalgia in 
adults;"Lamotrigine (an 
antiepileptic drug) for chronic 
neuropathic pain or 
fibromyalgia";CD006044;http 
://summaries.cochrane.org/C 
D006044/SYMPT_lamotrigin 
e-an-antiepileptic-drug-
forchronic-neuropathic-pain-
orfibromyalgia  
Lamotrigine is a 
medicine used to 
treat epilepsy, and so 
might be a useful 
medicine for 
neuropathic pain or 
fibromyalgia.  
Lamotrigine did not 
help the pain, and 
was no different from 
placebo except in 
causing more side 
effects. Adverse 
events were more 
frequent with 
lamotrigine than 
placebo, with rash in  
1 person in 27. -   
12 studies of 
reasonable quality 
that tested lamotrigine 
against placebo for a 
number of weeks. 
Almost half of the 
1511 people in the 
studies had painful 
limbs because of 
damaged nerves 
caused by diabetes, 
and seven different 
painful neuropathic 
conditions were 
examined. No studies 
looked at 
fibromyalgia. - See 
more at: 
http://summaries.coch 
rane.org/CD006044/S 
YMPT_lamotrigine- 
an-antiepileptic-
drugfor-
chronicneuropathic-
pain-
orfibromyalgia#sthash. 
VyD9Kv3y.dpuf  
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Carbamazepine for chronic 
neuropathic pain and 
fibromyalgia in 
adults;"Carbamazepine for 
chronic neuropathic pain and 
fibromyalgia in  
adults";CD005451;http://sum 
maries.cochrane.org/CD0054 
51/SYMPT_carbamazepine- 
for-chronic-neuropathic-
painand-fibromyalgia-in-
adults  
Carbamazepine was 
developed to treat 
epilepsy, but it is now 
used to treat various 
forms of chronic pain. 
- See more at:  
http://summaries.coc 
hrane.org/CD00545 
1/SYMPT_carbamaz 
epine-for-
chronicneuropathic-
painand-
fibromyalgia-
inadults#sthash.vNNP 
XVgz.dpuf  
There was not 
enough good quality 
evidence to say how 
well carbamazepine 
worked in any 
neuropathic pain 
condition. Pooling 
four small studies 
showed that it was 
better than placebo, 
but the result cannot 
be relied upon. 
There was not 
enough information 
from these studies to 
make any reliable 
comment on adverse 
events or harm.  
Carbamazepine is 
probably helpful for 
some people with 
chronic neuropathic 
pain. It is not 
possible to know 
beforehand who will 
benefit and who will 
not.  
10 studies involving 
418 people involved  
in testing 
carbamazepine. Studies 
were not generally of 
very good quality. Most 
were very small, as 
well as of short 
duration. Studies 
lasting only one or two 
weeks are unhelpful 
when pain can last for 
years. - See more at: 
http://summaries.coch 
rane.org/CD005451/S 
YMPT_carbamazepin 
e-for-
chronicneuropathic-
pain-andfibromyalgia-
inadults#sthash.vNNPX 
Vgz.dpuf  
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PycnogenolÂ® (extract of 
French maritime pine bark) 
for the treatment of chronic 
disorders;"Use of the 
antioxidant supplement 
PycnogenolÂ® to treat a 
variety of chronic 
disorders";CD008294;http://s 
ummaries.cochrane.org/CD00 
8294/CF_use-of-
theantioxidant-
supplementpycnogenolr-to-
treat-avariety-of-chronic-
disorders  
Pycnogenol® is a 
herbal dietary 
supplement extracted 
from French 
maritime pine bark 
whose main 
ingredient is 
procyanidin. 
Procyanidin is a 
powerful antioxidant 
also found in food 
such as grapes, 
berries, 
pomegranates, red 
wine and various 
nuts. Supplements 
containing 
procyanidin are 
widely marketed 
worldwide for the 
promotion of health, 
and for the 
prevention and 
treatment of chronic 
disorders. The 
rationale for this is 
that antioxidants 
neutralise reactive 
oxygen species 
(ROS; frequently 
referred to as "free 
radicals") which, 
apart from 
performing 
important bodily 
functions, can cause 
damage to cells and 
tissues if present in 
excessive amounts. 
Available 
supplements vary in 
the source and 
quantity of 
procyanidin, as well 
as in number and 
type of other 
ingredients they 
contain. We chose to 
focus on  
Pycnogenol® as this 
supplement is a  
Due to small sample 
size, limited number 
of trials per condition, 
variation in outcomes 
evaluated and 
outcome measures 
used, as well as the 
risk of bias in the 
included studies, no 
definite conclusions 
regarding the efficacy 
and safety of 
Pycnogenol® are 
possible.   
15 eligible 
randomised controlled 
trials with a total of 
791 participants 
which addressed 
seven different 
chronic conditions: 
asthma (two studies); 
attention deficit 
hyperactivity disorder 
(one study), chronic 
venous insufficiency 
(two studies), diabetes 
(four studies), erectile 
dysfunction (one 
study), hypertension 
(two studies) and 
osteoarthritis (three 
studies).  
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 standardised 
product, many trials 
have been 
conducted, and it is 
extensively 
marketed 
internationally   
  
            
Results: 193 search performed 10/16/14 using search terms "herbal medicine" and "Chronic 
pain" in Cochrane Summaries   
Relevant studies to non-cancerous fibromyalgia comorbidities  (depression, anxiety, headache, 
irritable bowel syndrome, chronic fatigue syndrome, systemic lupus erythematosus, and 
rheumatoid arthritis) and related chronic pain conditions and herbs manually pulled from 
search: 17  
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Cui X, Trinh K, Wang Y-J. Chinese 
herbal medicine for chronic neck pain 
due to cervical degenerative disc 
disease . Cochrane Database of 
Systematic Reviews 2010, Issue 1. 
Art. No.: CD006556.  
DOI:  
10.1002/14651858.CD00655 
6.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD006556/BACK_herbalmedicine-
for-cervicaldegenerative-
discdisease#sthash.0bXFNG9M.d puf  
Compound 
Qishe  
Tablet & 
Compound  
Extractum 
Nucis  
Vomicae  
For chronic neck 
pain with or 
without radicular 
symptoms, there 
is low quality  
evidence that 
Compound Qishe  
Tablet is more 
effective than 
placebo for pain 
relief, measured 
at the end of the 
treatment. 
However, the 
size of the studies 
was small and the 
effect was 
measured in the 
short-term. 
Further research 
is very likely to 
change both the 
effect size and 
our confidence in 
the results. There 
is a need for trials 
with adequate 
numbers of 
participants that 
address long-
term efficacy or 
effectiveness of 
herbal medicine 
compared to 
placebo.   
Two Chinese oral herbal 
medications  
were tested in three 
randomized  
controlled trials that 
included 701 adults with 
chronic neck pain with 
radicular signs or 
symptoms or 
myelopathy. One oral 
herbal medication was 
compared with Mobicox 
(nonsteroidal 
antiinflammatory 
medication) and 
Methycobal (drug to 
reduce numbness, 
tingling in the arms), 
and the other  
(Compound Qishe  
Tablet) with placebo and 
Jingfukang. A  
topical herbal medicine 
(Compound  
Extractum Nucis 
Vomicae) was 
compared with 
Diclofenac  
Diethylamine Emulgel 
(nonsteroidal 
antiinflammatory 
medication). - See more 
at:  
http://summaries.coch 
rane.org/CD006556/ 
BACK_herbalmedicine-
forcervicaldegenerative-
discdisease#sthash.0bXF 
NG9M.dpuf  
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Gagnier JJ, van Tulder MW, Berman 
BM, Bombardier C. Herbal medicine 
for low back pain. Cochrane 
Database of Systematic Reviews 
2006, Issue 2. Art. No.: CD004504.  
DOI:  
10.1002/14651858.CD00450 4.pub3  
Assessed as up to date: 15  
December 2005 - See 
more at:  
http://summaries.cochrane.or 
g/CD004504/BACK_herbalmedicine-
for-low-
backpain#sthash.MDoTN5GZ.dpu f  
herbal medicine 
for non-specific 
lowback pain.  
Harpagophytum 
Procumbens, Salix  
Alba and Capsicum 
Frutescens seem to 
reduce pain more 
than placebo. 
Additional trials 
testing these herbal 
medicines against 
standard treatments 
are needed. The 
quality of reporting 
in these trials was 
generally poor. Two 
high quality trials 
examining the 
effects of 
Harpagophytum 
Procumbens 
(Devil's Claw) 
found strong 
evidence that daily 
doses standardized 
to 50 mg or 100 mg 
harpagoside were 
better than placebo 
for short-term 
improvements in 
pain and rescue 
medication. 
Another high 
quality trial 
demonstrated 
relative equivalence 
to 12.5 mg per day 
of rofecoxib 
(Vioxx). Two trials 
examining the 
effects of Salix  
Alba (White Willow 
Bark) found 
moderate evidence 
that daily doses 
standardized to 120 
mg or 240 mg 
salicin were better 
than placebo for 
short-term 
improvements in 
pain and rescue 
medication. An 
additional trial 
demonstrated 
en randomized  
controlled trials that 
included 1567 
adults with non-
specific acute or 
chronic lowback 
pain. Two oral  
herbal medications,  
Harpagophytum  
Procumbens 
(Devil's  
Claw) and Salix 
Alba (White Willow 
Bark), were 
compared with 
placebo (fake pills) 
and with rofecoxib 
(Vioxx). Topical  
Capsicum 
frutescens 
(Cayenne) was 
compared with 
placebo and a 
homeopathic gel.  
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relative equivalence 
to 12.5 mg per day 
of rofecoxib. Three 
low  
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  quality trials on  
Capsicum 
Frutescens 
(Cayenne), 
examining various 
topical preparations, 
found moderate 
evidence that 
Capsicum 
Frutescens produced 
more favourable 
results than placebo 
and one trial found 
equivalence to a 
homeopathic 
ointment.  
 
Liu JP, Yang M, Liu Y, Wei ML, 
Grimsgaard S. Herbal medicines for 
treatment of irritable bowel 
syndrome. Cochrane Database of 
Systematic Reviews 2006, Issue 1. 
Art. No.: CD004116.  
DOI:  
10.1002/14651858.CD00411 
6.pub2 - See more at: 
http://summaries.cochrane.or 
g/CD004116/IBD_herbalmedicines-
for-treatment-ofirritable-bowel- 
syndrome#sthash.hU9phi70.d puf  
Various herbal 
preparations for 
IBS  
various herbal  
preparations 
(including single 
herbs or mixtures of 
different herbs) for 
treating people with 
irritable bowel 
syndrome were 
assessed.  
individualised 
Chinese herbal 
medicine, STW 5 
and STW 5-II, 
Tibetan herbal 
medicine Padma 
Lax, traditional 
Chinese formula 
Tongxie  
Yaofang, and 
Ayurvedic 
preparation. some 
herbal medicines 
improve global 
symptoms such as 
abdominal pain, 
diarrhoea and/or 
constipation. 
However, the 
methodological 
quality of the 
majority of clinical 
Seventy-five 
randomised trials, 
involving 7957 
participants with 
irritable bowel 
syndrome, met the 
inclusion criteria. 
The methodological 
quality of three 
double-blind, 
placebo-controlled 
trials was high, but 
the quality of 
remaining trials was 
generally low. 
Seventy-one 
different herbal 
medicines were 
tested in the 
included trials, in 
which herbal 
medicines were 
compared with 
placebo or 
conventional 
pharmacologic 
therapy.  
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trials evaluating 
these  
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  herbs was 
generally poor. 
There is evidence 
indicating that 
small, poor quality 
trials with positive 
findings are more 
likely to be 
associated with 
exaggerated 
effects. Although 
the included trials 
did not report 
serious adverse 
effects from using 
herbal medicines 
more research is 
needed to 
determine the 
safety of herbal 
medicines. In 
conclusion, herbal 
medicines might 
be promising for 
the treatment of 
irritable bowel 
syndrome.   
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Seidel S, Aigner M, Ossege  
M, Pernicka E, Wildner B, Sycha T. 
Antipsychotics for acute and chronic 
pain in adults. Cochrane Database of 
Systematic Reviews 2013, Issue 8. 
Art. No.: CD004844.  
DOI:  
10.1002/14651858.CD00484 
4.pub3 - See more at: 
http://summaries.cochrane.or 
g/CD004844/SYMPT_analge 
sic-effects-of-antipsychoticsin-
acute-and-chronic-
painfulstates#sthash.Xo1fwfPH.dpuf  
antipsychotics  Antipsychotics 
might be used as 
an add-on therapy 
in the treatment of 
painful conditions. 
Nevertheless, 
extrapyramidal 
and sedating side 
effects have to be 
considered before 
using 
antipsychotics for 
treating painful 
conditions. 
Results for 
antipsychotics in 
the treatment of 
different painful 
conditions are 
mixed and most 
sample sizes in 
the reviewed 
RCTs are small. 
Further studies on 
atypical 
antipsychotics in 
larger double-
blind placebo-
controlled studies 
that include 
standardised pain 
assessment and  
A total of 770 
participants were 
involved in the 11 
included studies. - 
See more at: 
http://summaries.coch 
rane.org/CD004844/S 
YMPT_analgesic- 
effects-
ofantipsychotics-
inacute-and-
chronicpainful- 
states#sthash.Xo1fwf 
PH.dpuf  
 
  documentation are 
warranted.  
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Moore RA, Straube S, Wiffen 
PJ, Derry S, McQuay HJ. 
Pregabalin for acute and 
chronic pain in adults.  
Cochrane Database of 
Systematic Reviews 2009, 
Issue 3. Art. No.: CD007076.  
DOI:  
10.1002/14651858.CD00707 
6.pub2 - See more at: 
http://summaries.cochrane.or 
g/CD007076/SYMPT_pregab 
alin-for-acute-and-
chronicpain-in- 
adults#sthash.6lvmfRNw.dpu 
f  
Antiepileptics (such 
as pregabalin) are 
medicines used for 
treating epilepsy - 
See more at:   
Pregabalin at doses of  
300 mg, 450 mg, and 
600 mg daily was 
effective in patients 
with postherpetic 
neuralgia, painful 
diabetic neuropathy, 
central neuropathic 
pain, and 
fibromyalgia (19 
studies, 7003 
participants).  
Pregabalin at 150 mg 
daily was generally 
ineffective. Efficacy 
was demonstrated for 
dichotomous 
outcomes equating to 
moderate or  
substantial pain relief, 
alongside lower rates 
for lack of efficacy 
discontinuations with 
increasing dose. The 
best (lowest) NNT for 
each condition for at 
least 50% pain relief 
over baseline 
(substantial benefit) 
for 600 mg 
pregabalin daily 
compared with 
placebo were 3.9 
(95% confidence  
interval 3.1 to 5.1) for 
postherpetic  
neuralgia, 5.0 (4.0 to 
6.6) for painful 
diabetic neuropathy,  
not stated  
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  5.6 (3.5 to 14) for 
central neuropathic 
pain, and 11 (7.1 to 
21) for 
fibromyalgia. There 
was no clear 
evidence of 
beneficial effects of 
pregabalin in 
established acute 
postoperative pain. 
No studies 
evaluated 
pregabalin in 
chronic nociceptive 
pain, like arthritis. 
Pregabalin has 
proven efficacy in 
neuropathic pain 
conditions and 
fibromyalgia.  
 
Williams AC de C, Eccleston C, 
Morley S. Psychological 
therapies for the management of 
chronic pain (excluding 
headache) in adults. Cochrane 
Database of Systematic  
Reviews 2012, Issue 11. Art.  
No.: CD007407. DOI:  
10.1002/14651858.CD00740 
7.pub3 - See more at: 
http://summaries.cochrane.or 
g/CD007407/SYMPT_psycho 
logical-therapy-for-adultswith-
longstandingdistressing-pain-
anddisability#sthash.B2SouCUv. 
dpuf  
CBT and behavior 
therapy  
Small to moderate 
benefits, more for 
disability, mood and 
catastrophic 
thinking than for 
pain, were found in 
trials which 
compared CBT with 
no treatment. Some 
of these were still 
positive six months 
later. Behaviour 
therapy showed few 
and only brief 
benefits. 
Psychological 
therapies can help 
people with chronic 
pain reduce negative 
mood (depression 
and anxiety), 
disability, 
catastrophic 
thinking, and in 
some cases, pain. 
Although the overall 
effect is positive, we 
do not know enough 
about exactly which 
42 trials of treatments 
which met our criteria, 
but only 35 provided 
data in a form that could 
be used. The two main  
types of psychological 
treatment are called 
cognitive behavioural 
therapy (CBT) and 
behaviour therapy. - See 
more at: 
http://summaries.coch 
rane.org/CD007407/S 
YMPT_psychological 
-therapy-for-adultswith-
longstandingdistressing-
pain-
anddisability#sthash.B2S 
ouCUv.dpuf  
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type of treatment is 
best for which 
person.   
 
Matthews P, Derry S, Moore 
RA, McQuay HJ. Topical 
rubefacients for acute and 
chronic pain in adults.  
Cochrane Database of  
Systematic Reviews 2009, Issue 
3. Art. No.: CD007403.  
DOI:  
10.1002/14651858.CD00740 
3.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD007403/SYMPT_topical 
-rubefacients-for-acute-
andchronic-
musculoskeletalpain-in- 
adults#sthash.TXMzmN3h.dp uf  
topical salicylates  The evidence does 
not support the use of 
topical rubefacients 
containing salicylates 
for acute injuries, and 
suggests that in 
chronic conditions 
their efficacy 
compares poorly with 
topical non-steroidal 
antiinflammatory 
drugs (NSAIDs). 
Topical salicylates 
seem to be relatively 
well tolerated in the 
short-term, based on 
limited data.   
Six placebo and one 
active controlled 
studies (560 and 137 
participants) in acute 
pain, and seven 
placebo and two 
active controlled 
studies (489 and 90 
participants) in 
chronic pain were 
included.   
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Eccleston C, Fisher E, Craig  
L, Duggan GB, Rosser BA, 
Keogh E. Psychological 
therapies (Internet-delivered) for 
the management of chronic pain 
in adults.  
Cochrane Database of 
Systematic Reviews 2014, Issue 
2. Art. No.: CD010152.  
DOI:  
10.1002/14651858.CD01015 
2.pub2 - See more at: 
http://summaries.cochrane.or 
g/CD010152/SYMPT_psycho 
logical-therapies-deliveredvia-
the-internet-for-adultswith-
longstandingdistressing-pain-
anddisability#sthash.uFGoYr5V. 
dpuf  
Psychological 
therapies (e.g.  
cognitive 
behavioural therapy) 
delivered via the 
internet  
We conclude that 
these findings are 
promising for 
psychological 
treatments delivered 
via the Internet for 
the management of 
chronic pain in 
adults, but more trials 
are needed to 
determine the 
efficacy of such 
therapies.  
15 trials that met our 
inclusion criteria. 
Four trials included 
individuals with 
headache pain, 10 
trials included 
individuals with 
nonheadache pain, 
and one trial included 
individuals with both 
headache and 
nonheadache pain.   
 
Miyasaka LS, Atallah ÁN, 
Soares B. Passiflora for 
anxiety disorder. Cochrane 
Database of Systematic  
Reviews 2007, Issue 1. Art.  
No.: CD004518. DOI:  
10.1002/14651858.CD00451 
8.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD004518/DEPRESSN_pa 
ssiflora-for-the-treatment-
ofanxiety-disorders-
inadults#sthash.pA0lREr6.dpuf  
Passiflora, a herbal 
medicine  
Given the lack of 
studies, it is not 
possible to draw any 
conclusions on the 
effectiveness or 
safety of passiflora in 
the treatment of 
anxiety disorders.  
Although the findings 
from one study 
suggested an 
improvement in job 
performance in 
favour of passiflora 
(post-hoc outcome) 
and one study 
showed a lower rate 
of drowsiness as a 
side effect with 
passiflora as 
compared with 
mexazolam, neither 
of these findings 
reached statistical 
significance.   
Two studies, with a 
total of 198 
participants, were 
eligible for inclusion 
in this review. Used 
Relevant randomised 
and quasi-randomised 
controlled trials of 
passiflora using any 
dose, regime, or 
method of 
administration for 
people with any 
primary diagnosis of 
general anxiety 
disorder, anxiety 
neurosis, chronic 
anxiety status or any 
other mental health 
disorder in which 
anxiety is a core 
symptom (panic 
disorder, obsessive 
compulsive disorder, 
social phobia, 
agoraphobia, other 
types of phobia, 
postraumatic stress 
disorder).   
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Miyasaka LS, Atallah ÁN, Soares B. 
Valerian for anxiety disorders. 
Cochrane Database of Systematic  
Reviews 2006, Issue 4. Art.  
No.: CD004515. DOI:  
10.1002/14651858.CD00451 
5.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD004515/DEPRESSN_va lerian-
for-
anxietydisorders#sthash.3dwXF2Hx. 
dpuf  
Valerian, an 
herbal remedy  
Since only one 
small study is 
currently available, 
there is insufficient 
evidence to draw 
any conclusions 
about the efficacy or 
safety of valerian 
compared with 
placebo or 
diazepam for 
anxiety disorders. 
RCTs involving 
larger samples and 
comparing valerian 
with placebo or 
other interventions 
used to treat of 
anxiety disorders, 
such as 
antidepressants, are 
needed.  
One RCT involving 
36 patients with 
generalised anxiety 
disorder was eligible 
for inclusion. This 
was a 4 week pilot 
study of valerian, 
diazepam and 
placebo. search was 
Randomised  
controlled trials 
(RCTs) and 
quasirandomised 
trials of valerian 
extract of any dose, 
regime, or method 
of administration, 
for people with any 
primary diagnosis of 
general anxiety 
disorder, anxiety 
neurosis, chronic 
anxiety status, or 
any other disorder in 
which anxiety is the  
primary symptom 
(panic disorder, 
obsessive 
compulsive 
disorder, social 
phobia, 
agoraphobia, other 
types of phobia, 
postraumatic stress 
disorder).  
Effectiveness was 
measured using 
clinical outcome 
measures and other 
scales for anxiety 
symptoms.  
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Cameron M, Gagnier JJ, Chrubasik S. 
Herbal therapy for treating rheumatoid 
arthritis. Cochrane Database of 
Systematic Reviews 2011, Issue 2. Art. 
No.: CD002948.  
DOI:  
10.1002/14651858.CD00294 
8.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD002948/MUSKEL_herb 
al-therapy-for-
rheumatoidarthritis#sthash.dFv5Qoew.dp 
uf  
Herbal 
interventions are 
defined as any 
plant preparation 
(whole, powder, 
extract, 
standardised 
mixture) used 
for medicinal 
purposes. . RA, 
your immune 
system, which 
normally fights 
infection, attacks 
the lining of 
your joints. This 
makes your 
joints swollen, 
stiff and painful. 
The small joints 
of your hands 
and feet are 
usually affected 
first. There is no 
cure for 
rheumatoid 
arthritis at 
present, so 
treatments are 
used to relieve 
pain and 
stiffness and 
improve your 
ability to move.   
Several herbal 
interventions are 
inadequately 
justified by single 
studies or  
non-comparable 
studies in the 
treatment of 
rheumatoid arthritis. 
There is moderate 
evidence that oils 
containing GLA 
(evening primrose, 
borage, or  
blackcurrant seed oil) 
afford some benefit in 
relieving symptoms 
for RA, while 
evidence for  
Phytodolor® N is 
less 
convincing.Tripterygi 
um wilfordii products 
may reduce some RA 
symptoms, however, 
oral use may be 
associated with 
several side effects. 
Many trials of herbal 
therapies are 
hampered by research 
design flaws and 
inadequate reporting. 
Further investigation 
of each herbal 
therapy is warranted, 
particularly via well 
designed, fully 
powered,  
confirmatory clinical 
trials that use 
American College of 
Rheumatology 
improvement criteria 
to measure outcomes 
and report results  
according to  
CONSORT 
guidelines.  
Twelve new 
studies were 
added to the 
update, a total 
of 22 studies 
were included.  
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Cramp F, Hewlett S, Almeida  
C, Kirwan JR, Choy EHS,  
Chalder T, Pollock J, Christensen R. Nonpharmacological 
interventions for fatigue in rheumatoid arthritis.  
Cochrane Database of  
Systematic Reviews 2013, Issue 8. Art. No.: CD008322.  
DOI:  
10.1002/14651858.CD00832 
2.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD008322/MUSKEL_nonpharmacologicalinterventions-
for-themanagement-of-patientreported-fatigue-
inrheumatoid- 
arthritis#sthash.iSsGqRK9.dp uf  
Physical 
activity and 
psychosocial 
therapy  
for Fatigue 
is a common 
and  
potentially 
distressing 
symptom for 
people with 
rheumatoid 
arthritis with 
no accepted 
evidence 
based 
management 
guidelines.  
This review provides 
some evidence that 
physical activity and 
psychosocial 
interventions provide 
benefit in relation to 
self-reported fatigue 
in adults with 
rheumatoid arthritis. 
There is currently 
insufficient evidence 
of the effectiveness 
of  
other 
nonpharmacological 
interventions.  
Physical activity 
has a small benefit 
for managing 
fatigue in people 
with rheumatoid 
arthritis. 
specifically: - 
Psychosocial 
therapy has a small 
benefit for 
managing fatigue in 
people with 
rheumatoid 
arthritis.  
  
- No other 
interventions showed 
a difference in 
managing fatigue in 
people with 
rheumatoid arthritis. 
This may have 
happened by chance.  
24 were 
identified for 
inclusion in the 
review with a 
total of 2882 
people.  
Specifically, 
physical 
activity 
interventions (n 
= 6 studies; 388 
participants), 
psychosocial 
interventions (n 
= 13 studies; 
1579 
participants), 
herbal medicine 
(n = 1 study; 58  
participants), 
omega- 
3 fatty acid  
supplementation 
(n =  
1 study; 81 
participants),  
Mediterranean 
diet (n  
= 1 study; 51 
participants), 
reflexology (n 
= 1 study; 11 
participants) 
and the 
provision of 
Health Tracker 
information (n 
= 1 study; 714 
participants).   
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Pittler MH, Ernst E. Feverfew for preventing migraine. 
Cochrane Database of Systematic Reviews 2004, Issue 1. 
Art. No.: CD002286.  
DOI:  
10.1002/14651858.CD00228 
6.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD002286/SYMPT_feverfe w-for-
preventingmigraine#sthash.UolN9Eue.d puf  
Feverfew  Results from these 
trials were mixed 
and did not 
convincingly  
establish that 
feverfew is 
efficacious for 
preventing migraine.   
There is insufficient 
evidence from 
randomised, 
doubleblind trials to 
suggest an effect of 
feverfew over and 
above placebo for 
preventing migraine.  
Five trials (343 
patients) met 
the inclusion 
criteria.   
Randomised, 
placebo-
controlled, 
double-blind 
trials assessing 
the efficacy of 
feverfew for 
preventing 
migraine were 
included.   
 
Pittler MH, Ernst E. Kava extract 
versus placebo for treating anxiety. 
Cochrane Database of Systematic  
Reviews 2003, Issue 1. Art.  
No.: CD003383. DOI:  
10.1002/14651858.CD00338 
3 - See more at:  
http://summaries.cochrane.or 
g/CD003383/DEPRESSN_ka va-
extract-for-
treatinganxiety#sthash.vk8QIdpU.dp 
uf  
kava for anxiety  The meta-analysis 
of seven trials 
suggests a 
significant treatment 
effect for the total 
score on the 
Hamilton Anxiety 
Scale in favour of 
kava extract. Few 
adverse events were 
reported in the 
reviewed trials, 
which were all mild, 
transient and 
infrequent. These 
data imply that, 
compared with 
placebo, kava 
extract might be an 
effective 
symptomatic 
treatment for 
anxiety although, at 
present, the size of 
the effect seems to 
be small. -   
Twenty-two  
potentially relevant 
double-blind, 
placebo-controlled 
RCTs were 
identified. Twelve 
trials met the 
inclusion criteria 
((n=700)).  
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Richards BL, Whittle SL, Buchbinder R.  
Neuromodulators for pain management 
in rheumatoid arthritis. Cochrane 
Database of Systematic Reviews 2012, 
Issue 1. Art. No.: CD008921.  
DOI:  
10.1002/14651858.CD00892 
1.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD008921/MUSKEL_neur 
omodulators-for-painmanagement-in-
rheumatoidarthritis#sthash.NqAtL4XY.d 
puf  
neuromodulators 
(broadly defined 
as substances 
which alter the 
way nerves 
communicate with 
each other and, 
consequently, the 
overall activity 
level of the brain. 
By acting on these 
nerve signals it is 
thought that these 
drugs can reduce 
the amount of 
pain felt by an 
individual. 
Neuromodulators 
sometimes used in 
pain management 
and assessed here  
include  
anticonvulsants 
(gabapentin, 
pregabalin, 
phenytoin, sodium  
valproate, 
lamotrigine, 
carbamazepine, 
levetiracetam, 
oxcarbazepine, 
tiagabine and 
topiramate), 
ketamine, 
bupropion, 
methylphenidate, 
nefopam, 
capsaicin and the  
cannabinoids.) for 
rhuematoid 
arthritis  
There is 
currently weak 
evidence that 
oral nefopam, 
topical 
capsaicin and 
oromucosal 
cannabis are all 
superior to 
placebo in 
reducing pain 
in patients with 
RA. However, 
each agent is 
associated with 
a significant 
side effect 
profile. The 
confidence in 
our estimates is 
not strong 
given the 
difficulties 
with blinding, 
the small 
numbers of  
participants 
evaluated and 
the lack of 
adverse event 
data. In some 
patients, 
however, even 
a small degree 
of pain relief 
may be 
considered 
worthwhile. 
Until further 
research is 
available, 
given the 
relatively mild 
nature of the 
adverse events, 
capsaicin could 
be considered 
as an addon 
therapy for 
patients with 
persistent local 
We included 
randomised  
controlled trials 
which compared any 
neuromodulator to 
another therapy 
(active or placebo, 
including 
nonpharmacological 
therapies) in adult 
patients with RA 
that had at least one 
clinically relevant 
outcome  
measure.Four trials 
with high risk of bias 
were included in this 
review. Two trials 
evaluated oral 
nefopam (52 
participants) and one 
trial each evaluated 
topical capsaicin (31 
participants) and 
oromucosal cannabis 
(58 participants).  
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pain and 
inadequate 
response or 
intolerance to 
other 
treatments. 
Oral nefopam 
and 
oromucosal 
cannabis have 
more 
significant side 
effect profiles 
however and 
the potential 
harms seem to 
outweigh any 
modest benefit 
achieved.  
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Linde K, Berner MM, Kriston L. St 
John's wort for major depression. 
Cochrane  
Database of Systematic  
Reviews 2008, Issue 4. Art.  
No.: CD000448. DOI:  
10.1002/14651858.CD00044 
8.pub3 - See more at:  
http://summaries.cochrane.or 
g/CD000448/DEPRESSN_st. 
-johns-wort-for-
treatingdepression.#sthash.cpTrZv0Y 
.dpuf  
St JOHNS Wort 
for depression  
The available 
evidence suggests 
that the hypericum 
extracts tested in 
the included trials 
a) are superior to 
placebo in patients 
with major 
depression; b) are 
similarly effective 
as standard 
antidepressants; c) 
and have fewer side 
effects than 
standard 
antidepressants. The 
association of 
country of origin 
and precision with 
effects sizes 
complicates the 
interpretation.  
29 studies in 5489 
patients with 
depression that 
compared treatment 
with extracts of St. 
John's wort for 4 to 
12 weeks with 
placebo treatment or 
standard  
antidepressants. The 
studies came from a 
variety of countries, 
tested several 
different St. John's 
wort extracts, and 
mostly included 
patients suffering 
from mild to 
moderately severe 
symptoms.  Trials 
were included if 
they: (1) were 
randomised and 
double-blind; (2) 
included patients 
with major 
depression; (3) 
compared extracts 
of St. John's wort 
with placebo or 
standard 
antidepressants; (4) 
included clinical 
outcomes assessing 
depressive 
symptoms.  
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Price JR, Mitchell E, Tidy E, Hunot 
V. Cognitive behaviour therapy for 
chronic fatigue syndrome in adults. 
Cochrane Database of  
Systematic Reviews 2008, Issue 3. 
Art. No.: CD001027.  
DOI:  
10.1002/14651858.CD00102 
7.pub2 - See more at:  
http://summaries.cochrane.or 
g/CD001027/DEPRESSN_co 
gnitive-behaviour-therapyfor-
chronic-
fatiguesyndrome#sthash.eLgdVlPR. 
dpuf  
CBT for chronic 
fatigue  
CBT is effective in 
reducing the 
symptoms of fatigue 
at post-treatment 
compared with 
usual care, and may 
be more effective in  
reducing fatigue 
symptoms compared  
with other 
psychological 
therapies. The 
evidence base at 
follow-up is limited 
to a small group of 
studies with 
inconsistent 
findings. There is a 
lack of evidence on 
the  
Fifteen studies 
(1043 CFS 
participants) were 
included in the  
review. Randomised 
controlled trials 
involving adults 
with a primary 
diagnosis of CFS, 
assigned to a CBT 
condition compared 
with usual care or 
another 
intervention, alone 
or in combination.  
  comparative 
effectiveness of 
CBT alone or in 
combination with 
other treatments, 
and further studies 
are required to 
inform the 
development of 
effective treatment 
programmes for 
people with CFS.  
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Appendix B.  
Herbs used for Pain and Related Conditions in Appalachia:                      
Anecdotal Sources/Herbal Texts 
Sources: Manual Search conducted March-April 2015 through West Virginia University Library  
Service (including databases PubMed, AltmedWatch, Library of Congress), WV Public Library search, 
Google Search (with additional cross-referencing in all materials yielding items of interest to  
Appalachian herbs, botanicals, folk remedies, folk traditions, flora, non-timber plant products) with no 
publishing time range; Physical sources manually searched for 'Rheumatism;' 'Analgesia;' 'Pain;' 
'Arthritis;' 'Inflammation;' 'Gout;' and, 'Headache'  
 ****Potential or known Narcotic - exercise caution 
 ***potential toxicity  
 **known toxicity but not mentioned in this 
literature 
Red lettering indicates use for 
Inflammation 
 *known toxicity YELLOW indicates a replicate 
herb 
Herb identified in 
Appalachian Text 
Parts  
Used/Prepation  
Method(s) 
Known for: Source 
Alfalfa (Medicago 
sativa) tops    Rheumatism 
Crellin, J. K., et al. (1990). 
Herbal medicine past and 
present. Durham, Duke 
University Press. 
   
Angelico (a. 
atropurpurea) 
Tonic, roots and 
leaves 
Chronic  
Rheumatism 
Crellin, J. K., et al. (1997). 
Trying to give ease : 
Tommie Bass and the 
story of herbal medicine.  
& Crellin, J. K., et al.  
(1990). Herbal medicine 
past and present. 
Durham, Duke 
University Press.  
Durham, Duke University 
Press. 
   
  
Apple  
Tea, syrup, and 
Tonic of Bark or 
fresh leaves 
Rheumatism;  
arthritis Crellin, J. K., et al. (1997). T 
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Balm of Gilead 
Balm of Gilead sap 
(not given) 
(contains 
crystalline 
populus, closely  
resembling 
salicin) Rheumatism 
Amjad, H. (2006). Folk 
Medicine of 
Appalachia: A Vanishing 
Tradition. , lulu.com 
(selfpublished). 
Buds boiled in oil Pain; salves 
Shelton, F. (1965). 
Pioneer comforts and 
kitchen remedies;: 
Oldtimey highland 
secrets from the Blue 
Ridge and Great Smoky 
Mountains, Hutcraft. 
   
Balm of Gilead/Balsam 
poplar/balm 
buds/Carolina 
poplar/cottonwood/hac 
kmatack/poplar 
balsam/tacamahac 
poplar/tackamahac  
(Salicaea) 
Tincture from  
Winter buds in  
February and 
March, before 
opening Rheumatism;Gout 
Krochmal, A., et al. 
(1971). A guide to 
medicinal plants of 
Appalachia. Washington,, 
U.S. Forest Service; for 
sale by the Supt. of Docs. 
   
Balm of Gilead/Bam 
a Gilly (Populus 
balsamifera, P.  
candicans) 
Salve, from 
buds;infusion 
Rheumatism;  
Strengthen nerves 
Bolyard, J. L. (1981). 
Medicinal plants and 
home remedies of 
Appalachia. Springfield, 
Ill., Thomas. 
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Balmony/White 
turtlehead/Bitter 
herb/Fishmouth/Saltrheum  
weed/Shellflower/smo 
oth  
snakehead/snakehead/ 
snakemouth/true 
snakehead/turle 
bloom/turle head 
(Scrophulariaceae) 
Herb, gathered 
when flowering; 
leaves, Gathered 
in Spring 
Reducing 
inflammation 
Krochmal, A., et al. 
(1971). A guide to 
medicinal plants of 
Appalachia. 
Washington,, U.S. 
Forest Service; for sale 
by the Supt. of Docs. 
   
Bay (magnolia) Tonic Rheumatism, sleep 
Crellin, J. K., et al. 
(1997). Trying to give 
ease :  
Bearsfoot  
Salve, Root and 
leaves 
Rheumatism;  
arthritis 
Crellin, J. K., et al. 
(1990). H 
Beech Tonic Rheumatism Crellin, J. K., et al. (1997). 
T 
Bergamot/White horsem infusion, from 
leav 
Rheumatism Bolyard, J. L. (1981). 
Medi 
Bethroot Tea, Rhizome 
Rheumatism; 
headache 
Crellin, J. K., et al. 
(1990). H 
Birch (B. lenta) Bark, leaves, 
juice  
(Rheumatism; Gout Crellin, J. K., et al. 
(1990). H 
Black Birch Sap (in salve) Rheu; massage Shelton, F. (1965). 
Pionee 
Black CohoshBlack 
Cohosh/Black  
Tonic, roots Rheumatism Crellin, J. K., et al. (1997). 
T 
snakeroot/Rattleweed/ 
Squawweed/Cocash  
(Indian name)/Bugbane  
Tincture, 
Poultice or tea, 
of boiled root 
Rheumatism; 
soothe pain 
Bolyard, J. L. (1981). 
Medi 
Black Haw/Crampbark Bark Rheumatism Crellin, J. K., et al. 
(1990). H 
Black Snakeroot  Root Rheumatism Crellin, J. K., et al. 
(1990). H 
Blue cohosh/Blueberry 
cohosh/blueberry 
root/papoose root/ Sqaw 
root/ Yellow ginseng 
(Caulophyllum 
thalictroides L.) 
Rhizomes and  
roots, gathered 
in fall 
Chronic 
rheumatism 
Krochmal, A., et al. 
(1971). 
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Blue vervain/blue 
verbena/ironweed/  
simpler's joy/verbain/wild 
hyssop (Verbenaceae) Herb and root Antirheumatic 
Krochmal, A., et al. 
(1971). 
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Boneset 
Tea, Leaves and 
roots 
Rheumatism; 
headache Crellin, J. K., et al. (1997). T 
Boneset/Thoroughwort 
/Feverwort/Indian  
Sage/Agueweed 
(Eupatorium 
perfoliatum) 
Decoction of roots 
and leaves Rheumatism Bolyard, J. L. (1981). Medi 
Bowman's  
Root/ipecac/Indian 
physic Tonic, bark   Rheumatism Crellin, J. K., et al. (1997). T 
Buckeye 
Buckeye 
Fruit Rheumatism Wilson, C. R. and W. R. 
Ferr 
Salve, Seeds 
(nonpoisonous 
half) and bark Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Buckeye* (Aesculus 
glabra, A. octandra ) Fruit 
Rheumatism; used 
in place of opium  
(10 grains  
powdered buckeye  
fruit rind = 3 grains  
opium) Bolyard, J. L. (1981). Medi 
Burdock Roots, seeds Rheumatism Crellin, J. K., et al. (1990). 
H 
Burdock Tea, roots & seeds Rheumatism Shelton, F. (1965). Pionee 
Burdock/Great Burdock  
(Arctium lappa ) seed and roots 
Rheumatism;Gout;  
Inflammations Bolyard, J. L. (1981). Medi 
Butterfly Weed Tea, Root 
Rheumatism;  
Anodyne 
Crellin, J. K., et al. (1990). 
H 
Button snakeroot Root Rheumatism; Gout Crellin, J. K., et al. (1997). T 
Catnip (Nepeta cataria ) Tea 
Sleep Aid, Nervous  
Depression,  
Debility 
Amjad, H. (2006). Folk 
Med 
Cedar Oil, tops, "apples" 
Chronic  
Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Celery; Smallage (wild) fruits, roots, tops 
Rheumatism; 
Inflammation; 
migraine 
Crellin, J. K., et al. (1990). 
H 
Chamomile  flowers   
Aches, pains, 
bruises 
Crellin, J. K., et al. (1990). 
H 
   180  
Chaparral/Creosote 
bush*** 
Tea and external, 
leaves Rheumatism Crellin, J. K., et al. (1990). H 
Chestnut/American  
Chestnut (Fagaceae) 
tea from leaves 
and inner bark 
Rheumatism;  
arthritis Bolyard, J. L. (1981). Medi 
Chicory Tea, of leaves Rheu; stomach Shelton, F. (1965). Pionee 
Club  
Moss/Moss/Running  
Cedar Tops Rheumatism Crellin, J. K., et al. (1990). H 
Cohoshes (black, blue, 
white) 
Rhizome, roots  
(beat up the root) 
Rheumatism, 
soothe pain, allay 
irritability, possible 
anti-inflammatory Crellin, J. K., et al. (1990). H 
Colic Root (Aletris) 
Roots gathered in  
fall Rheumatism Collins, K. C. and L. Hunter 
Collards 
Roots, applied 
externally 
Arthrtitic Joints for 
pain 
Brunvand, J. H. (1996). 
American folklore : an 
encyclopedia. New York, 
Garland Pub. 
   
Corn Silk Styles, stigmas Rheumatism; Gout Crellin, J. K., et al. (1990). H 
Cottonwood Tree 
in liniment with 
turpentine, Bark, 
leaves, green fruit Rheumatism Crellin, J. K., et al. (1990). H 
Cucumber tree  
(magnolia) Bark 
Rheumatism 
(claimed "the best") Crellin, J. K., et al. (1997). T 
Cucumber  
tree/Wahoo/Cucumber  
magnolia 
(Magnoliaceae) Bark Rheumatism  Bolyard, J. L. (1981). Medi 
Dandelion (Taraxacum 
officinale) 
decoction, roots 
and leaves 
Rheumatism;  
bursitis;arthritis Bolyard, J. L. (1981). Medi 
Devil's  
shoestring/Goat's Rue Tea, Root Rheumatism Crellin, J. K., et al. (1997). T 
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Echinacea/Purple  
Coneflower (Echinacea ) 
Extracts, of roots  
gathered in the  
fall 
Chronic 
inflammation Collins, K. C. and L. Hunter 
Elderberry (Sambucus 
canadensis ) 
Flowers and juice 
of berries Rheumatism Amjad, H. (2006). Folk Med 
Elderberry/Common  
elder (  Sambucus  
canadensis ) Berries Rheumatismic gout Bolyard, J. L. (1981). Medi 
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Garlic Tea, fresh roots Rheumatism Shelton, F. (1965). Pionee 
Gentian  Root Rheumatism Crellin, J. K., et al. (1997). T 
Ginger (Zingiber 
officinale) (not given) Rheumatic pain 
Amjad, H. (2006). Folk 
Med 
Ginseng 
Ginseng  
Roots Rheumatism? Crellin, J. K., et al. (1990). 
H 
Roots, chewed 
Arthritis/  
Rheumatism 
Goodwin, J. G. (1985). 
Goin 
Ginseng (Panax 
quinquefolia ) 
Tea, of roots 
gathered in fall 
Arthritis; calming 
effect on nerves 
Amjad, H. (2006). Folk 
Med 
Ginseng/Seng/Sang/Tar 
tar  
root/Fivefinger/Redber 
ry/Garantoqueen (Panax 
quinquefolium ) Tea, from root 
Rheumatism;  
arthritis;bursitis Bolyard, J. L. (1981). Medi 
Goldenseal/Yellowroot  
(Hydrastis canadensis ) Tea, from root 
Rheumatism;  
arthritis;bursitis Bolyard, J. L. (1981). Medi 
Gotu Kola Leaves, whole herb Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Ground Ivy 
Tea, from Leaves  
(green or dry) Headache 
Crellin, J. K., et al. (1990). 
H 
Holly/American  
Holly/Huver Bush  
(Aquifoliaceae) Decoction of bark In place of opium Bolyard, J. L. (1981). Medi 
Hops (Humulus lupulus ) Poultice  
Inflammatory 
conditions 
Amjad, H. (2006). Folk 
Med 
Horehound  
(Marrubium vulgare) (not given) Rheumatism 
Amjad, H. (2006). Folk 
Med 
Horse  
Chestnut/Buckeye 
Tree/Common 
horsechestnut (Aesculus 
hippocastanum L.) 
Bark and fruit, 
gathered in fall 
(carried around) Rheumatism 
Krochmal, A., et al. 
(1971). 
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Horseradish/Scurvy  
Grass  
Poultice, Roots and 
Leaves (used  
as 
counterirritant)bark, 
leaves, and  
Rheumatism and 
paralytic complaints 
Crellin, J. K., et al. (1990). 
H 
Hydrangea root Rheumatism Crellin, J. K., et al. (1997). T 
Indian hemp/Dogbane Root Rheumatism Crellin, J. K., et al. (1997). T 
Indian hemp/North-
andsouth root 
(Apocynum  cannabinum)  
Decoction of Root, 
gathered in fall 
Rheumatism;  
arthritis;bursitis; 
migraine Bolyard, J. L. (1981). Medi 
 
Poultice, of dried  
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Jimsonweed*/apple of 
peru/apple peru/devil's 
trumpet/Jamestown 
weed/jimsonweed 
datura/mad apple/stink 
apple/stinkweed/stink 
wort/stramonium/thor n 
apple (Solanaceae) 
Leaves and tops 
when flowering, 
seeds when 
mature 
Anodyne 
sedative/Antispasm 
odic 
Krochmal, A., et al. 
(1971). 
Joe-Pye-Weed  
(Eupatorium sp. ) Root Rheumatism Crellin, J. K., et al. (1997). T 
Lady-slipper/Moccasin 
flower/Nerve root 
(Cypripedium spp.) Root, dried leaves 
Sedative; 
Antispasmodic; 
allays pain Bolyard, J. L. (1981). Medi 
Lemon 
fruit, peel, volatile 
oil 
Rheumatism
Anti-
inflammatory;  
Crellin, J. K., et al. (1990). 
H 
Licorice Rhizome, roots   Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Maidenhair Fern  
(Adiantum pedatum ) Roots Rheumatism Collins, K. C. and L. Hunter 
Mayapple****/ Mandrake  
(Berberidaceae) Decotion, of Root 
Rheumatism;  
bursitis;arthritis Bolyard, J. L. (1981). Medi 
Milkweed/Common 
milkweed/Common 
silkweed/cottonweed/s 
ilkweed/swallowwort/wild 
cotton (Asclepiadaceae) 
Roots, gathered in 
fall Rheumatism 
Krochmal, A., et al. 
(1971). 
Milkweed/cottonweed/ 
silkweed/wild cotton 
(Asclepiadaceae) 
 
Inflammatory  
Rheumatism Bolyard, J. L. (1981). Medi 
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Moonseed/common 
moonseed/canada 
moonseed/maple 
vine/Texas 
sarsaparilla/vine 
maple/yellow 
parilla/yellow sarsaparilla  
(Menispermaceae) 
Rhizomes and  
roots, gathered in 
fall Arthritic conditions 
Krochmal, A., et al. 
(1971). 
 Mountain   
Tea/Checkerberry/Teab 
erry (Gautheria  
 
Muscle 
ache/Rheumatism  
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Pennyroyal/pennyrile/ 
Pudding grass/Squaw 
mint/Stinking 
balm/Tickweed 
(Hedeoma pulegioides ) 
fresh or dried 
leaves 
Headache;  
Rheumatism Bolyard, J. L. (1981). Medi 
Peppermint (Mentha 
piperita ) 
fresh leaves 
applied externally 
headache; slight 
anesthetic; local 
pain Bolyard, J. L. (1981). Medi 
Pine Sap and bark oil Massage; stiffness Shelton, F. (1965). Pionee 
Pine 
tops, bark, sap, 
tar, turpentine,  
rosin Rheumatism Crellin, J. K., et al. (1990). H 
Pipsissewa/Common 
pipsissewa/Bitter 
wintergreen/fragrant 
wintergreen/ground 
holly/king's cure/lovein-
winter/noble pine/Pine 
tulip/prince's 
pine/princess 
pine/pyrole/rheumatis 
m weed/  
waxflower/wintergreen  
(Pyrolaceae)  
Leaves and herbs, 
gathered in late  
summer or early  
fall Anti-rheumatic Krochmal, A., et al. (1971). 
Pipsissewa/Spidercheck 
ered  
wintergreen/Striped 
wintergreen  (not given) 
Arthritis/Rheumatis 
m/Bursitis Bennett, Allen and Green, 
Pleurisy Root (Asclepias 
tuberosa ) Tea, of roots  Rheumatism Amjad, H. (2006). Folk Med 
Pleurisy Root/Butterfly 
Weed (Asclepias 
tuberosa ) 
Tea, of roots 
gathered in fall Aching muscles Collins, K. C. and L. Hunter 
Poke 
Poke (Phytolacca 
americana )* 
Poke*/Pokeweed/Poke  
root/Poke salat/Poke   
Internal and 
external, Root 
and berries  Rheumatism Crellin, J. K., et al. (1997). T 
Ash-roasted root 
applied externally Inflamed joints Collins, K. C. and L. Hunter 
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beryy/Jalap/Cancerroot 
/Scoke/Garget  
Tea or tincture of 
berries; decoction  Rheumatism;arthrit 
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Pokeweed*  
Berries (small 
quantity) Rheumatism 
Amjad, H. (2006). Folk 
Med 
Pokeweed*/American 
nightshade/cancer 
jalap/cancerroot/chong 
ras/coakum/cocum/cok 
an/common 
pokeberry/crowberry/g 
arget/  
inkberry/jalap/pigeonb 
erry/ pocan/pocan 
bush/poke/pokeberry/ 
pokeroot/red-ink 
plant/red  
wood/scoke/skoke/Virg 
inia poke 
Root, gathered 
in fall; ripe 
berries made 
into wine Rheumatism 
Krochmal, A., et al. 
(1971). 
Poplars (including  
Yellow) 
Tonic, from bark, 
root bark, and 
salves from buds Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Prickly Ash Prickly Ash  
Chewed tree bark 
(not root) and tea 
from berries Rheumatism Crellin, J. K., et al. (1997). T 
(Xanthoxylum 
americanum) 
Syrup of berries 
and bark Rheumatism 
Amjad, H. (2006). Folk 
Med 
Prickly Pear fruit, fleshy leaves Acute rheumatism 
Crellin, J. K., et al. (1990). 
H 
Pussy Willow/Possum  
bush/Swamp willow  
(Salix spp.) 
tea, from limbs or 
leaves 
Headache; Pain;  
Gout Bolyard, J. L. (1981). Medi 
Quaking Aspen Tea, of bark Muscle pain Shelton, F. (1965). Pionee 
Queen Anne's Lace Tops and roots Rheumatism Crellin, J. K., et al. (1997). T 
Ratsbane/Quaker's 
buttons (Nux vomica )* 
Ratsvane/Pipsissewa 
minute quantities Rheumatism; gout 
Amjad, H. (2006). Folk 
Med 
Leaves, roots, 
whole plant Rheumatism Crellin, J. K., et al. (1997). T 
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Redroot****/Blodroot/ 
puccoon 
(Papaveraceae) tonic or bitters 
Rheumatism;Gout; 
Arthritis 
Krochmal, A., et al. 
(1971). 
Redroot*/Blodroot/coo 
nroot/pauson/puccoon/ 
puccoon root/red 
Indian paint/red 
puccoon/snakebite/sw 
eet  
slumber/tetterwort/tur 
meric/white puccoon  
(Papaveraceae) 
Rootstock when 
flowering, in late  
summer or early  
fall 
pain  
reliever;sedative 
Krochmal, A., et al. 
(1971). 
Sampson snakeroot  
Tea, Tonic and 
root Rheumatism 
Crellin, J. K., et al. (1997). 
T 
Sampson's 
snakeroot/marsh 
gentian/straw-colored 
gentian/striped gentian  
(Gentianaceae)  
Tonic of Roots, 
gathered in fall Rheumatism/Gout  
Krochmal, A., et al. 
(1971). 
Sarsparilla Rhizome, roots Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Sasparilla/Sasparillo/Sa 
safarilla/Safarilla/Sasfril 
ler/Sarsparilla/Moonse 
ed (Menispermum 
canadense) 
Sassafras 
Sassafras 
Tea or tonic, from 
root Rheumatism/Gout  Bolyard, J. L. (1981). Medi 
Root bark, wood, 
pith, leaves Rheumatism 
Crellin, J. K., et al. (1997). 
T 
Tea (roots 
and bark), oil 
of sassafras 
Rheu; general 
tonic/massage; pain Shelton, F. (1965). Pionee 
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Sassafras/Sassafac/Sass 
afrax (Sassafras 
albidum) 
Decoction from 
root Rheumatism Bolyard, J. L. (1981). Medi 
Seneca  
snakeroot/Senneker 
snakeroot/Sinnaker 
snakeroot/Milkwort/Ra 
ttlesnake Root (Polygala 
senega ) Root Rheumatism; gout Bolyard, J. L. (1981). Medi 
Senega 
Sevenbark 
Root Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Leaves, roots, 
bark  
Arthritis/Rheumatis 
m 
Crellin, J. K., et al. (1990). 
H 
Shepherd's Purse 
(Capsella bursapastoris) Poultice Inflammation 
Amjad, H. (2006). Folk 
Med 
Skullcap  
Tonic, Leaves, 
stem, whole plant 
Rheumatism, 
nervous conditions Crellin, J. K., et al. (1997). T 
Smartweed/Celery/Pars 
ley 
Salves and tea, 
from Whole plant Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Soapwort 
Tea, of 
roots/external 
Rheumatism; 
gout/Boils;skin 
sores Shelton, F. (1965). Pionee 
Solomon's Seal Boiled root Inflammation 
Amjad, H. (2006). Folk 
Med 
Spanish Moss  
(Tillandsia usneiodes ) (not given) Rheumatism 
Amjad, H. (2006). Folk 
Med 
Spicebush (Linderia 
benzoin ) Berries  Rheumatism 
Amjad, H. (2006). Folk 
Med 
Spicewood/Spicebush/ 
Wild allspice (Linderia 
benzoin) 
oil from fruit, 
applied externally Rheumatism Bolyard, J. L. (1981). Medi 
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Spikenard (Aralia racemosa ) 
Spikenard/American 
spikenard/American 
sarsaparilla/Indian root/life-of-
man/old man's root/petty 
morel/pigeon weed/spignet 
(Araliaceae) 
Spikenard/Spignet/Spik 
enard/Goutwort/Petty 
morrell/Indian root (Aralia 
racemosa ) 
Squaw Root/Black Cohosh 
Squaw root/cohosh 
bugbane/battle weed/black 
cohosh/black 
snakeroot/blueberry/bl ue  
ginseng/bugbane/coho sh/heart-
leaved rattletop/heart-leaved 
snakeroot/meadow rue 
leontice/papoose root/rattle 
root/rattlesnake 
root/rattletop/rattleweed/richwe 
ed/yellow ginseng 
(Ranunculaceae) 
Root 
Rheumatism/Rheu 
m accompanied by 
back pain/Arthritis 
Amjad, H. (2006). 
Folk Med 
Tea from roots, 
gathered in 
Summer and 
fall Rheumatism 
Krochmal, A., et al. 
(1971). 
Decoction 
Rheumatoid 
arthritis;backaches 
Bolyard, J. L. (1981). 
Medi 
(not given) Rheumatism 
Amjad, H. (2006). 
Folk Med 
Rhizomes and 
roots, 
gathered in 
the fall 
Chronic 
rheumatism 
Krochmal, A., et al. 
(1971). 
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Star Grass  
Star-root/Stargrass**** 
sip (in alcohol), 
roots Rheumatism Shelton, F. (1965). Pionee 
Root Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Swamp Root  (not given) Rheumatism 
Amjad, H. (2006). Folk 
Med 
Sweet Birch 
Sweet 
Birch/Black 
birch/cherry 
birch/mountain 
mahogony/River 
birch/Spice birch 
(Corylaceae) 
Sweet Birch/Black  
Birch/Cherry  
Birch/Spice  
Birch/Mountain  
Mahogony (Betulaceae) 
Roots, bark  
(distilled) Massage Shelton, F. (1965). Pionee 
Bark and twigs, 
gathered May to  
September Antirheumatic 
Krochmal, A., et al. 
(1971). 
Twigs, cones, 
bark, leaves, and 
juice 
Pain relief; 
antirheumatic Bolyard, J. L. (1981). Medi 
Sweet Fern (Comptonia 
peregrina ) 
Tansy 
Tobacco (Nicotania 
tabacum) 
Tea, of leaves and 
tops Rheumatism Collins, K. C. and L. Hunter 
Tea Aches and Pains 
 
Juice or ointment, 
applied externally Rheumatic pains  Bolyard, J. L. (1981). Medi 
Veratrum/hellebore*** 
* 
Salve, from 
rhizome and 
roots (much attn 
given for many 
alkoloids present 
and their role in 
muscle-relaxant 
and  
antihypertensive 
actions -JF 
Morton (1977, 
pp.58-64) Rheumatism; gout 
Crellin, J. K., et al. (1990). 
H 
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Virginia Snakeroot 
Tea, or in wine or 
whiskey, Rhizome 
and roots Arthritis 
Crellin, J. K., et al. (1990). 
H 
Watercress/nasturtium/ 
true watercress 
(Brassicaceae) Herb, at any time Rheumatism 
Krochmal, A., et al. 
(1971). 
Waxflower  
(Ratsbane)** Tea, of leaves Rheumatism Shelton, F. (1965). Pionee 
White ash/American 
Ash/American white 
ash/biltmore 
ash/biltmore white 
ash/cane ash/smallseed 
white ash (Oleaceae) 
Inner bark of 
trunk and roots, 
stem, both in  
Spring Antiarthritic 
Krochmal, A., et al. 
(1971). 
White Ash/Ash  
(Fraxinus americana? ) Bark, and leaves 
Rheumatism; gout; 
arthritis Bolyard, J. L. (1981). Medi 
White Pine (Pinus 
strobus) 
Resin from inner 
bark, sprigs Rheumatism Bolyard, J. L. (1981). Medi 
White Walnut Bark Boiled, crushed 
Applied to sore 
joints Shelton, F. (1965). Pionee 
Wild Black Cherry  
(Prunus serotina ) 
Bark, Inner Bark,  
Leaves, Twigs  
Rheumatism; gout; 
arthritis Bolyard, J. L. (1981). Medi 
Wild Yam Tuber Rheumatism Crellin, J. K., et al. (1997). T 
Willow Twigs, chewed on Body pain 
Stephenson, S. L. (2013). 
A 
Willow (Salix sp) 
Willow/Red Root 
Bark Rheumatism 
Amjad, H. (2006). Folk 
Med 
Bark Rheumatism 
Wilson, C. R. and W. R. 
Ferr 
Wintergreen  
salves, of leaves 
and oil Rheumatism 
Crellin, J. K., et al. (1990). 
H 
Witch Grass ("Quack") Tea, of roots Rheumatism Shelton, F. (1965). Pionee 
 Appendix C.   
Literature Review - Prevalence of Herbal Use in General US population (2002-2012) 
3,985 Records identified Dec 2012 through AgeLine, PsycArticles, PsycInfo, PubMed Medline, Scopus, AltHealthWatch using terms "CAM Survey," "CAM Use," "CAM Usage," "Botanical," 
"Herb,", "Biological Supplement," "Herbal Remedy," or "Herbal Remedies," and NOT "Intervention," or "Trial;" Option 'Health Professions' and Geographic Location 'United States' 
selected when available (Publication range 2001-2012; samples >500) --> Total studies reviewed = 34 (including 11 retrieved  
from cross-referencing)--> 32 studies of adults 18+ 
Author 1 (year)  Sample  
Location/Reference  (N)  
Sample  
Population  
(criteria,  
geograpy, 
socio) 
Type of sampling/ 
tool and  
Definition of CAM 
used in study 
Response  
Rate if  
app Major findings Prevalence/ Comments/limitations 
Mehta DH,  
Gardiner PM,  
Phillips RS,  
McCarthy EP 
. Herbal and dietary supplement  
disclosure to health care 
providers by individuals with 
chronic conditions. J Altern 
Complement Med.  
2008;14(10):1263–1269 5456 
Herbal 
supplement 
users (in past 
yr) in a  
national adult 
sample 
2002 National Health 
Interview 
Survey/crosssectional 
study - 28 CAM therapies 
broken down into 6 
dichotomous groups: Alt 
Med Systems, Biologically-
based therapies,  
Manipulative & 
BodyBased methods, 
Mind- 
Body Interventions,  
Energy Therapies, 
SelfPrayer 74.00% 
only 33% of herbal and dietary supplement 
users reported disclosing use of herbal and 
dietary supplements to their conventional 
health care provider. Among herbal and 
dietary supplement users with chronic 
conditions, less than 51% disclosed use to 
their conventional health care provider. 
Hispanic (adjusted odds ratio and 95% 
confidence interval=0.70 [0.52, 0.94]) and 
Asian American (adjusted odds ratio and 
95% confidence interval=0.54 [0.33, 0.89]) 
adults were much less likely than 
nonHispanic white Americans to disclose 
herbal and dietary supplement use. Having 
less than a high school education (adjusted 
odds ratio and 95% confidence interval=0.61 
[0.45, 0.82]) and not having insurance 
(adjusted odds ratio and 95% confidence 
interval=0.77 [0.59, 1.00]) were associated 
with being less likely to disclose herbal and 
dietary supplement use.  Those more likely 
to discluse herbal and dietary supp use to 
conv health  
LIMITATIONS w NHIS: disclosure of herbs and 
supps not supp-specific - it is only a general 
disclosure question!language, many herbs 
inquired about are marketed to NHW pop, no 
questions about physician  
characteristicsPREVALENCE ONLY FOR BBT.On 
average,  
2002 NHIS/ national providers were those with 4>= clinic 67.6% used CAM in the past 12 months, AA CAM users were slightly older 
than cross-sectional -  A  
when prayer for health was included.  
 multistaged, clustered  nonusers 
 sample design was  Users were more likely older (43.3 +/- 0.4 (mean age [standard error] 43.3 [0.4]  
 used, and self- versus 39.5 +/- 0.5 years; p < 0.0001);  versus 39.5 [0.5] 
reported information female (60.9% versus 44.0%; p < 0.0001), years; p   0.0001). In addition, they were was obtained using  
college educated (17.4% versus 9.8%; p <  
 computer-assisted  more likely to be 
 personal interview  0.0001); and insured (91.0% versus 88.1%; female (60.9% versus 44.0%; p   0.0001),  
(CAPI) techniques. 17  p < 0.0001) compared to nonusers. Prayer have a college CAM modalities into  was the most 
common CAM used by  education (17.4% versus 9.8%; p   0.0001),  
C.M. Brown, J.C. Barner, K.M.  four broad categories:  
Richards, T.M. Bohman (1) Alternative more than 60% of respondents, followed and have insurance 
 Medical Systems  by herbals (14.2%) and relaxation  coverage (91.0% versus 88.1%; p   0.0001).  
Patterns of complementary  (acupuncture,  (13.6%). A majority utilized CAM to treat Although 
and alternative medicine use  Ayurveda, homeopathic illness. The use of CAM was significantly a small difference, CAM users were more in African-Americans treatment,  
African- naturopathy); (2) (p < 0.0001) higher across all the disease likely to Americans in  Biologically-Based  states common in 
AAs compared to  be married (p   0.0197) and have incomes   
J Altern Complement Med, 13  non- Therapies nonuse.  19.6% of the sample had ever  $20,000 (p   
(2007), pp. 751–758 institutionalize (chelation therapy, folk  used CAM, and 14.2% had used CAM in  0.0020). The proportion of participants d,national  medicine, 
herbal  
 4256 sample  products, special 74.30% the 12 months.  Of those who had used  who were not currently 
 
   195  
  
K.T. Xu, T.W. Farrell 
Determinants of utilization:  
the complementary and 
substitution between 
unconventional and mainstream 
medicine among racial and ethnic 
groups 
Health Serv Res, 42 (2007), pp. 811–
826 46,673 
non- 
institutionalize 
d, civilian adults 
18+ from a 
national sample 
.Hispanics and 
blacks were 
oversampled. 
The Medical  
Expenditure Panel Survey in 
1996 and 1998 - 12 CAM 
modalities.  sampling frame 
for the household survey 
component was drawn from 
respondents in the National 
Health Interview Survey.  
chiropractics, massage 
therapy, herbal remedies, 
spiritual healings or 
prayers, nutritional 
advice, acupuncture, 
meditation/imagery/ 
relaxation, homeopathy, 
traditional medicine, 
biofeedback training, 
hypnosis, and others. not given 
CAM - herbals - in the last year, 48.9%  
Multivariate analyses were conducted to 
test whether each type of CAM and MSM 
(mainstream med) were complements or 
substitutes within a racial and ethnic 
group, controlling for respondents’ 
sociodemographics and health. More 
complementary relationships between 
CAM and physician visits were found in 
Nonhispanic Whites and Asians than in  
other groups. All significant relationships  
betweenCAMtypes 
and physician visits amongHispanics and 
other races (predominantlyNative  
American 
Indians) were substitution. 
Herbal CAM was used by 34.35% nonhispanic 
whites, 33.31% of Hipanics, 18.83% of Blacks, 
34.68% of Asians, and by 18.67% of  
respondents who stated they were a race of 
'other' (90% of which were Native American 
Indians).  Herbal use was top choice of CAM 
for conditions cancer (31%), emphysema 
(36%), arthritis (38%), asthma (35%), 
depression and anxiety disorders (38%).  
Herbal medicine was found to be a 
complement to MSM among Asians (marginal 
effects= .984) and the substitutions of herbal 
remedies for MSM within the Other group 
was the strongest of all sig relationships 
found in the study (marginal effects = -3.23).   
for each racial/etnic group, there are one or 
two rpedominant CAM types and the 
preveenct types differ by race.   
LIMITATION: ghome or over-the-counter 
CAM, such as herbs, was not specified so 
underestimates are likley!  additionally  
 
Sawni A,  
Thomas R 
. Pediatricians' attitudes, 
experience and referral 
patterns regarding  
complementary/alternative 
medicine: a national survey. BMC 
Complement Altern Med. 
2007;7:18 648 
 fellows of the 
American  
Academy of 
Pediatrics in 
July 2004. 
An anonymous, selfmade, 
self-report, 27item 
questionnaire - 17 CAM 
therapies; 
acupuncture/acupress 
ure, aromatherapy, 
ayurvedic medicine, 
biofeedback, chiropractic, 
energy healing/polarity, 
herbs (North American, 
Chinese), high dose anti-
oxidant vitamins, 
minerals, homeopathy, 
guided imagery, lifestyle 
diets (Ornish, 
marcrobiotics etc) 
massage therapy, prayer 
healing, reflexology, 
relaxation (yoga, 
mediation etc) touch. For 
each therapy the 
respondents indicated 
therapies  
practiced,  
personal/family use, 
referral for treatment,  
and rated the therapies 
as effective, safe, 
harmful or didn't know. 18.50% 
The median age ranged from 46–59 yrs; 
52% female, 81% Caucasian, 71% 
generalists, & 85% trained in the US. Over 
96% of pediatricians' responding believed 
their patients were using CAM. 
Discussions of CAM use were initiated by 
the family (70%) & only 37% of 
pediatricians asked about CAM use as 
part of routine medical history. Majority 
(84%) said more CME courses should be 
offered on CAM and 71% said they would 
consider referring patients to CAM 
practitioners. Medical conditions referred 
for CAM included; chronic problems 
(headaches, pain  
management, asthma, backaches) (86%), 
diseases with no known cure (55.5%) or 
failure of conventional therapies (56%), 
behavioral problems (49%), & psychiatric 
disorders (47%). American born, US 
medical school graduates, general 
pediatricians, & pediatricians who 
ask/talk about CAM were most likely to 
believe their patients used CAM (P < 
0.01). 6/3/2013 Pediatricians who talk to 
patients about CAM are generalists rather 
than a subspecialists and in  
herbs and megavitamins were used 
personally by 17% of the pediatricians 
although herbs was the therapy believed 
to be the most harmful (61%). 5% practice 
using herbs, 17% use on self or within their 
families, 10% refer for herbs, 52% believe 
herbs may be effective, and 15% believe 
they are safe. LIMITATION: they didn't 
include geographic location in their 
analusis! also, this survey could have 
assessed nurse practitioners and family 
physicians but did not, and could have 
gathered more info about CAM use for 
specific therapies.   
 Arcury TA, Grzywacz JG, Bell RA, 
Neiberg RH, Lang W, Quandt SA.  
(2007) Wake Forest Scool of  
Medicine NOT GIVEN! 
adults aged 
65 and older  
who were  
Black,  
Hispanic,  
Asian, or  2002 NHIS/national White.
 cross-sectional not given 
Herbs were an important component of the health 
self-management of older adults.  
11.9% OF ADULTS IN THIS SAMPLE USED HERBS.   
Whereas about one quarter of Asian and  
Hispanic elders used herbal remedies, about 10% of 
Black and White elders used them. Older adults 
differed by ethnicity in the herbs they used and their 
reasons for using herbs (Most widely used: 
echinacea (3%, garlic 2.9%, ginkgo 2.0%, ginger 1.3% 
ginseng 1.3%and saw palmetto (1.2%)(most widely 
used by ASIANS: ginger 9.1%, ginseng 6.6%, garlic 
6.0%) (HISPANICS: chamomile 5.1%, echinacea3.6%) 
(WHITES: echinacea 3.2%, garlic 2.9%, hinkgo 2.1%) 
(BLACKS: garlic 3.2%, ginger 1.8%). Predictors of 
herb use included gender, age, and health status. 
Ethnicity and region of the country, indicators of 
culture, and education, a personal resource, were 
significant predictors of herb use when personal and 
health characteristics were controlled. 
A complex set of factors is associated with the 
inclusion of herbs in the health selfmanagement of 
older adults, with cultural and personal resources 
being extremely important.Very few of the older 
respondents (n = 29, 4.2%) who had used herbs had 
used an  
herbal provider. About 2 in 5 (41.6%) individuals 
who had used an herbal remedy had told their 
conventional health care provider about this use. 
The most common reasons were to supplement 
conventional treatment (31.7%), or because it 
would be interesting (27.2%).  
Although Asian older adults were the most 
frequent users of herbal remedies (28.1%), 
their list of specific herbs used was the 
shortest. Ginger supplements (9.1%), 
ginseng (6.6%), and garlic supplements 
(6.0%) were Asian elders' most widely used 
herbal remedies. However, 7.3% of Asian 
respondents indicated that they did not 
know the name of an herb that they had 
used, and 6.4% indicated that they had 
used another herb not on the list. Almost 
one fourth (23.8%) of Hispanic older adults 
reported having used an herbal remedy.  
LIMITATION: i would have liked to have 
seen a trend test for age, and where 
sample sizes were low they should have 
used Fisher's exact test.  they also used 
multiple imputation for missing values on 
income but did not specify their 
imputation methods.  LIMITATION WITH 
NHIS: specific herbs included in this 
analysis may indicate a bias toward those 
used by whites, limited sample size of 
older adults from "all ethnic groups" 
Bardia A, Nisly NL,  
Zimmerman B, Gryzlak B,   
Wallace B (2007) 609 
all adults taking 
echinacea, 
garlic, ginseng, 
kava, soy, st jons 
wort 2002 NHIS 74.30% 
Overall, 54.9% used herbs for their evidencebased 
indications.  When discluding echincacea but using 
all other herbs combined, women (OR=1.81), those 
with college edu (OR=1.55), graduate edu 
(OR=2.91), were more likely to use the herbs based 
on their scientific merit then their counterparts.  In 
contrast, blacks (OR=.51) and adults <40 (OR=.43); 
40-59 yrs (OR=.48) were sig less likely to use herbs 
in accordance to what their evidence-based usage 
stipulates.  For echinacea, no pattern existed.   With 
the exception of echinacea and ginseng, 2/3 of 
respondents did not use commonly consumed  
herbs in consonence with a scientific standard 
LIMITATION w NHIS: does not reveal the user's source 
of info  LIMITATION: didn’t include respondents who 
used more than 1 herb.  Evidence base for certain 
herbs could have changed.  Did not evaluate 
possibilities for any 182 type of interactions with 
scripts or OTC.   
  
Barnes, PM, and  Bloom, B  
(2008) 
75,764 + 
31044 
all children 
and adults in 
the US 
2002 NHIS (adults only) 
and 2007 NHIS (adults and 
children) 
87.1% in  
2007 and  
74.3% in  
2002 
In 2007, the CAM therapies most commonly used by 
US adults in the past year were nonvitamin, 
nomineral BBT (17.7%).  These were also the most 
common CAM therapies used by children in the 
rpevious year (3.9%).  Children whose parents used 
CAM were about  
2x as likely as all US children to have used BBT (9.2% 
and 3.9%).  In 2007, one of the most commonly 
used BBT by adults was echinacea (19.8%), and by 
children for health reasons was echinacea (37.2%) 
and a combination herb pill (17.9%).  For adults 
younger than 65 yrs, in both 2002 and 2007, those 
with provate health insurance were more likely than 
those with public health insurance or uninsured 
adults to use biologically-based therapies.   
The NHIS CAM supplement changed from 2002 to 
2007.  traditional healing traditions were added in, 
while the # of diseases treated with CAM was 
expanded by 8.  The section on BBT was expanded by 
10 and an additional component of 'use in the last 30 
days' was added.  Lastly, questions on CAM use on 
children were added.   
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Bhargava, Vibha, hong Gong- 
Soon, Montalto, C.P. (2012) 
University of Georgia, Iowa  
State University, & Ohio State  
University 23,393 
nationally 
representative 
sample  adults 
2007 National 
Health Interview 
Survey/cross-sectional 
study 
not 
quantitative ly 
stated in 
article 
Total Respondents more likely to live in the  
South (36.7%), make $65k more per year (37.9%), 
82.95% had health insurance, more likely to have 
an education less than college (73.3%). This study 
highlights the need for more data with information 
on factors relevant to explaining CAM use such as 
price of self-care and practitioner-based CAM and 
health insurance coverage for practitionerbased 
CAM for application of a health economic model. 
nearly 17% of respondents had used herbs 
within rpevious 12 months.  those who 
worked less than full time were more likely 
to use herbs compared with those who 
worked full time or more. individuals 65 
and older were more likely to use herbs 
than those aged 35–44. The predicted odds 
of use of herbs among those who exercised 
were almost 77% higher than those who 
did not exercise.  The predicted odds of use 
of chiropractic and herbs were lower 
among smokers than nonsmokers. The rate 
of herbal use among the entire sample was 
17%. Most prevalent herbal usage was in 
the South (32.3%), an income of $65k+ 
(45.5%), had health insurance (86.1%), 
worked full tim or more (47.2%), had 1-2 
chronic health conditions (45.2%).  
Although 87.3% of those who used herbs 
self-described their health status as 
'Excellent', 'Very good' or 'Good', 21.7% 
said they were depressed.   
Davis MA, West AN,  
Weeks WB, Sirovich BE  
(2011) 23393 
national adult 
sample 18+  2007 NHIS not given 
11.7% of adults used herbals and 
nonvitamin supps for helath promotion 
purposes, which was in the top two 
most common modalities used for  
promotion.stat sig diffs between LIMITATION w NHIS: missing data for treatment 
and health promotion users, 
income so DID NOT INCLUDE IN THIS 
inc health status, 
obese, active ANALYSIS. health status measures are selfsmoker, any func limitation.  
reported and so susceptible to medical or therefore, there are two distinct types 
psychological conds.   They also stated of CAM users.  Health promotion users that 
health promotion users have rates of have sig better self-reported health conv 
health services use comparable to status and have healthier behaviors those of non-
users but was a poisson reg overall when compared w tx users. poss given the 
dataset?  Not sure.   
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Dawn M. Upchurch, Ph.D.,1 Claire  
E. Dye, MSPH,1 Laura Chyu,  
Ph.D.,2 Ellen B. Gold, Ph.D.,3 and  
Gail A. Greendale, M.D.4 (2010)  
UCLA, Northwestern, UC, UCLA 5849 
Women Aged  
40–59 Years 
2002 NHIS / national 
cross-sectional -  A 
multistaged, clustered 
sample design was used, 
and selfreported 
information was obtained 
using computer-assisted 
personal interview (CAPI) 
techniques 74.30% 
Overall, 46% of midlife women used any 
type of CAM in the past 12 months.  The 
top five specific CAM therapies used 
were herbs and natural products. Top 
health conditions used herbs for: other,  
head/chest cold, menopause, stomach or 
intestinal illness,  
Arthritis/gout/lupus/fibromyalgia, 
Anxiety/depression, joint pain and 
stiffness 
Herbs*** 
TOTAL 25.4% 
N= 5849 
White N= 3933, 26.2% 
Black n= 879, 19.5% 
Hispanic N=896, 23.3% 
Asian N=141,33.8% -------overall, 
significant Ors among herbal use showed 
Foreign-Born (1.4), hs grad (1.44), some 
college (2.26), college grad or more (2.7), 
co-habitating status (1.9), live in the west 
(1.64), insured (.8), 'Good' self-rated 
health status (1.27), former smoker 
(1.39),  
      lifetime alcohol abstainer (.54)  
Ellison, C.G., Bradshaw M., 
Roberts, C.A. (2012) University 
of Texas, Duke University, UNC  
Chapel Hill 3,032 
25-74 yr olds, 
national 
sample from  
1995 
1995–1996 
crosssectional 
National Survey of 
Midlife Development 
in the United States.   
not 
quantitative ly 
stated in 
article 
Compared to religious-only (OR=.56) or neither 
spiritual or religious (OR=.61), spiritual AND religious 
persons are relatively likely to employ BBT.  Compared 
to spiritual only persons, spiritual and religious 
individuals are 43% more likely to use body–mind 
therapies in general; however, when this category 
does not contain prayer, meditation, or spiritual 
healing, they are 44% less likely. Religious only 
individuals are disinclined toward CAM use.  After 
controlling for established predictors including 
educational attainment, personality, social support, 
and access to conventional medicine, the present 
study demonstrates that spirituality and religiousness 
are associated, in unique ways, with CAM use.  
15.3% engaged in biological therapies.  The Odds of 
using biological  therapies among those spiritiual & 
religious & those only spiritual  were less than 1 
(around .5) among both adj and non-adj models. 
POTENTIAL LIMITATON: they used so many 
psychological variables as covariates in their model 
but didn't specify whether or not they were valid 
measures! 
Elmer, G.W., Lafferty W.E., Tyree 
P.T., Lind B.K. 5052 
white or African 
American adults 
aged 65 and older 
5 years( time periods 1994, 
1995, 1997, 1999 
measured) of the 10year 
prospective population-
based cohort study  
(Cardiovascular Health 
Study) - However, location 
is unclear-  
NW US? not given 
Garlis, ginkgo, and ginseng were all in the top  
7 most commonly used products.  African Americans 
used significantly more garlic than their white 
counterparts (p=.003), while there were no diffs 
between race in the use of ginseng or ginkgo.  Usage 
of herbs increased in all 4 time periods, ranging from 
6.3% to  
15.1%.  5.8% of participants took combinations 
considered to have a sig risk for an adverse reaction.   STRENGTH: all CAM products within 2 weeks assessed.  
LIMITATION: no doses assessed and don’t know if CAM 
products and rx meds were taken simultaneously 
LIMITATIONS w NHIS: did not ask about all herbs with 
substantial market share such as green tea, bilberry, 
grapeseed, cranberry, aloe, goldenseal, or about herbs 
commonly used by racial and ethnic minorities. 
LIMITATION: selfreport, term 'natural herbs' could have 
been misclassified by respondents, ethnocentric and 
medico-centric bias in the survey instrument which 
may have contributed to an  
underestimation of the prevalence of CAM and herb 
use in particular especially among Nonwhite ethnic 
groups. 
Gardiner, P., Graham,R.,  
Legedza A, Ahn, A, Eisenberg,  
D.M. (2007) 
19% of sample reported using using an herb for their 
own health and treatment. 10% of these respondents 
had ever seen an herb practitioner, and 5% had seen 
one in the past year.  The most frequent conditions 
for which herbs were used include both acute (head 
or chest cold and stomach or intestinal illness) and 
chronic conditions (musculoskeletal conditions such 
as back pain, neck pain, arthritis, gout, fibromyalgia, 
lupus, knee probs, joint pain, or stiffness).84% of 
those who used herbs also used an OTC med, and 
21% of OTC users took herbs in the prior 12 months.  
72% of those who used herbs also used a prescription 
med in the last year, while 21% of prescription-med 
users took herbs in the prior 12 months. Factors  
all adults 18 associated with herb use are living in the and over in the west  (OR=1.41), being 45-64, female  (OR=1.36), 
US, national uninsured, having a higher edu, using meds   
 31044 sample 2002 NHIS 74.30% (OR=1.46) and being a non-hispanic 'other'  
 race. Respondents who did not have medical    
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Grzywacz JG, Lang W, Suerken  
C, Quandt SA, Bell RA, 
Arcury TA. Age, ethnicity, and 
use of complementary and 
alternative medicine in health 
self-management. J  
Health Soc 
Behav 2007;48:84–98. 30545 
white black 
hispanic and 
asian national 
adult sample NHIS 
74.3% cited 
in other 
literature 
but 89.6% 
cited in this 
article 
Results suggest that ailments such as bodily 
pain, chronic conditions, and functional 
impairment are associated with use of 
complementary and alternative medicine 
among midlife and younger adults, but 
these associations are  
generally 
attenuated among older adults. Greater 
impairment is associated with reduced odds 
id BBT.  An inc in the # of chronic conds is 
assctd w an increase in the odds of using BBT 
among midlife adults, whilse the effect of 
increasing bodily pain on use of BBT are 
strongest for young adults and weakest for 
older adults, with midlife adults in the 
middle.Hypothesized ethnic differences 
received 
weak support. These findings suggest that 
different interpretations of ailments and 
appropriate responses may explain why 
complementary and alternative medicine is 
used by fewer older adults. 
The three most widely used 
forms of complementary medicine among all 
adults in the past year were self-prayer, 
biologically 
based therapies (22.1% of all adults here), and 
mind-body interventions.  Asians reported 
greater use 
of an alternative medical system, biologically 
based methods, mind-body interventions, and 
energy therapies, whereas blacks and Hispanics 
reported relatively low rates of use 
of these modalities.  Greater impairment is 
associated with reduced 
odds of reporting use of biologically based 
therapies, but it is associated with  
increased 
odds of reporting self-prayer for health 
purposes. LIMITATION w NHIS: does not 
contain measures of how ailments are 
interpeted - only asks one question about the 
importance of each modality for health 
maintenance - only asked of the indivduals who 
used the modality.  future  
    descriptions of CAM use by age and  
Grzywacz, JG, Lang W, Suerken  
C, Quandt SA, Bell RA, Arcury  
TA (2005) 
Gurjeet S. Birdee, MD, MPH,  
Russell S. Phillips, MD, Roger  
B. Davis, ScD, Paula Gardiner,  30,785 
all adults 18 and 
over in the US, 
national sample 
2002 NHIS 
2007 National Health 
Interview Survey data 
excluding 
vitamin/mineral 
usagebut including 
acupuncture; ayurveda; 
biofeedback; chelation 
therapy; chiropractic or 
osteopathic 
manipulation; energy 
healing therapy; 
hypnosis; massage; 
naturopathy;  
movement techniques  
(Feldenkreis,  
Alexander technique, 
pilates, and Trager  
Psychophysical 
Integration); 
homeopathy; Asian 
mind-body techniques  
(yoga, tai chi, and/or  
Fewer non-hispanic blacks use BBT than nonhisp 
others (predom Asian) and non-hisp whites.  Appx 1/2 
of BBT users are using CAM to treat an existing 
condition, but 45% use these modalities for illness 
prevention and health promotion.  Use of CAM and 
BBT to treat an existing condition increases linearly 
across adulthood. As age increases, use of BBT for 
prevention decreases.  The opposite is true for BBT 
and treatment. Therefore, BBT use among middle-
age is highest. The majority of Hisps and non-hisp 
whites are using BBT for treatment , whereas the 
majority of non-hisp blacks and non-hisp others use 
these modalities for illness prevention and health  
promotion.  The log odds (logit model) of  prev of BBT given (22%). Strength of this using BBT in 
early adulthood are lower for study was that they used an age^2  
89.6% given hisps and non-hisp blacks than for non-hisp but that is whites, and the log odds of using a BBT variable in 
the model to capture the for the increase across adulthood among hisps so curvilinear age-CAM association 
household that later in life the odds of using a BBT are dicumented in the lit (and it was sig for response greater 
among hisps than non-hisp whites  
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MD, MPHc (2010) Harvard,  
Beth Israel, Boston University 
 nationally 
distributed 
sample among  
individuals <18  
 9,417 years of age  
BBT!) and they addressed missing data! rate - 
here (and blacks).  after midlife, the log odds of they used using BBT decrease for both non-hisp whites Limitation 
potential retrospective recall other and blacks by age, gender, and edu.   
In 2007, pediatric CAM users were more likely to 
take prescription medications, have a parent who 
used CAM, and have chronic  
conditions such as anxiety or stress, biologically-based therapies were used by 4.7% musculoskeletal 
conditions, dermatologic of the sample.  Use of biologically based conditions, or sinusitis (significant 
therapies correlated with being an adolescent confounding factors were controlled for). CAM versus 
being an infant or toddler, white versus use was least common in the South and most non-Hispanic 
black or Hispanic, living in the common in the West.  Research is required to West versus the South, 
and parents being guide pediatricians in making college educated versus parents completing 
recommendations on CAM modalities for less than high school. Biologically based children including 
potential risks and/or therapies were also associated with delays in benefits and interactions with 
conventional health care because of difficulties with access, therapies.  There was nearly equal CAM 
use and medical conditions including insomnia, between boys and girls, higher use among non- fever, 
reflux, and sinusitis. LIMITATIONS: data Hispanic white patients, higher use among collected from an 
adult proxy which is educated families, and regional variations susceptible to recall bias. # of children 
with  
 76.50% with a low use in the South. chronic conds small, limiting power,  
  
Hildreth and Elman, 2007 
K.D. Hildreth, C. Elman 
Alternative worldviews and 
the  
utilization of conventional 
and complementary 
medicine 
Sociol. Inq., 77 (2007), pp. 
76–103 
Jamie C. Barner, Ph.D., 
Thomas M. Bohman, 
Ph.D., Carolyn M. Brown, 
Ph.D., Kristin M. 
Richards, Ph.D. 
(2010) University of Texas 
at  
Austin 
1,672 
31-65 yr olds, 
national 
sample from  
1995 
1995–1996 
crosssectional 
National Survey of 
Midlife  
Development in the 
United States (MIDUS) .  
2002 NHIS/ national 
cross-sectional -  A 
multistaged, clustered 
sample design was used, 
and selfreported 
information was 
obtained using 
computer-assisted 
personal interview 
(CAPI) techniques. 15 
cam modalities 
measured 
60.80% 
74.30% 
Higher self-rated spirituality is 
associated with a greater probability of 
CAM use and the use of more 
techniques. Although higher self-rated 
religiosity does not distinguish CAM 
users from nonusers, it is associated 
with adopting significantly fewer 
techniques. Assuming that the religious 
versus spiritual worldviews are 
differentiated by religious individuals’ 
greater embeddedness 
in community and institutional  
“orthodoxies” (e.g., adherence to a set 
of prescribed beliefs), a religious 
worldview appears to carry over to 
constrain 
the use of nonconventional practices 
and providers. It may also be that 
CAM’s tendency to secularize otherwise 
sacred techniques makes this type of 
care less attractive to these users 
(Goldstein 1999).  Openness shows 
itself to be a  
Limitation: interpretation of tables 
confusing: means were given for 
categorical variables, the diffs 
between model 1 and 2 (and 3!) were 
never explained, and OR's werent 
given  Herbal 
WEIGHTED: 
past 12 month 
N=3,394,228 cam for 
treatment: n= 1,660,353 
(48.9%) cam for 
prevention:                                      
n=1,709,464 (50.4%)                                         
Folk medicine 
WEIGHTED: 
past 12 month 
N=27,141 cam for 
treatment: n=21,259 
(78.3%) cam for 
prevention:    
n=5,882 (21.7%)       LIMITATION: didnt 
break down CAM modality by table 
LIMITATION w NHIS: CAM for treatment 
answer 'no' does not necessarily imply 
prevention, does it?  wording of these 
questions could be improved.  terms such 
as "home remedies" and culturally  2,952 
African- 
Americans who 
used CAM in the 
past 12 months  
Approximately 1 in 5 (20.2%) who used CAM in the 
past 12 months used CAM to treat a  
specific condition. Less than 50% (48.9%)  of AA 
CAM users used BBT for treatment, with the 
exception of folk medicine.  Ten of the 15 CAM 
modalities were used primarily for treatment by 
African-Americans. CAM for treatment was 
significantly (P < .05) associated with the following 
factors: graduate education, smaller family size, 
higher income, region (northeast, midwest, west 
more likely than south), depression/anxiety, more 
physician visits, less likely to engage in preventive 
care, more frequent exercise behavior, more 
activities of daily living (ADL) limitations, and neck 
pain. Twenty percent of African-Americans who 
used CAM in the past year were treating a specific 
condition. Alternative medical systems, 
manipulative and body-based therapies, and folk 
medicine, prayer, biofeedback, and energy/Reiki 
were used most often.  
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Jones, L., Sciamanna C.,  
Lehman, E. (2009) 1438 
all adults 18 and 
over in the US, 
national sample 
who  
used herbs  
alone 2007 NHIS 
LIMITATION w NHIS: depends on respondents' 
knowledge of CAM therapies and/or their 
willingness to accurately report use.  Also does not 
survey nursing home and chronic care home 
residents, who make up a huge portion of the  
the association between herbal use in the individuals who should be receiving past 12 months 
and receiving influenza and/or vaccinations.  LIMITATION: could have also  
not given pneumonococcal vaccine was not significant assessed ever using CAM vs past year alone 
Kannan VD, Gaydos LM,  
Atherly AJ, Druss BG (2010) 23393 all adults 2007 NHIS 
Motivaton for CAM use was neither 
associated with a lower prob nor a 
lower rate of conventional medicine  
not given utilization. 
Kennedy, J, Wang, C, Wu C.  
(2008) 
Using the unadjusted model -- Patients more  
they say it likely to disclose herb and supp use: Females was 90% but 
(OR=1.4), >65 yrs (OR=2.2) vs 18-24, those with  
actually  public health insurance (OR=1.6) vs private  LIMITATION:  likely an underestimate of effect wasn't given 
health insurance, poor/fair self-assessed  since they ommitted respondents who used because  health status 
(OR=1.5) , those hospitalized in  herbs and told a NP, PA, or dentist.  This study they did  the past 12 months 
(OR=1.9) vs not, and 6 or  was not clearly written and they didn't even their  more MD visits in past year 
(OR=2.2) vs 1.   describe which covariates they used in their  
 adults >=18 in  analysis  Patients least likely to report herb and supp  adjusted model.  Therefore, the results of the  
the US,  using  use were ALL races compared to whites,  unadjusted ORs were interpreted. they used an national  2002 NHIS/cross-
 different  Hispanic (OR=.6) vs non-hisp, not being a US  inflated response rate for a core they didnt  
 5196 sample sectional cores citizen (OR=.3)  even use (household at 90% when it was adult)! 
Mehta DH, Phillips RS, Davis 
RB, McCarthy EP. Use of 
complementary and 
alternative therapies by 
Asian Americans. Results 
from the National Health 
Interview Survey. 
J Gen Intern Med  
2007;22:762–767. 
all  
nonhispanic 
whites and 
asian 
amaericans 
among a  
national adult  
21359 sample 
2002 National Health 
Interview 
Survey/crosssectional 
study - 21 CAM therapies 
excluding prayer 
grouped into five broad 
categories: alternative 
medical systems 
(Ayurveda, acupuncture, 
homeopathy, folk 
medicine, naturopathy), 
bodywork therapies 
(chiropractic care, 
massage), 
biologicallybased 
therapies (dietbased 
therapies, megavitamin 
therapy, chelation 
therapy), mind/body 
therapies  
(biofeedback, energy 74.3% cited 
healing, hypnosis, tai in other  
chi, qigong,  literature meditation, 
guided  but 89.6% imagery, 
progressive  cited in this relaxation, 
deep  article - breathing, yoga), 
and  which is the herbal 
medicines. total household response 
rate. 
Herbal meds were used by 25% of the asian sample and 19% of the NHW sample 
(p<.01).  AA used herbs less freq than NHW to treat specific med conds (38% vs 59% 
p<.01).  Overall, 42% of AA and 38% of NHW reported using at least one CAM 
modality in the past year (p=0.06) (Table 2). After adjustment for sociodemographic 
characteristics, health care access, and illness burden, AA were as likely to use CAM 
as NHW [aPR=1.09, 95% CI (0.94, 1.27)]. Asian Americans were less likely than NHW 
to disclose 
the use of herbal medicines (16 vs. 34%,  
prev of BBT given.  
Limitation: they did log 
p<0.001) and mind/body therapies (15 vs. 
reg but didn’t put 
results in a tables, then 25%, p<0.05).  herbal medicines were  reported 
non-sig findings as sig!  used more often by Chinese (32%) than  LIMITATION 
WITH NHIS: they don’t 
by Filipinos (26%) and Asian Indians  
oversample 
AA, and don’t describe many (19%). Among AA, CAM use was  modalitlies 
embedded in Asian traditions 
associated with being female, having  
(may create 
an ethnocentric bias that higher education, and having a chronic 
 underestimates the prevalence of CAM medical condition; foreign-birth 
was not use among AAs).  Many herbals described 
associated with CAM use. For 
both  
in NHIS aerr unique to the US and are groups, almost half reported that 
herbal commonly marketed to middle-class 
medicines used in combination with 
 
NHW.  additionally, NHIS does not conduct 
conventional medicine would 
be more  
the survey in any other language than helpful (49 vs. 48%; p=0.81) and 
that they english and spanish 
   202  
  
Misra, Ranjita ; 
Balagopal,  
Padmini ; Klatt, 
Maryanna ;  
Geraghty, Maureen 
(2010 )  
Texas A&M 
self-made survey used herbal medicines because they based on the 
revised 
Health Promotion  
Lifestyle, Profile II.   
CAM use was 
derived from 
five questions 
(three close-ended 
and two open- 
American  ended) that  Older age, female gender, unmarried, Indian 
adults assessed and higher income was associated with in seven U.S. 
respondents’  use of dietary and herbal cities with vegetarian status: 
 supplements.  30.4% used dietary high  ‘‘Are you a  and herbal 
supplements.  use of  
concentration vegetarian?’’ ‘‘Are herbal and dietary of AIs: you currently taking 
supplements among males indicated  
 Houston, TX; dietary and herbal  they were older, moreeducated, had higher English  
Phoenix, AZ; supplements?’’ and proficiency, and were tobacco Washington, ‘‘Do you use 
any users compared to AI females.   
 DC; Boston,  alternative medical  However, females were 1.8 times  
 MA; San  systems (AMS, also more likely to Alt med systems and  
 Diego, CA;  referred to as  herbal supplements than males (table  
 Edison, NJ;  Whole Medical  4).  married respondents 
 and Systems) such as  were 2.8 times more likely to use  strength: they did cronbachs a on  
 Parsippany,  Ayurveda, dietary and herbal supplements than  subscales!, assessed for inter-rater  
 1824 NJ. homeopathic  37% non-married.   reliability,  
treatment, and  
 
Nahin RL, Barnes PM,  
Stussman BJ, Bloom B. 
Costs of complementary 
and alternative medicine 
(CAM) and frequency of 
visits to CAM 
practitioners: United 
States, 2007. Natl Health 
Stat Rep. 2009;  
(18): 1-14. 22290+ 
Cross-sectional/ 2007  
nationally 
National Health representative 
Interview Survey data.  
/ US 35 CAM therapies 
In 2007, 3.9% of adults used BBT in the past year.  In 
2007, adults in the United States spent $33.9 billion 
out of pocket on visits to CAM practitioners and 
purchases of CAM products, classes, and materials. 
Nearly twothirds of the total out-of-pocket costs that 
adults spent on CAM were for self-care purchases of 
CAM products, classes, and materials during the past 
12 months ($22.0 billion), compared with about one-
third spent on practitioner visits ($11.9 billion). 
Despite  
this emphasis on self-care therapies, 38.1  LIMITATION: total costs were calculated using million adults 
made an estimated 354.2  estimates of the most recent purchase * # of million visits to practitioners of 
CAM.  A total  purchases per yr, which is not nec completely  
not of 44% of all out-of-pocket costs for CAM, or accurate.  NHIS LIMITATIONS: recall bias quantitative about $14.8 billion, was 
spent on the possible, prev estimates for small population ly stated in purchase of nonvitamin, nonmineral, natural subgroups 
not great bc only taken at one point  
article products. in time 
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Nahin, R, Dalhammer, JM,  
Stussman BJ (2010) 31044 
all adults 18 and 
over in the US, 
national  
sample 2002 NHIS 74.30% 
OR's only given for general CAM use and not  
BBT 
19.3% of adults did not use conventional care within the 
past year despite the fact that 38.4% of these 
individuals had one or mroe health needs, with almost 
25% having a serious chronic or acute medical 
condition.  Instead of conventional care, 24.8% of these 
individuals used CAM.  68.5% of those only using CAM 
used BBT.  24.8% of those not using conventional care 
used some form of CAM, with 12% reporting one or 
more health needs and using CAM.  Of all individuals 
using CAM only, 21.6% thought conventional med 
treatments wouldn't help, and 20.4% said conv med 
treatments were too expensive.  The majority (54.1%) 
said they thought it would be interesting to try.   
Nahin, RL, Dahlhamer JD,  
Taylor BL, Barnes PM,  
Stussman BJ, Simile CM, 
Blackman MR, Chesney  
MA, Jackson M, Miller H, and 
McFann KK (2007) 31044 
national adult 
sample 18+  2002 NHIS 
Engaging in liesure time physical 
activity, having consumed alcohol in one's 
life but not being a current heavy drinker, 
and being a former smoker are 
independently associated with the use of 
CAM.  Obese are slightly less likely to use 
CAM than individuals with a healthy BMI.  
No sig 74% bw flu vaccine and CAM use.   
strengths: assessed colinearity to compare 
models 
Neiberg, Rebecca H. ; Aickin,  
Mikel ; Grzywacz, Joseph G. ;  
Lang, Wei ; Quandt, Sara A. ;  
Bell, Ronny A. ; Arcury,  
Thomas A. (2011) Division of  
Public Health Sciences,  
Department of Biostatistical 
Sciences, , Winston-Salem, 
NC. 
College of Medicine, , Tucson, AZ. 
Department of Family and 
Community Medicine, , 
Winston-Salem, NC. 
Division of Public Health  
Sciences, Department of 
Epidemiology and Prevention, , 
Winston-Salem, NC. 27,862 
national adult 
sample 18+  2002 NHIS 
Linkset analysis, a method of estimating cooccurrence 
beyond chance  to identify possible sets of CAM use. 
Results: Most adults use CAM therapies from a single 
category. Approximately 20% of adults combined two 
CAM categories, with the combination of mind-body 
therapies and biologically based therapies estimated 
to be most common.  Only 5% of adults use therapies 
representing three or more CAM categories. 
Combining therapies across multiple CAM categories 
was more common among those 46-64, women, 
whites, and those with a college education. 
Conclusions: The results of this study allow 
researchers to refine descriptions of CAM use in the 
adult population. Most adults do not use a wide 
assortment of CAM; most use therapies within a single 
CAM category. Sets of CAM use were found to differ 
by age, gender, ethnicity, and education in ways 
consistent with previous  
74.30% research. 
Biologically-based therapies were observed in 5.5% of 
those who used a single modality with a significant 
probablity that biologically based and other CAM types 
are linked. Among the 20.6% of linkset users, singificant 
associations were seen between biologically-based 
users and 10.6% of those who used mind-body 
therapies, among other combinations of CAM use (less 
than 10.6%). There was a significant difference by 
genderbetween those who used both biologically-
based therapies and mindbody therapies (male 5.6%, 
fem 7.6%), those who used biologically-based therapies 
+ alt health systems + mindbody therapies (males .4%, 
fem .8%), and those who used all 4 CAM modalities 
(biologically-based, alt health systems, manipulative 
methods, and mindbody therapies) (males .5%, fem 
.8%).  Among those who used both alt health systems 
and biologically-based therapies, significant diffs 
occurred for whites > blacks & whites > hispanics.  For 
biologically-based +  
manipulative methods, whites > hispanics, for 
biologically-based + mind-body, hispanics > whites.  
Among those who used an alt system + biologically-
based + mind-body therapy, Hispanics> whites.  
biologically-based + mindbody + manipulative methods 
are significantly whites> asians & whites > blacks.  
However, when all 4 modalities were used, whites were 
> blacks & whites > hispanics utilized them together.  
Those who used mind-body therapies + biologically-
based therapies were more significantly more likely to 
be 45-54 yrs old.   
  
  
Nguyen, H.T., Grzywacz, JG  
Lang, W, Walkup M, Arcury, T  
(2010) 1683 
2002 NHIS  + 2003 MEPS  
longitudinal 89.6% for component on 
the NHIS; not  
adults aged 55+ same sample from  given for  
nationally 2002 NHIS MEPS 
interaction effects not possible due to low 
sample sizes of other forms of CAM measured. RCTS mremain nec to evaluate the saftey and efficacy 
of CAM in older adults STRENGTHS: dealth w missing income issue by using a dichotomous measure 
which may have helped BBT was used by 20.4% of this sample. The use a little & reliability (a) of the 
functional score of Biologically based therapies predicted assessed,  LIMITATION: but not for the 
physical better functional status (using a validated HRQoL and mental HRQoL. analysis reports scale 
and adjusting for many factors) (-1.14 short-term 1 year effects, interaction effects lowered func 
status score between those were not included due to low rates of some using BBT vs no BBT) (p<.01) 
in 1 year modalities 
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Nguyen, Long T., Davis, Roger  
B., Kaptchuk, Ted J., & Phillips,  
Russell S. (2011) National  
Center for Health Statistics 23,393 
nationally 
representative 
sample   
2007 National 
Health Interview 
Survey/cross-
sectional study.  
General CAM usage 
and health status 
not 
quantitative 
ly stated in 
article 
37% of U.S. adults used complementary and 
alternative medicine and 63% did not use any 
CAM. Compared to those who did not use CAM, 
CAM users were more likely to rate their health 
as 'Excellent' (adjusted-odds ratio (AOR) = 1.14, 
95% CI = [1.03,1.26]). Conclusion:  
We found a significant association between 
CAM use and self-rated excellent health and 
health improvement over the prior year. 
Prospective trials are required to determine 
whether CAM use is causally related to 
excellent health status and better health than  
in the prior year.  NOT ASSESSED, ABSTRACT ONLY AVAIL 
Picciano, F., Dwyer, J.T.,  
Radimer, K.L., Wilson,  
D.H., Fisher, K.D., Thomas, 
P.R., Yetley, E.A.,  
Moshfegh A.J., Levy P.S.,  
Nielsen, S.J., Marriott,  
B.M. (2007)  10136 
All kids <=18 yrs 
age 
99-2000 and 2001-
2002 NHANES national 
survey (some pops 
oversampled) not given 
.8% prevalence for any botanical supplements, 
with no sig diffs by sex.  The most commonly used 
botanical supplements were ginseng, echinacea, 
ginkgo, and grape seed extract (they also inc citrus 
bioflavenoids which are not a natrual herb or 
extract).  Few children  
younger than 3 had used botanical supplements, 
and the maximum prevalence was only 1% in 
teenagers.   
These data the first to include info on the use of 
botanicals in addition to nutrient-containing 
detary supps among children.  I wish they had 
made a table of the botanicals, however - they 
were only available via reporting through the 
write-up.  STRENGTH of NHANES is info from 
label recorded directly by trained pros in 
interviewers homes, LIMITATIONS of NHANES 
are cross-sx data, use of proxies under 16 may 
have caused misclassification , diffs in 
methodology and defs over time may limit the 
comparison of prevalence data 
Susan J. Blalo37:37hD;  
Philip J. Gregory, 
PharmD; Rajul A. Patel, 
PharmD, PhD; Linda L.  
Norton, PharmD; 
Leigh F. Callahan, PhD;  
Joanne M. Jordan, MD,  
MPH (2009) UNC Chapel  
Hill, Creighton University,  
Thomas J Long School of  
Pharm and Health  
Sciences, University of 
the Pacific, Thurston 
Arthritis Research 
Center 2523 
Population-based 
epidemiological study - 
Johnston County  
Osteoarthritis Project  
(1991-2004) survey - 
TWO COHORTS  
COLLAPSED TOGETHER 
-  which contained a 
list of 51 products 
including herbs and 
botanical products,  
natural products  
civilian, obtained from animal 
noninstitutiona sources natural lized, 
white or hormones (eg,  
African  phytoestrogen 
American  pills), and foods that  
residents, aged are sometimes 45 years 
or  consumed for older, of 
 medicinal purposes as 
Johnston  well as an open-ended  
County, North  query.  vitamins and  
Carolina (AA's  minerals not assessed  
oversampled) in this survey not given 
19.3 (n=488) of participants used at least 1 
herb/natural product and there were stat sig 
diffs by gender (women), race (whites), and edu 
(better eductated) in bivariate analyses. Among 
those who used both conventional medications 
and herbs/natural products, more than 1 in 5 (97 
[21.9%]) were using a combination of products 
associated with a 
potential interaction. Odds of exposure to a 
potential interaction' 
were lower among people who had health 
insurance and increased 
with the number of products used.  A total of 168 
potential interactions were identified. As shown 
in Table 4, 115 ofthe 168 potential interactions 
(68.5%) 
involved garlic and cytochrome P450 3A4 
substrates (eg, amlodipine, atorvastatin, 
simvastatin, verapamil). Although the 
severity of most ofthe 168 potential interactions 
was classified 
as "moderate," 27 (16.1%) were classified as 
"high" in severity.  The bivariate analyses 
indicate that the 
odds of exposure to a potential interaction 
increase as fatigue, 
number of comorbidities, number of herbs used, 
number of 
OTC medications used, and number of prescription 
medications 
used increase. In addition, individuals with health 
insurance 
excluded all missing data so sample size for full 
model (herb users who used at least one med as 
well) went down to 419. STRENGTH: extensive 
array of natural herbs/products LIMITATION: 
interaction data utilized as basis were case-
reports 
Upchurch DM , Chyu L,  
Greendale GA, Utts J, Bair 
YA, Zhang G, Gold E (2007) 17295 
national adult 
women sample  
18+  2002 NHIS 
BBT the 2nd most freq reported  
(23.8%) after prayer.  Foreign-born 
women were more likely to use BBT 
than US-born women (but remember 
they didnt control for confounders!) 
menopause in the top 10 conditions  
74% only for BBT 
 STRENGTHS: addressed income 
nonresponse and compared missing vs 
no missing: no diff in effects 
LIMITATION: missing values for smoking 
alcohol and  
BMI imputed.  No Cis reported  
LIMITATION w NHIS:underestimates 
likely in ethnic communities of women 
since traditional healers not yet inc in 
dataset.  many trad practices maybe not 
considered "alternative" since they may 
be perceived as common in some 
communities, resulting in potential 
misclassification 
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Wade, C, Chao M.T.,  
Kronenberg, F (2007) 804 
Adult Chinese  
Women in the 
US - national 
sample 
national telephone 
survey of health 
practices and services 
utilization April-Sept  
2001  
Women didn't use CAM to treat cancer or conditions 
related to pregnancy.  The highest  
rates of CAM use were for depression and  potential limitation: # of foreign-born Chinese 
menopausal symptoms.  Of those who used  women was very high, and higher SES found in 
CAM, 29% used only chinese herbs and  this sample compared to other Chinese in the 
acupuncture and 33% used chinese herbs and country, potentially limiting generalizability.  
acupuncture along with other CAM therapies.   The only obviously significant OR was for Most 
of the Chinese herb use was wo a script  herb/acu users who were less likely to have from 
a TCM practitioner (18% of sample).   excellent health status but there was no There was a 
statistically significant difference reference category listed!  income missing was in acculturation 
score between those who  high but STRENGTH: no diffs found between  
 used Chinese herbs and acupuncture only vs.  those who withheld their income and those  
73% other CAM use (p<.01).   who did not 
Yuanting Zhang, Elizabeth  
B. Fein and Sara B. Fein  
(2011)  2653 
a nationally 
distributed, 
but not 
representativ 
e, consumer 
opinion panel 
and was 
limited to 
healthy 
mothers with 
healthy term 
or near-term 
singleton 
infants. 
at least 2 time 
periods  
documented: Infant  
Feeding Practices 
Study II, a 
longitudinal survey 
of women studied 
from late pregnancy 
through their 
infant's first year of 
life 2005-2007 
ine percent of infants were given dietary 
botanical supplements or teas in their first year 
of life, including infants as young as 1 month. 
Maternal herbal use (P < .0001), longer 
breastfeeding (P < .0001), and being Hispanic 
(P = .016) were significantly associated with 
giving infants dietary botanical supplements or 
teas in the multivariate model. Many 
supplements and teas used were marketed 
and sold specifically for 94% infants.  
9% of mothers in the sample 
reported giving DBS and teas to 
their infants on at least one of the  
questionnaires, 
and 4% of the mothers reported 
giving DBS and teas on more than 
one questionnaire.  mothers were  
more likely to give their 
infants DBS and teas if they had used 
DBS themselves (OR 3.69) compared 
to mothers who had not, were 
primiparous, were older, had higher 
education or higher income, and were 
married (using 
    0.05). Geographically, giving 
DBS and teas to infants was most 
common in the West and least common 
in the Midwest.  The 4 most common 
reasons that mothers fed DBS and teas 
to their infants 
were to help with fussiness, digestion, 
colic, and relaxation STRENGTH AND  
LIMITATION: short recall (2 weeks), 
LIMITATION: likely an underestimiate of 
effect exists bc of exposure to herbs 
through breastfeeding mothers to 
infants, no # of doses.  likely an 
overestimate of herbal use bc regular 
tea was counted as  
well.  overrepresented NHW, older  
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